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Complex diseases including osteosarcoma (OS) and rheumatoid arthritis 
(RA) require careful disease management. There is a need to update therapeutic 
treatments for these diseases, accommodating a more targeted and structurally 
supportive therapy. The risk of off-target toxicity could be reduced through the use of 
a hydrogel to deliver and anchor a selective peptide-conjugated prodrug (PCP), 
cleavable by an overexpressed protease at the disease site.  
This study investigates the development of novel Hydrogel-PCP systems, 
aiming to selectively release naproxen (NAP) from the PCP component, through 
selective cleavage by matrix metalloproteinase 14 (MMP14), a proteolytic enzyme 
overexpressed within osteosarcoma and rheumatoid arthritis. Collagen-based 
hydrogels were initially functionalised with the photo-active monomer 4-vinylbenzyl 
chloride, prior to drug conjugation and photo-crosslinking under UV light. In light of 
no network formation by various photo-crosslinking methods a change in the 
crosslinking strategy was made. Chemical crosslinking using (4-(4,6-dimethoxy-
1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride) (DMTMM), successfully formed a 
gelatin based hydrogel-NAPPCP system (gel-NAPPCP). The release of NAP from 
gel-NAPPCP was analysed using LCMS after a 72-hour MMP14 recombinant 
enzyme assay was carried out. Cleavage by MMP14 at the Hof-Gly peptide bond in 
NAPPCP, a recognised cleavage site, did not occur, however the release of a NAP 
metabolite was detected at increased concentrations in more acidic conditions, 
providing an alternative for future drug release.  
The DMTMM-induced crosslinking reaction takes place under physiological 
temperatures, allowing the exploration of an injectable in situ network forming gel-
NAPPCP system, which was explored in synthetic bone cavities. Initial investigations 
demonstrate successful gel-NAPPCP hydrogel formation in these cavities, a 
promising step towards a more clinically desirable device compared to surgical 
implantation.  
To conclude, this study provides a proof of concept for future investigations 
to improve MMP14 selective cleavage of NAPPCP in a hydrogel system to selectively 
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Rheumatoid arthritis and osteosarcoma are complex diseases, often affecting 
the bone around a joint, particularly the knee in osteosarcoma [1] and the wrist in 
rheumatoid arthritis [2]. Whilst rheumatoid arthritis is a disease most commonly 
affecting adults, osteosarcoma occurs most frequently during childhood and 
adolescence. Osteosarcoma (OS) often requires surgery and powerful 
chemotherapy as a treatment, which is known to cause significant side-effects and 
unwanted toxicity to healthy tissues. In contrast rheumatoid arthritis (RA) is an 
autoimmune disease which is often treated by the use of disease-modifying 
antirheumatic drugs, immunosuppressors, for which off-target toxicity can also be 
detrimental [3]. For the treatment of both diseases, improved drug delivery could be 
significantly beneficial in reducing off-target toxicity. Treatment development for both 
diseases, particularly osteosarcoma, has seen very few advances in therapeutic 
treatments for many years. There is a clinical need for new interventions for both OS 
and RA: 
• to reduce unwanted toxicity in healthy tissues 
•  improve efficiency of treatment delivery 
• provide structural support to tissues 
• maintain the therapeutic effect of treatments.  
A major objective of drug delivery in disease therapeutics is the transportation 
of sufficient drug to the disease site, whilst reducing drug exposure to unaffected, 
healthy tissue [4]. By minimising the damage to healthy tissue caused by off-target 
drug toxicity, the therapeutic index is increased [5], allowing for the administration of 
a higher concentration of therapeutic agent (add another supporting reference) [6]. 
There are a wide variety of highly toxic therapeutic drugs, such as several 
chemotherapies, that could be utilised to better target other, less life-threatening 
diseases.  An example of a chemotherapeutic drug which is currently used to treat 
another non-cancerous disease is methotrexate. Methotrexate is a highly effective 
cytotoxic drug used to treat several autoimmune diseases including rheumatoid 
arthritis [7] and Crohn’s disease [8], although the mechanism by which methotrexate 
causes a therapeutic effect in cancer and rheumatoid arthritis is thought to be 
different [9]. Nevertheless, from a toxicological perspective it is crucial to deliver any 
therapeutic agent, particularly non-selective cytotoxic agents, to a disease site in a 
local fashion to reduce the risk of off-target toxicity. Delivery of a drug to the desired 
disease site is achieved through two main strategies, which aim to alter the 
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pharmacokinetic capabilities of the particular drug: The first of these methods 
involves the use of a drug delivery vehicle, such as nanoparticles or hydrogel 
conjugation of the drug to the gel, which release drugs through their own 
physiochemical properties, for example in response to temperature change [10, 11].  
The second method involves covalent modification of the drug, temporarily 
inhibiting the drug’s bioactivity (creating a so-called ‘prodrug’) in order to safely 
deliver it to the disease site [12].  
The prodrug strategy offers several key advantages over the use of a drug 
delivery vehicle, particularly the reduced amount of inert materials left behind after 
drug metabolism and the minimised risk of premature drug release. Both of these 
advantages reduce the metabolic stress on the patient, further increasing the 
therapeutic index of the particular drug administered [13]. Due to the advantages 
prodrugs appear to have over the use of delivery vehicles, it is feasibly unsurprising 
that many more prodrugs have been developed and approved by the US Food and 
Drug Administration (FDA) compared to the delivery vehicle method. A recent 
example is the antibody-drug conjugate polatuzumab vedotin, which in June 2019 
was granted accelerated approval by the FDA for the treatment of adults with 
relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [14].  
This project explores the possibility of combining both drug delivery methods 
to produce a novel, clinically relevant therapeutic treatment. Many complex diseases 
such as cancer or rheumatoid arthritis could benefit significantly from a prodrug, 
loaded onto a drug delivery vehicle, reducing the risk of off-target activation, leading 
to unwanted toxicity. Peptide-drug conjugates (also known as peptide-conjugated 
prodrugs) offer a selective drug release strategy through the exploitation of an 
overexpressed proteolytic enzyme within the disease site and have demonstrated 
increased drug therapeutic index. Peptide-conjugated prodrugs (PCPs) are generally 
delivered intravenously (as they would be degraded in stomach acid if administered 
orally), with little control surrounding how they reach the target site. Conjugating a 
PCP to a hydrogel network, before either implanting or injecting the hydrogel to act 
as a delivery vehicle would anchor the selective prodrug in place at the disease site, 
further limiting the risk of unwanted toxicity. Hydrogels are 3-dimensional polymer 
matrices with unique properties, one of which is the similar consistency to connective 
tissue, allowing them to act as tissue scaffolds, to promote processes including bone 
regeneration [15], as well as many being biodegradable [16, 17]. 
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A novel system such as the one described here, is clinically desirable, for the 
treatment of rheumatoid arthritis, as it provides a selective and localised drug delivery 
system, through a completely biodegradable tissue support network. There are two 
possible delivery routes applicable to the gel system proposed: implantation and 
delivery by injection (Figure 1.1.) 
 
Figure 1.1. Commonly used clinical delivery routes. Delivery strategies versus 
proposed Hydrogel-PCP delivery strategies. The proposed Hydrogel-PCP 
consists of an active drug (naproxen) conjugated to peptide sequence, 
selective to matrix metalloproteinase 14 (MMP14) cleavage at the Hof-Gly 
peptide bond. The PCP is further conjugated to a collagen-based biopolymer, 





1.1 Project Aims and Objectives 
Therapeutic treatments, displaying reduced off-target toxicity are sought after 
for the treatment of complex diseases such as rheumatoid arthritis and 
osteosarcoma. The aim of this proof of concept study is to address the clinical 
requirement of a more targeted therapy to treat osteosarcoma and rheumatoid 
arthritis.  
Naproxen, a non-steroidal anti-inflammatory drug well-known for its’ anti-
tumour effects and treatment of rheumatoid arthritis, will be conjugated to a peptide 
sequence, selective towards the active site of MMP14 to form a naproxen-PCP which 
will be coupled to a collagen-based biopolymer. The hydrogel-system will then be 
assessed for its’ relevance in targeting the diseases: osteosarcoma and rheumato id 
arthritis as well as to outline a possible clinical delivery route for the proposed drug 
delivery system. 
The combination of medicinal chemistry and biomaterials outlined here aims 
to pave a path for new knowledge and direction in the selective toxicology research 
field. This will be achieved by providing a concept for a new, selective device to 
replace the somewhat stagnant therapeutic methods in the treatment of rheumatoid 
arthritis and osteosarcoma, which have seen little advances in therapies in the last 
decade. A series of objectives outlined below, shed light upon the path in which the 
research will follow to achieve the aim of the study.  
 
1.1.1 Project objectives 
1. Synthesise a Hydrogel-PCP system from a collagen-based biopolymer, using UV 
irradiation of a photo-active molecule to induce network formation. 
There are two methods to achieve this objective:  a) Following conjugation of 
the photo-active molecule to free amino groups of the biopolymer, further 
coupling of the selected drug compound will be carried out, prior to UV-induced 
network formation and b) encapsulation of a drug-conjugated biopolymer sample 
within a separate, photo-activate, functionalised biopolymer sample. To 
determine the most suitable degree of functionalisation with the selected photo-
active molecule, a series of reactions will take place at varying molar excesses, 
following which the determination of remaining available amino groups (for drug 
conjugation and photopolymerisation to occur) will take place, before conjugating 




2. Using a chemical crosslinker, synthesis a collagen-based Hydrogel-PCP system. 
The use of direct chemical crosslinking removes the need for a photo-active 
molecule and provides an alternative method of forming a hydrogel network, as 
well as providing an alternative delivery route option, i.e. via injection in situ.  
Varying molar excesses of chemical crosslinker will be reacted to assess the 
changes in gelation times to provide insight into a suitable gelation time to support 
the injectable delivery route. The use of DMTMM as a chemical crosslinker, as 
opposed to the traditionally used EDC/NHS will also be explored.  
 
3. Carry out a recombinant enzyme assay to assess initial drug release. 
Necessary to confirm the selective release by MMP14 from the drug-
conjugated hydrogel system. The release profile may require modifications to the 
selected sequence to optimise the release by MMP14. An area to consider is the 
affect the hydrogel may have upon the release profile as MMP14 is a known 
collagen and gelatinase proteolytic enzyme and therefore may favourably cleave 
sites away from the peptide drug-conjugate cleavage site.  
 
4. Perform acid degradation assays on Hydrogel-PCP systems to assess the initial 
drug release.  
Acid degradation studies allow for the confirmation of drug presence within 
the Hydrogel-PCP system, should no selective drug release be observed. This 
would inform which further investigations or modifications to the Hydrogel-PCP 
system may be carried out to attempt to optimise the device.  
 
5. Investigate a possible delivery route of the Hydrogel-PCP system. 
The synthesis of a new therapeutic device requires a clinically viable delivery 
route. Therefore, the investigation into the most suitable delivery route for the 
relevant Hydrogel-PCP, is a necessary objective within this proof of concept 
study. If no viable delivery route can be developed, the Hydrogel-PCP concept 
must be adapted or be proven inadequate to continue investigating. A therapeutic 



















2.0 Literature review 
This chapter outlines the key aspects of the thesis and reviews the literature 
related to the design of a novel Hydrogel-PCP system. It first discusses peptide-drug 
conjugates and their recent developments within a therapeutic setting. The use of 
hydrogel networks as drug delivery vehicles, to provide localised and controlled drug 
release, are then reviewed. The target diseases, osteosarcoma and rheumatoid 
arthritis are discussed before considering the most suitable attributes for the 
Hydrogel-PCP such as: 
• The biomaterial to form the hydrogel network from 
• The proteolytic enzyme for drug release 
• The active drug to be selectively released from the system. 
The finalised design of the Hydrogel-PCP system and its clinical significance are the 
reviewed. 
 
2.1 Peptide-drug conjugates  
Peptide-drug conjugates (PDCs) are an evolving class of prodrugs, formed 
by the covalent coupling of a specific peptide sequence (often recognised and 
cleaved by a target enzyme) to a drug, possibly via an additional cleavable linker and 
are often used to selectively target tumour cells [18]. The amino acid sequence can 
be adapted to control the physiochemical properties of the drug conjugate as well as 
to accelerate or decelerate the active targeting of a particular receptor or proteolytic 
enzyme present at the tumour site. Therefore, the utilisation of peptides to form a 
prodrug incorporates a substantial degree of functionality into PDCs. The short 
peptide chain length of approximately 8-12 amino acids often seen in PDCs (the 
typical optimal length for enzyme recognition) compliments the method further by 
being readily biodegradable and rarely eliciting any undesirable immunogenic 
response [19]. The variety in amino acid combinations allows for an easily achievable 
preparation of many different PDCs, as well as the manipulation of the sequence 
providing control over conjugate properties such as ionisation and hydrophobicity, 
which influence the bioavailability of PDCs in vitro and in vivo [20]. Peptide-
conjugated prodrugs generally have a low molecular weight, allowing simple 
purification via High-Performance Liquid Chromatography (HPLC) techniques. The 
control of PDC molecular weight and purity is crucial when optimising the 
pharmacokinetics of PDCs. Previous work has demonstrated the importance of the 
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peptide sequence: minor modifications, for example a single amino acid change to 
the peptide sequence of a PDC can cause significant changes to the way the peptide 
conjugate is recognised and metabolised by the target proteolytic enzyme [21]. This 
significant alteration to a PDC’s performance in drug delivery, is not only affected by 
a change in the amino acid sequence but also the drug and linker molecule used. 
Two key areas of PDC research with regards to drug delivery involve 1) The reduction 
of off-target toxicity and 2) self-assembling PDCs. 
 
2.1.1 Using peptide-drug conjugates to reduce unwanted toxicity 
An identified trait amongst more traditional anticancer drugs is their non-
selective nature, often leading to the failure of chemotherapy treatment due to dose-
limiting toxicity, for which the cardiovascular system is a common site for unwanted 
toxicity [22]. The use of PDCs is known to reduce off-target toxicity amongst highly 
toxic chemotherapies whilst also being able to overcome another common issue, 
drug insolubility in water. The conjugation of an anticancer drug to a hydrophilic 
peptide conjugate can increase the solubility of the insoluble drug, allowing for 
greater functionality and safer delivery of the drug itself [20]. In this section a 
commonly used peptide-type, integrin-targeting, is outlined due to the enhancement 
of drug delivery observed.  
Integrin targeted peptide-drug conjugates address the goal of delivering 
anticancer therapeutics to a disease site whilst limiting or avoiding the fallout of off-
target toxicity in healthy tissues. In any treatment, particularly in cancer, the first step 
of interaction between a therapeutic agent and the cell occurs at the cell’s exterior 
surface; this mechanism is an area to be exploited, because of the differences in the 
expression of receptors and/or enzymes on or around tumour cell surfaces compared 
to that of normal tissues. The vast array of overexpressed receptors and enzymes 
found in tumour masses allows for a greater diversity in PDC design, providing a 
more specific and selective targeting platform, tailored to a particular cell type. 
Integrins are a type of regularly targeted and identified receptors, as they are critical 
for physiological development, maintenance and repair of tissues, making them ideal 
receptors for cancerous tissues to overexpress, where they have been associated 
with enhancing cell metastasis and angiogenesis through the cooperation of serine 
proteases and metalloproteases [23, 24].  
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In 2016, Cox et al developed cysteine-knot mini-proteins (knottins) peptide-
drug conjugates, using a variety of drug-linker strategies to highlight an optimal 
conjugate as an effective inhibitor of tumour growth in a series of malignant cell lines, 
by delivering the drug, gemcitabine (GEM) [25]. The group provided evidence 
showing integrin-binding was crucial for potency, the mechanism for cellular 
internalisation is mediated by the integrin (αvβ6) and the GEM payload was 
successfully released intracellularly. This was demonstrated across a wide variety of 
malignant cell lines including U87MG and D270 glioblastoma cell lines, breast MB-
468, ovarian A2780 and pancreatic cell lines BxPC3 and PANC-1 [25].  
The αvβ6 integrin is a receptor involved in cell adhesion and commonly found 
to be overexpressed in cancerous cells compared to healthy cells. Conibear et al 
(2017), synthesised β6 targeting compounds, through solid-phase protein synthesis, 
consisting of integrin-targeting peptides, cytotoxic platinum (IV) prodrugs and 
fluorescent or affinity probes joined with flexible linkers [26]. 
Although several other drug conjugate strategies such as antibody-drug 
conjugates have proven promising for targeted drug delivery, peptide-drug 
conjugates are more readily optimised and modified to improve the targeting 
properties towards cancer cells and other diseased cell types, to develop cleavable 
linkers for the conjugation of therapeutic drugs [27, 28]. Optimisation of the peptide-
drug conjugate allows for control over the targeting, making it more or less selective, 
depending on the balance between therapeutic effect and unwanted toxicity. 
Conibear et al (2017) demonstrated the flexibility of using a PDC design for integrin-
targeted drug delivery using the “Y” structure to form the PDC, oxali-Pt-Y-1 
(oxaliplatin based platinum (IV) prodrug with Y shaped branch scaffold), with a 
versatility allowing each module of the structure to be interchangeable for more 
suitable components depending on the target. An example of this would be the 
adaptation of the peptide conjugate to target alternative integrins other than β6, or 
even other receptor types overexpressed in the targeted disease [26]. The Y shaped 
module design synthesised by Conibear et al (2017) distinguished itself from 
previously discussed antibody-drug conjugates and peptide-drug conjugates [25] due 
to the two targeting peptides incorporated into the PEG27 linkers. The selective uptake  
of oxali-Pt from the oxali-Pt-Y-1 structure from cells was confirmed, as was the 
retention of the cytotoxic activity [26].  
The study by Conibear et al (2017) serves as one example of a new selective 
approach using PDCs to safely deliver a therapeutic agent to a disease site whilst 
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limiting the amount of off-target toxicity by selecting a target release trigger 
overexpressed in the disease site and not in the healthy tissue. This improves the 
therapeutic index of the selected drug, allowing a higher drug dose to be administered 
before the maximum tolerated dose (MTD) is achieved.  
 
2.1.2 Self-assembling peptide-drug conjugates 
Peptide-drug conjugates were initially designed to improve solubility and 
provide functional diversity by taking advantage of short hydrophilic peptides. 
Through research, a tendency for peptide segments to undergo self-aggregation has 
been identified, capitalising on the combination of low molecular weight hydrophobic 
drugs and hydrophilic peptide segments. The use of self-assembling peptides has 
expanded in recent years with regards to drug delivery. Here, the examination of self-
assembling peptides and their use in drug delivery is discussed.  
An important class of drug carriers relies on the use of hydrogels, an area of 
biomaterials with significant drug release capabilities [29-31]. Hydrogels in recent 
years have drawn much interest in their use as drug delivery vehicles, and in their 
early days, the research field focussed on the use of polymer-based hydrogels [32]. 
The research field has now branched out into supramolecular hydrogels too, due to 
the formation of aqueous assemblies of low molecular weight gelators through 
interactions [31, 33]. Supramolecular hydrogels, particularly, peptide-based, possess 
unique characteristics including, biocompatibility, low-toxicity and biodegradability. 
The formation of peptide-based hydrogels can also be initiated due to stimuli 
changes, such as temperature or pH, suggesting a promising alternative to polymeric 
hydrogels. Peptide-based hydrogels have demonstrated significant success in drug 
delivery, an example of which involved the use of self-assembling N-
fluorenylmethoxycarbonyl diphenylalanine to react with positively charged poly-L-
lysine by electrostatic interactions. The self-assembled nanofibers formed helical 
structures similar to fimbrial antigens and showed antigenic activities, serving as a 
vaccine to trigger strong antitumour immune responses without any antigen and 
adjuvant [34]. Activated T cell responses were demonstrated without the addition of 
antigens, leading to the suppression of tumour growth [34]. Furthermore, the 
injectability of the self-assembling peptide-based hydrogels, provides a clinical 
advantage when compared with many polymeric, implantable hydrogel devices, due 
to the less invasive nature of delivery, as well as a reduction in the risk of infection 
and therefore unwanted toxicity. 
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Altunbas and colleagues demonstrated a sustained release of curcumin, an 
anti-inflammatory and anti-tumorigenic compound extracted from turmeric root 
(Curcuma longa), from self-assembling peptides in a non-invasive injectable system 
[35]. One of the more significant areas of the research by Altunbas et al (2011) is the 
insolubility of curcumin in aqueous solutions which often limits the therapeutic uses, 
however encapsulation of curcumin and self-assembling peptide gelation that occurs 
in aqueous, physiological conditions, appears to overcome the curcumin insolubility 
complications.  Research carried out has demonstrated curcumin is capable of 
inducing apoptosis in a variety of cancer cell lines, including MCF-7 and MDA-MB 
cell lines in a time and dose-dependent manner [36]. A 2009 review of curcumin and 
the effects it has upon cancer cell lines describes how it can selectively kill tumour 
cells and not the healthy cells, through the regulation of several cell signalling 
pathways, including but not limited to: cell survival pathway (Bcl-2), tumour 
suppressor pathways (p53 and p21) and the cell-proliferation pathway (c-myc) [37]. 
In relation to the use of self-assembling peptides, Altunbas and colleagues 
demonstrated growth of the human medulloblastoma cell line, DAOY on hydrogels 
not loaded with curcumin, however hydrogels loaded with curcumin inhibited DAOY 
cell growth. Further investigations showed that curcumin, released from the MAX8 
hydrogels was functional, however in hydrogels containing a greater peptide 
concentration there was evidence of decreased cell death, thought to be due to the 
peptide inhibiting curcumin from freely moving through the hydrogel network due to 
hydrophobic interactions resulting in a slowed drug release in higher peptide 
concentrations [35]. These findings demonstrate an area where drug release is not 
only possible using self-assembling peptides as delivery vehicles, but also 
controllable by altering the peptide concentration versus the drug concentration to 
suit the delivery strategy.  
Self-assembling peptides have proven to be strong candidates for drug 
delivery, as the rate of drug release can be controlled. The self-assembling peptide 
hydrogels themselves demonstrate versatility through the variety of applications they 
can be used for including drug delivery [38], tissue engineering [39] and wound 
healing [40]. The advantages of self-assembling peptides when compared to 
polymeric hydrogels appear superior, however the selection of the hydrogel type 
relies heavily upon the specific end-use application. Several polymeric hydrogels 
provide properties similar and, in some cases, superior to those of self-assembling 




2.2 Hydrogel systems and their use as drug delivery vehicles 
Recently, hydrogels have become an area of focus for delivering anticancer 
treatments due to their wide tunability and cross-linking properties. Hydrogels consist 
of 3-dimensional networks, made up of hydrophilic polymers, cross-linked either by 
physical intra-/inter- molecular attractions or through covalent bonds. Their ability to 
readily absorb water and biological fluids is very much desired in applications such 
as wound healing [41], due to their similar consistency to the extracellular matrix. The 
hydrophilic properties of hydrogels are largely due to the presence of hydrophilic 
moieties, for example carboxyl, amide, amino and hydroxyl groups within the 
polymeric backbone chains [42-44] as well as the presence of crosslinks among 
polymer chains, which prevents the dissolution of the polymer in water. Hydrogels 
were originally used for contact lenses after Wichterle et al developed a poly(2-
hydroxyethyl methacrylate)-based hydrogel over 50 years ago [45]. Research within 
the hydrogel field has progressed considerably since the work of Wichterle et al, 
particularly within the last 20 years. As the field of research has expanded, the variety 
of biomedical applications associated with hydrogels has broadened and now 
includes, but is not limited to, wound healing [46], tissue engineering and drug 
delivery as well as controlled drug release [47]. There are now several types of 
hydrogel, widely used to address these applications; three popular types are 
homopolymer, copolymer and the previously discussed self-assembling peptide 
systems. Both, homo and copolymer hydrogels originate from either synthetic-based 
or biopolymer-based materials, of which the biopolymer-based materials will form the 
basis of this research project. Each of these hydrogel types have advantages and 
disadvantages depending on the type of application desired, for example the self-
assembling peptide-based hydrogels lack covalent bonding [48] and as a result are 
generally mechanically weaker than a crosslinked homo- or copolymer.  
Due to their tissue-like consistency and tuneable characteristics through 
functionalisation of the backbone polymer, hydrogels have become extremely 
popular as tissue engineering scaffolds or drug release devices. As well as their 
tuneable characteristics, a wide range of polymeric biomaterials, from both natural 
and synthetic sources can be used as a starting material. The extensive variety 
allows a hydrogel to have unique properties, such as being magnetic, 
thermosensitive and photo-active, each of which has recently demonstrated a use as 
a delivery vehicle for localised drug delivery. Similarly, to the type of hydrogel 
material, the unique properties required of the hydrogel system depend upon the type 
of application, the delivery of the device and if used for drug delivery desired rate of 
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Table 2.1. Examples of the variety of hydrogel materials, cross-linking methods and applications present in current literature.  
1 Denotes biopolymer-based hydrogels 
2 Denotes synthetic-based hydrogels 




Using hydrogels as delivery vehicles for therapeutic drugs, enables greater 
therapeutic doses to be administered, as well as a reduced risk of off-target toxicity 
which, as discussed earlier, is a major clinical drawback within disease treatments, 
particularly anticancer treatments. In this section, three key varieties of hydrogels will 
be discussed alongside current literature, to aid in the selection of a suitable hydrogel 
material and type for the design of a novel Hydrogel-PCP system in Chapter 2.3.4. 
 
2.2.1 Thermosensitive hydrogels 
The use of thermosensitive hydrogels as drug delivery vehicles has become 
increasingly popular, particularly the lower critical solution temperature (LCST) gels. 
This is due to their ability to appear in a liquid polymer form at room temperatures, 
however upon being implanted or exposed to physiological temperatures they stiffen 
to become more gel-like, forming a hydrogel network [64]. Their liquid state at room 
temperature allows drugs to be mixed with them, which are loaded onto the hydrogels 
in response to temperature increase. An advantage of using a thermosensitive 
hydrogel is the removal of a chemical stimuli which is usually required to trigger the 
release of a drug from its vehicle. Drug diffusion from thermosensitive gels can play 
a crucial role in drug release [65].The process of liquid to gel is also reversible which 
allows thermosensitive hydrogels to be easily implanted and removed from the target 
site [66, 67]. An example of a thermosensitive hydrogel used in drug delivery is the 
triblock copolymer composed of poly(D,L-lactic-co-glycolic acid) (PLGA) and 
polyethylene glycol (PEG) also known as PLGA-PEG-PLGA. Some advantages of 
this copolymer are its simplistic design, which does not require organic solvents for 
either its synthesis or purification, and that the polymer is also biodegradable and 
biocompatible. From a drug delivery perspective, the PLGA-PEG-PLGA hydrogel can 
deliver both hydrophilic and hydrophobic drugs, has little systemic toxicity, and has 
been widely used as a cancer drug delivery vehicle [68]. In 2001, Zentner et al used 
PLGA-PEG-PLGA to deliver paclitaxel to tumour sites - controlling the release for up 
to 50 days, whilst demonstrating minimal drug release in healthy tissue [60]. More 
recently this gel has been used in a co-delivery study of 3 commonly used anticancer 
drugs, doxorubicin (DOX), cisplatin (CDDP) and methotrexate (MTX) for the 
treatment of osteosarcoma. As with many other cancer therapeutic drugs, DOX, 
CDDP and MTX are non-selective and highly cytotoxic agents which are linked to off 
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target toxicity [69-71]. Therefore, the need to safely deliver these drugs is key and 
has been demonstrated by Ma et al [59].  
Ma et al, using a 20 wt.% PLGA-PEG-PLGA hydrogel, due to its appropriate 
sol-gel transition temperature and gelation time, loaded DOX, CDDP and MTX and 
assessed the in vitro drug release [59]. MTX and DOX demonstrated an initial fast 
release for 2 days after administration, before a sustained release over 10 days. 
CDDP however, exhibited 70% release in the first 2 days, thought to be due to its 
enhanced solubility and reduced substitution of Cl⁻ ion activity [72].  
 
The group’s in vitro study indicated the hydrogel demonstrated 
cytocompatibility in both the osteosarcoma cell lines (Saos-2 and MG-63) as well as 
the normal tissue cell line (L929). Cytotoxicity was assessed using an MTT assay, 
which exhibited enhanced cytotoxicity on Saos-2 and MG-63 cell lines when the 
hydrogels were co-loaded with all three drugs. In vivo, it was shown by Ma and 
colleagues that drug-loaded PLGA-PEG-PLGA hydrogels demonstrated increased 
tumour inhibition efficacies for up to 16 days, compared to treatments with free drugs. 
It must also be noted that in this study, co-loaded hydrogels exhibited greater 
antitumour effects than hydrogels loaded with a single drug [59].  
In terms of reducing off-target toxicity, which as previously stated is a key 
objective in selective methods of treatment, Ma et al also assessed systemic toxicity 
effects. During the in vivo study, body weight checks were carried out, which 
indicated low systemic toxicity was associated with this method of localised treatment 
due to no significant weight loss shown in the mice [59]. 
To further assess the off-target toxicity, H&E stains were also carried out on 
the organs of sacrificed mice including, liver, heart, kidney and spleen. No obvious 
abnormalities were shown by the H&E staining, suggesting no off-target toxicity 
during the study, due to the localised methods of treatment [59].  
The study by Ma et al serves as a key example of enhanced delivery and 
sustained antitumour effects which can be achieved using thermosensitive hydrogels 
as delivery vehicles for anticancer drugs. Of course, there are various other 
thermosensitive hydrogels which could be used, for example the PECT based 




2.2.2 Magnetic hydrogels 
Magnetic hydrogels are another variation of hydrogels used for several 
applications, including drug delivery. A common nanoparticle used to give the 
hydrogels their magnetic characteristics is a magnetic iron oxide nanoparticle 
(MION). Due to their unique properties, small size, low toxicity, availability as well as 
their detection and separation techniques, to mention a few, MIONs make ideal 
compounds to be used in the production of nanoparticles. Another reason as to why 
MIONs are commonly used is that they can be coated in a wide range of materials 
[76] such as polymers, for example PEG, which can form hydrogels through surface 
initiated photopolymerisation. The release of therapeutic drugs coupled to these 
magnetic hydrogels can be carried out by passing alternating magnetic fields (AMF) 
through them. The AMF causes an increase in temperature of the hydrogel, leading 
to an increased rate of diffusion of the drug. A 2012 study by Meenach et al 
demonstrated the efficacy of paclitaxel, that was delivered by PEG-iron oxide 
hydrogel nanocomposites, was increased when temperatures reached hyperthermic 
levels (41-45⁰C) in A549 lung carcinoma cells [77]. 
A key advantage of using MIONs to deliver therapeutic drugs is by pulsating 
the hydrogels using AMF, which provides controlled bursts of drug release to the 
target area. There are several ways in which research groups have used MIONs to 
benefit their drug delivery hydrogel vehicles either by using the technique alone or 
combining it with another type of hydrogel such as a thermosensitive hydrogel [78]. 
A recent paper has demonstrated the use of magnetic and pH responsive K-
carrageenan/chitosan complexes for the controlled release of methotrexate (MTX) 
[79]. It was shown that a greater quantity of MTX could be loaded onto the hydrogels 
with a higher magnetic content, thought to be due to the high surface area of the 
nanoparticles, as well as methotrexate’s favourable interactions with hydroxyl groups 
of magnetite [80]. In terms of the magnetic hydrogels, drug release at different pHs 
was identified. It was found that MTX at a pH level of 5.3 released approximately 50% 
of the total MTX within the first 4hrs after administration, with the rest being released 
at a sustained rate over the next 48hrs. However, at a pH of 7.4, approximately 68% 
of the administered MTX was released over the initial 4hrs, and the majority of the 
remaining released over the next 7hrs [79]. 
This study provided the concept for the delivery of MTX, and potentially other 
therapeutic drugs, using magnetic and pH responsive hydrogels which could be 
applied to other types of hydrogel in the future. The Mahdavinia et al study also 
20 
 
compliments research carried out by other groups such as that by Davaran et al in 
2014 who used poly(NIPAAm-MAA-VP) magnetic (Fe₃O₄) hydrogel nanocomposites 
as an effective carrier for targeting in drug delivery systems as an anticancer 
treatment method [81]. Similarly to the work of Meenach et al (2012), Davaran and 
colleagues observed increased drug release at 40⁰C in acidic conditions compared 
to 37⁰C, however drug release was assessed in basic conditions at 37⁰C which may 
have also affected the drug release [81]. 
All in all, the use of magnetic hydrogels and the varying degree of drug release 
at different pHs have displayed impressive results in their use as anticancer drug 
delivery vehicles. 
2.2.3 Photopolymerisation hydrogels 
The increasingly popular use of photo-active molecules to functionalise the 
desired biomaterial can provide control over the network architecture as well as the 
mechanical and swelling properties. The photo-crosslinking strategies have been 
applied to the formation of synthetic polymer systems where their tunability and 
biocompatibility have been reported in detail [82-84]. Photo-activated hydrogels have 
been used for a variety of applications including the generation of on-demand H₂O₂ 
in cell culture [85], tissue engineering [86] and localised drug delivery [87]. However, 
the use of solely photo-activated hydrogels in drug delivery as opposed to a hybrid-
type hydrogel is relatively new, particularly where the use of harmful UV light to form 
the hydrogel is avoided [88]. 
In 2012, Bakó and colleagues synthesised a methacrylated PGA (MPGA) 
based hydrogel via free radical polymerisation in a photoinitiator-supplemented PBS 
solution containing 30% w/w of MPGA. Metronidazole, was loaded as a drug onto 
the hydrogel, and the release rate was assessed by immersing the MPGA loaded 
gels in PBS and HPLC of the supernatant at regular time intervals[87].  
The release measurements were carried out in five parallel experiments to 
ensure reliable data. Bakó et al (2012) found that drug release was primarily ruled by 
the hydrogel swelling behaviour due to the rapid increase of swelling in the first two 
hours, which prompted the initial burst effect. After 2 hours, the rate of drug released 
remained at a sustained level for the next 6 hours. It must be noted that release 
profiles were carried out by Bakó et al in in vitro conditions only, where mixing speeds 
and the amount on medium was increased [87]. Therefore, drug release would likely 
be slower when tested in in vivo or ex vivo environments. 
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During the toxicological assessment, when compared with PGA, the MPGA 
polymer exhibited no notable differences in either an MTT or LDH assay. For both 
polymers, the cytotoxicity did not exceed 4%, and was therefore deemed non-toxic. 
The MPGA hydrogels were also analysed and again were shown to be non-toxic. In 
the hydrogel form, the LDH assay demonstrated cytotoxicity levels of 3.82% and the 
MTT assay results were 104.2%, indicating no cell toxicity [87].  
These results provide strong evidence for the use of MPGA and the potential 
for other solely photo-activated hydrogels in drug delivery due to their non-toxic 
nature. Another key point that must be noted, is the use of blue dental light, as 
opposed to UV light to induce hydrogel network formation, which has become a 
greater sought-after method of forming hydrogels due to the unwanted radiation 
associated with UV light, combine with the ability to induce network formation in situ, 
for example in the mouth during dental procedures.   
There is a limited amount of research involving the use of photo-crosslinked 
hydrogels for the delivery of anticancer drugs. In 2010, Dadsetan et al synthesised 
oligo (poly(ethylene glycol) fumarate) (OPF) hydrogels modified with sodium 
methacrylate (SMA), through photopolymerisation under UV light [51]. The group 
loaded DOX onto hydrogels by incubating the gel discs in 1 ml of aqueous DOX at 
varying concentrations at 37°C. It was demonstrated that non-SMA modified OPF 
hydrogels showed greater initial burst release of DOX as well as an overall amount 
released during the 15-day assay. The higher the SMA content the lower the release 
seen over 15 days; however, release could have continued for a greater period of 
time, which was not assessed in this study. Over the 15 days, in non-SMA modified 
OPF hydrogels, 100% of the loaded DOX was released whereas the HG-SMA50 
exhibited 57% DOX release and the HG-SMA300 (high density charged hydrogels), 
just 20% [51]. This sustained release, may be more advantageous when targeting 
certain cancers, as recent studies have shown a lower, more sustained release can 
provide greater control over the cancer growth, prolonging the tumour progression 
time [89]. 
In terms of cell toxicity however, Dadsetan and colleagues demonstrated that 
although the release of DOX was lower, the cell toxicity was significant in the 
osteosarcoma cell line MG63, with the maximum killing effect at DOX concentrations 
greater than 1 μg/ml. The group also showed the toxicity between hydrogels loaded 
with DOX versus hydrogels without DOX loading. As expected in hydrogels lacking 
DOX, the MG63 cells maintained their viability, indicating the non-toxic nature of the 
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hydrogels, whereas the DOX loaded hydrogels exhibited significant toxicity with 
minimal cell survival over three days [51]. 
 
2.2.4 Overcoming solubility complications 
Another challenge that many anticancer drugs, such as paclitaxel, face is the 
insolubility in aqueous environments [90]. Insolubility poses real obstacles in terms 
of the delivery of a therapeutic agent, not only in cancer but all forms of therapeutic 
treatments [91]. This is because if a drug is insoluble then it cannot be readily 
administered by intravenous methods or dissolved to couple to a vehicle. The use of 
hydrogels has shown significant progress in recent times for the delivery of 
hydrophobic, insoluble drugs [92-94]. Various techniques  have been applied towards 
overcoming the insolubility of anticancer drugs using hydrogels, from peptide 
nanofibers [94] to the complete encapsulation of the therapeutic agents in micelles 
[95]. In 2016 Li et al designed and synthesised injectable multidomain peptide (MDP) 
hydrogels, which contain a hydrophobic binding pocket. The MDP consists of a 
peptide made of alternating hydrophilic and hydrophobic amino acids with charged 
residues at both termini. In aqueous solutions, this design allows hydrophobic side-
chains to aggregate, forming a peptide dimer. Several peptide dimers form a further 
sequester of hydrophobic residues from contact with the surrounding aqueous 
solutions [94]. Interestingly, Li and colleagues were able to alter the release profile of 
the loaded drugs, by increasing the amount of drug encapsulated within the formed 
nanofibers. It was demonstrated, that the greater the encapsulation of the anticancer 
drug SN-38, the slower the release profile, showing 60% total drug release over 8 
days in the most encapsulated hydrogel (K2(SL)3SA(SL)2K2). The other two loaded 
hydrogels tested by Li et al demonstrated more than 90% release of SN-38 in the 
initial 24 hours [94]. Another anticancer drug which was assessed, daunorubicin, 
exhibited short term drug release (95% release over the initial 4 hours) from the 
hydrogels, irrespective of the encapsulation. The group also demonstrated the drug 
release of anti-inflammatory (diflunisal and etodolac) and antibiotic drugs 
(levofloxacin and norfloxacin), which could be used as combinational therapies when 
treating certain diseases [94].  
The work reported by Li et al is just one example of the use of hydrogels to 
overcome the inconvenience of delivering insoluble therapeutic drugs in an ever-
growing field of research [95-97]. By using hydrogels to deliver both soluble and 
insoluble drugs, unlike liquid-based drug carriers, hydrogels can remain within the 
23 
 
disease site, which enables the localised targeting of a drug, reducing the amount of 
off-target toxicity [98, 99]. 
To summarise, hydrogels are useful vehicles for the delivery of drugs to a 
target site requiring therapeutic treatment, as their tuneable properties allow for a 
wide variety of applicable characteristics to suit a range of environments, whilst 
reducing the risk of unwanted off-target toxicity. The unique tailoring of hydrogel 
characteristics, result in finely tuned properties, selected to be specific towards the 





2.3 Targeted diseases and Hydrogel-PCP system component selection 
Peptide drug conjugates, also known as peptide-conjugated prodrugs (PCP), 
are a sequence of peptides, covalently coupled to a drug with a view of delivering the 
conjugated drug to a target site for release in a localised area to improve the drug 
efficiency or reduce unwanted off-target toxicity [20]. There are several means of 
achieving drug release from a PCP, two methods involve 1) a localised, passive 
release from the natural break down of the biodegradable PCP and 2) a selective 
release, targeting an overexpressed enzyme in the disease, or condition the drug is 
aimed at treating. The latter of these methods requires a protecting endcap to avoid 
any unwanted metabolism of the peptide chain, whilst the middle section of the chain 
being selective to an active site of an overexpressed proteolytic enzyme [100]. Many 
diseases require pathological changes to promote symptoms, of which, enzymes 
often play a key role, whether that involves an up or down regulation of enzyme 
expression. Overexpression of these enzymes makes them ideal targets to exploit 
when using PCPs to target the disease [101]. Peptide-conjugated prodrugs also 
begin to address the complication of delivery of insoluble drugs, which particularly in 
diseases such as cancer, appear to be the more successful therapeutic treatments 
[102]. However, PCPs are not the only way to overcome insolubility, or deliver a drug 
for a localised treatment, as previously discussed, hydrogels are also useful delivery 
vehicles. The careful selection of the base material used for the hydrogel, could allow 
PCPs to be conjugated to the polymer, enhancing the localised delivery of a drug, 
particularly if the PCP was used as a selective release mechanism by targeting an 
overexpressed proteolytic enzyme to cleave and release the therapeutic drug in the 
disease tissue whilst reducing the release to normal tissue [103, 104]. Selection of a 
suitable hydrogel base material is necessary depending upon the intended delivery 
site. For example, where a disease occurs in a site under mechanical pressures such 
as within a joint, the hydrogel base material would also be required to withstand 
similar levels of mechanical stress, although the selected material cannot be too rigid, 
as between a joint the gel would need to be fluid and move, as cartilage, the 
connective tissue between joints does. Using hydrogels to deliver a selective PCP 
could provide a tissue support network whilst administering a therapeutic agent to the 
affected area.  
For the purposes of this study two different diseases were selected as 
possible treatment targets; these were osteosarcoma and rheumatoid arthritis, which 
both require clinical interventions to provide a more targeted therapeutic strategy. 
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2.3.1 Osteosarcoma – overview of cancer 
Collectively, cancer is a leading cause of death worldwide and was 
responsible for approximately 9.6 million deaths during 2018 according to the World 
Health Organisation. Cancer occurs as the result of a mutation which causes the 
rapid division of abnormal cells, able to grow beyond their usual boundaries by 
evading apoptosis and acquiring limitless replicative potential. Evading apoptosis is 
one of 6 hallmarks of cancer published by Hanahan and Weinberg in 2000 [105], 
describing 6 common traits that oversees the transformation from healthy cell to 
cancerous (malignant) cell (Figure 2.1.).  
 
Figure 2.1. Hallmarks of cancer. The majority of cancers acquire the same set 
of functional capabilities during development through a range of mechanical 
strategies. 
 
Cancer Hallmark – Growth signal self-sufficiency: The ability of cancer cells 
to generate their own growth signals reduces the dependence on stimulation from 
their healthy tissue microenvironment. In normal cells, the majority of soluble 
mitogenic growth factors (GF) are produced by one cell type, which in turn stimulates 
the proliferation of another, however cancer cells acquire the ability to synthesise 
their own GFs which they are responsive to, allowing the establishment of a positive 
feedback cycle, often referred to as autocrine stimulation [105]. As well as producing 
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their own GFs, certain types of cancer cells overexpress growth factor cell surface 
receptors, usually tyrosine kinase [106]. The overexpression of GF receptors may 
lead to hypersensitive responses to moderate levels of GF which would not normally 
trigger proliferation. For example, the human epidermal growth factor receptor 4 
(HER4) is overexpressed in osteosarcoma and promotes cell survival and 
chemoresistance [107].  
Cancer Hallmark – antigrowth signal insensitivity: Whilst becoming self-
sufficient in the production of their own growth factors, cancer cells also become 
unresponsive towards antigrowth signals. Antigrowth signals work through two 
mechanisms, 1) forcing cells out of an active proliferative state and into a quiescent 
(G0) state or 2) by permanently relinquishing their proliferation potential by being 
induced into postmitotic states [105]. For cancer cells to thrive, antiproliferative 
signals must be evaded, often through the disruption of the retinoblastoma protein 
(pRb) pathway. When in a hypophosphorylated state, pRb prevents cell proliferation 
by sequestering and altering the function of E2 Transcription Factors (E2F), 
controlling the expression of genes required for progression from G1 to S phase 
during the cell cycle [108]. Cancer cells disrupt the pRb pathway, leading to the 
liberation of E2F, allowing cell proliferation to occur irrespectively of antigrowth factor 
signals which would ordinarily prevent advancement through the G1 phase of the cell 
cycle.  
Cancer Hallmark – Evading apoptosis: The rate of cell proliferation is not the 
only factor governing the expansion of tumour cell populations, the rate of cell attrition 
which is mostly represented by programmed cell death, apoptosis also plays a part. 
Apoptosis is monitored by stimuli indicating whether a cell should live or die and is 
usually triggered by the mitochondria in response to proapoptotic signals, releasing 
cytochrome C [109]. The Bcl-2 family of proteins regulate mitochondrial cell death 
signalling through several proapoptotic (Bax, Bak, Bid, Bim) and antiapoptotic (Bcl-
2, Bcl-XL and Bcl-W) proteins, as well as the p53 tumour suppressor gene which 
induces apoptosis in response to DNA damage, leading to the upregulation of Bax 
expression to stimulate the release of cytochrome C from mitochondria. Evading 
apoptosis is a crucial trait for cancer cells to acquire in order to form a tumour mass. 
Evidence to support this consensus can be seen in a paper by Liu et al (2018), where 
RACK1 (receptor of activated protein kinase C 1) was overexpressed, leading to the 
facilitation of Bcl-2 expression and the restraint of Bim expression, in turn causing 
increased chemoresistance towards cisplatin [110], a chemotherapeutic drug 
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interfering with DNA replication within the cell leading to apoptosis induction [111], 
causing the prevention of apoptosis. 
Cancer Hallmark – limitless replicative potential: The three previously 
described hallmarks, all involve the uncoupling of a healthy cell’s natural growth 
program from signals within the environment. Although cells can provide themselves 
with growth signals and evade apoptosis, studies have indicated that this is not 
always sufficient enough to ensure expansive tumour growth. Cells managing to 
evade apoptosis still require the ability of limitless replicative potential, allowing them 
to continually divide above the usual 60-70 doublings seen in various normal human 
cell types. In healthy cells chromosomal telomeres, comprised of some thousands of 
repeats of 6 base pairs (bp) sequence elements become 50-100bp shorter upon each 
cell division, thus allowing the counting of cell generations to be possible. The loss of 
telomeric DNA from the ends of the chromosome at each cell cycle replication is due 
to the inability of DNA polymerases to fully replicate the 3’ ends of chromosomal DNA 
during the S phase of the cell cycle [112]. Over the course of successive replication 
cycles, the erosion of telomeres ultimately causes them to lose their ability to protect 
the ends of the chromosomal DNA. Once unprotected, chromosomal ends fuse 
leading to karyotypic disarray associated with crisis, resulting in the death of the 
affected cell [112, 113]. Telomere maintenance is observed in many malignant cells 
[114], the majority of which do so through the upregulation of the telomerase enzyme, 
lengthening the telomeric DNA [115]. Mechanisms causing the upregulation of 
telomerase often revolve around a mutation within the core promotor region of the 
telomerase reverse transcriptase (TERT), which is an essential molecule for the 
catalytic activity of telomerase [116]. These mutations increase TERT transcriptional 
activity by creating de novo consensus binding motifs for E-twenty-six (ETS) 
transcription factors [117], leading to limitless replicative potential.  
 
Cancer Hallmark – Sustained angiogenesis: The nutrients supplied to a tissue 
region are vital to cellular function and survival. Once a tissue is developed, the 
growth of new blood vessels – angiogenesis – is carefully regulated as cells lack the 
intrinsic ability to promote blood vessel growth. In order for a cell mass to progress 
to a larger size, to provide the essential oxygen and nutrients it requires, neoplasia’s 
must develop angiogenic capabilities [118, 119].  
The ability to induce and sustain angiogenesis is discretely acquired during 
tumour development by an “angiogenic switch” from vascular quiescence. Hanahan 
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and Folkman showed three transgenic mouse models acquired angiogenic 
capabilities, activated in mid-stage lesions, before the appearance of full-blown 
tumours [118]. The switch is activated by changing the balance of angiogenesis 
inducers and inhibitors. A common strategy involves altering gene transcription. 
Many tumours are shown to have increased vascular endothelial growth factor 
(VEGF) compared to normal tissue [118, 120, 121]. Another is the downregulation of 
endogenous inhibitors such as thrombospondin-1, which can be caused by a loss of 
p53 function [122], commonly seen in many tumours. Proteolytic enzymes such as 
MMP14 (matrix metalloproteinase-14) are also shown to promote angiogenesis and 
inhibit apoptosis by mediating VEGF in a variety of cornea [123] and breast 
carcinomas [124]. 
Cancer Hallmark – Tissue invasion and metastasis: The complex processes 
of invasion and metastasis enables cancer cells to escape the primary tumour site 
and colonise a new site within the body where, space and nutrients do not initially 
limit the metastasised tumour growth. Extracellular proteins play crucial roles in 
tumour metastasis, degrading the extracellular matrix (ECM) allowing migration and 
invasion to occur. Matrix metalloproteinases (MMPs) are a well-researched family of 
proteins for their roles in tumour metastasis and the acquisition of other cancer 
hallmarks. In oral squamous cell carcinoma, the transcription factor, Snail (SNAI1) 
upregulates MMP2 and MMP9, initiating epithelial-mesenchymal transition (EMT) 
[125]. Epithelial-mesenchymal transition is the process by which epithelial cells lose 
their cell polarity and cell-cell adhesion, achieving cell invasive and migratory 
characteristics. A widely observed cell-to-environment change in cancer involves E-
cadherin, a homotypic cell-to-cell interaction molecule expressed in epithelial cells. 
Coupling between cells via E-cadherin bridges allows the transmission of antigrowth 
signals [126]. Function of E-cadherin is lost in many epithelial cancers by 
mechanisms including the mutational inactivation of E-cadherin genes, 




2.3.2 Osteosarcoma – the disease 
Osteosarcoma (OS) is the most common type of bone cancer and commonly 
arises in children and adolescence. The 5-year survival rate of localised 
osteosarcoma is approximately 80%, however those with metastatic osteosarcoma 
have a significantly lower survival rate. Survival rates in the decade leading to 2009 
have shown little increase, suggesting a need for new treatment options [127, 128]. 
The disease itself is a malignant, abnormal growth of osteoblasts usually originating 
from the metaphysis of long bones and are known to metastasise early on in their 
progression, of which a usual metastatic site is the lungs (pulmonary metastases). 
Lung metastases osteosarcoma patients have poor prognosis, and a 5-year survival 
rate of approximately 30% according to the 2019 study by Huang et al [129] despite 
having surgery and chemotherapy treatments.  
The exact cause of osteosarcoma remains unknown, however defects in pRb 
and p53 genes play key roles in the development of OS. Mutations in pRb gene are 
observed in a high percentage of osteosarcoma and small cell lung carcinomas. In 
patients carrying germline Rb mutations, osteosarcoma is the second most common 
cancer type, with greater than 70% of cases demonstrating a molecular change or 
mutation at the Rb locus [130, 131]. Similarly, p53 plays a variety of different roles 
within the development of OS as p53 regulates the cell cycle, apoptosis and cell 
differentiation [132]. In human patients with Li-Fraumeni syndrome, an autosomal 
dominant hereditary disorder linked to germline mutations of the p53 tumour 
suppressor gene, OS is reported to occur more frequently [133, 134]. It is 
unsurprising that mutations in p53 lead to cellular acquisition of several key cancer 
hallmarks in osteosarcoma, of which mesenchymal stem cells and preosteoblasts 
have been identified as the cellular origin of OS [135, 136]. 
The diagnosis of OS involves radiological investigations including but not 
limited to: x-ray, CT scans and MRI scans. Radiological investigations suggest 91% 
appear in the metaphyseal areas of long bone, of which almost 50% of 
osteosarcomas occur around the knee [137]. After complete history, clinical 
examinations and imaging have been carried out, a biopsy is used to confirm the 
diagnosis and reveal the specific type and grade of the tumour [137]. Open incisional 
biopsies are performed through small incisions and have a major advantage of 
providing adequate quantities of tissue for histopathology, immunohistochemistry 
and genetic studies. However, open biopsies require more time and risk 
contamination of normal tissues during the surgical procedure. Closed method 
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biopsies, particularly percutaneous core needle biopsies have advanced significantly 
to become a safe and accurate method for diagnosing bone tumours. A Jamshidi 
needle is used to take multiple cores from a representative region of the tumour and 
is a less extensive and less time-consuming outpatient procedure, carried out under 
local anaesthesia with minimal soft tissue trauma and less contamination of normal 
tissue by tumour cells [137, 138]. Several research groups support core needle 
biopsies as it provides sufficient sample for diagnosis with minimal complications 
[139-141]. As suggested by the American Joint Committee on Cancer, a 4 grade 
system is used for osteosarcoma, with grades 1 and 2 considered as “low-grade” and 
grades 3 and 4 “high-grade” [142]. This is supported by the World Health 
Organisation which groups the grades into a two tier system (low and high-grade) 
[143]. Low-grade osteosarcoma is considered to be non-metastatic, whereas high-
grade is of a higher risk of metastasis, where chemotherapy tends to be mandatory 
in patients with a high grade diagnosis [144]. 
Current treatments for osteosarcoma include neoadjuvant chemotherapy, 
followed by surgery to remove the primary tumour and any evident metastatic 
disease, followed by further chemotherapy after surgery [145]. The most accepted 
chemotherapeutic for osteosarcoma is methotrexate (at very high doses), a DNA 
synthesis disrupting agent which irreversibly competitively inhibits dihydrofolate 
reductase (DHFR) which catalyses the oxidation of folates (Figure 2.2.). DHFR 
inhibition prevents the production of thymidylate in DNA synthesis, leading to cell 
proliferation arrest and eventually apoptosis or autophagy  [146]. Methotrexate is 
administered with a leucovorin rescue which is an antidote to methotrexate and 
replenishes depleted tetrahydrofolate stores, a mainstay treatment of OS 
chemotherapy [146]. Combinational chemotherapy between MTX and other drugs 
such as doxorubicin are used to improve survival rates compared to MTX alone [147-
149]. Other treatments of OS include non-steroidal anti-inflammatory drugs which are 
widely used to reduce pain and inflammation, but are also toxic to certain cancers 
[150]. Several sarcomas, including osteosarcoma express cyclooxygenase-2 (COX-
2) [151, 152]. Non-steroidal anti-inflammatory drugs significantly inhibit COX-2 at a 







Figure 2.2. Structural similarities between methotrexate and folic acid. 
Methotrexate (left) and folic acid (right). 
 
There is a crucial need for clinical intervention with regards to osteosarcoma 
treatments. The current medical therapy for this disease has seen little change for 
the last 50 years and still relies heavily on the aforementioned chemotherapy-
surgery-chemotherapy strategy [154]. Ignoring the non-selective and invasive nature 
of the current treatment, the need for improved treatment deliveries are required to 
improve patient welfare. Chemotherapy is plagued with side-effects including but not 
limited to: hair loss, nausea, fatigue and anaemia, all of which can contribute to an 
already unpleasant illness. New, more selective means of targeting OS are required 
and in recent years there have been several promising developments such as the 
study carried out by Shan et al (2020) which locally delivered methotrexate and 
alendronate in a controlled manner, using an injectable thermosensitive hydrogel as 
a delivery vehicle [155]. Shan et al observed inhibited tumour growth, as well as a 
reduction in bone destruction and lung metastasis caused by OS using the injectable 
delivery device [155]. The use of a hydrogel to deliver a novel therapeutic treatment 
is advantageous in complex disease such as osteosarcoma and rheumatoid arthritis 
where the drugs commonly required for treatment are often capable of causing 
severe off-target toxicity. By selectively releasing the therapeutic agent in a localised 
manner, the off-target toxicity can be reduced, limiting the side effects of 
chemotherapy as well as damage to healthy tissues around the disease site. 
As described, cancers require a set of characteristics in order to achieve 
immorality, evade apoptosis and invade tissues and therefore the up or down 
regulation of particular cellular components must occur, for example enzyme 
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expressions. Often a tumour overexpresses the matrix metalloproteinase (MMP) 
family of enzymes, to achieve tissue invasion due to their ability to degrade the 
extracellular matrix and involvement in angiogenesis [156-158]. The exploitation of 
overexpressed proteolytic enzymes could pave the way for a new, selective 
therapeutic osteosarcoma treatment using a PCP delivery strategy. The use of a 
PCP, particularly if a chemotherapeutic agent were to be conjugated, would allow for 
a safer delivery route to the tumour site, minimising the risk of off-target toxicity and 
damage to healthy tissues. As previously described in Section 2.2, hydrogels are 
another suitable delivery strategy to target osteosarcoma and could be implanted at 
the time of surgery or injected for in situ network formation to administer therapeutic 
drugs to the tumour site. The advantages of a selective and localised administration 
of a chemotherapeutic drug such as MTX improves the therapeutic index of the 
particular drug, allowing for a higher dose, or prolonged drug administration to be 





2.3.3 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a long-term disease affecting joints, caused by 
an autoimmune disorder, however the exact cause remains unclear. Approximately 
80% of patients carry the epitope of the HLA-DRB1*04 cluster [159]. Rheumatoid 
arthritis usually arises during productive years of adulthood (between 20-40 years of 
age). According to the World Health Organisation, prevalence varies between 0.3 
and 1% and is more common in women and developed countries, and within 10 years 
of onset over 50% of patients are unable to carry out full-time work [160]. Warm, 
swollen and painful joints are amongst the most common symptoms of RA, as well 
as stiffness in joints, particularly after periods of rest. These symptoms are a result 
of inflammation around the joint and over time this inflammation leads to the erosion 
and damaging of the joint surface, for example cartilage degradation [161]. 
Inflammation occurs within the synovial membrane, the innermost part of the joint, 
which is normally a thin layer, a few cells thick [162]. 
Various immune modulators (cytokines and effector cells) as well as signalling 
pathways are involved in the pathophysiology of RA [163]. Pro-inflammatory 
cytokines such as IL-6 and TNF-α are involved in RA pathogenesis, playing dominant 
roles including, B and T cell proliferation, increased MMP and cytokine release [164] 
as well as osteoporosis [165] and cardiovascular disease promotion [166]. Tissue 
degradation is associated with the accumulation of several cell populations within the 
synovial membrane and the formation of a proliferating pannus. These cell 
populations include, macrophages, both T and B lymphocytes and dendritic cells 
[167]. The space where cartilage and pannus meet is occupied predominantly by 
macrophages and fibroblast-like synoviocytes (FLS) which have the potential to 
secrete proteolytic enzymes of which matrix metalloproteinases and cathepsin 
mRNA are expressed from the earliest stages of RA [168]. The FLSs synthesis of 
MMPs triggers the disassembly of type-II collagen (cartilage) networks, leading to the 
alteration of glycosaminoglycan content and water retention directly causing 
biomechanical dysfunction [169]. Endogenous enzyme inhibitors, such as tissue 
inhibitors of metalloproteinases (TIMPs) have failed to reverse the destructive 
cascade and articular cartilage has limited regenerative potential. These ultimately 
lead to the destruction of surface cartilage and the appearance of joint-space 
narrowing [159, 169]. 
Treatment of RA commonly involves the use of disease-modifying anti-
rheumatic drugs (DMARDs) or non-steroidal anti-inflammatory drugs (NSAIDs) either 
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separately or in combination with each other. Of the disease-modifying anti-
rheumatic drugs, methotrexate is the first choice due to its ability to overcome the 
immune cells attacking joints. The prodrug, sulfasalazine is another common choice 
of DMARD used to treat RA. Routine choices of NSAID to be prescribed to treat 
rheumatoid arthritis include ibuprofen and naproxen. Oral medication or injections 
are the most common forms of treatment for RA; however, these are non-selective 
and potentially expose healthy tissue to off-target toxicity, particularly where 
methotrexate is used.  
Rheumatoid arthritis, like osteosarcoma, requires an updated therapeutic 
strategy, to enhance the targeted delivery of treatments. The novel Hydrogel-PCP 
described here, addresses the clinically relevant needs of RA with regards to 
treatment, through the suggestion of a novel system to selectively deliver therapeutic 
treatments in a localised manner to reduce off-target toxicity. Various hydrogel 
therapies for rheumatoid arthritis have been researched [170], particularly hyaluronic 
acid (HA) based hydrogels [171]. Hyaluronic acid is major component of synovial fluid 
and cartilage and has been used to deliver therapeutic treatments, whilst protecting 
cells and anatomical structures against mechanical stress. Kim et al (2011), 
synthesised tyramine modified HA, injectable hydrogels which during crosslinking 
encapsulated the anti-inflammatory drug, dexamethasone [172]. Sustained release 
of dexamethasone was accomplished up to a month after delivery in in vitro and in 
vivo assessments.  
More selective release methods could be applied to treat RA such as the 
exploitation of the overexpressed proteolytic enzymes within the synovial membrane 
to actively release a therapeutic drug from a peptide conjugate. This differs from the 
approaches by researches such as Kim et al, as drug release is dependent upon a 
proteolytic enzyme overexpressed within the disease site and lower levels in healthy 
tissue, limiting the risk of off-target drug release. Similarly, the hydrogel system 
proposed here, could serve structural support network, to alleviate pain caused by 
mechanical stresses within the joint. The selection of a hydrogel base material with 
a similar consistency to cartilage, for example HA or type I collagen with implantable 
delivery applications could be implanted at the site of cartilage degradation to provide 
a supporting structure around the joint to relieve bone erosion [173]. Furthermore, 
the implanted hydrogel may be subject to degradation by cartilage degrading 
enzymes more favourably over cartilage, leading to the indirect protection of 
remaining cartilage within the affected areas.  
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2.3.4 Biomaterial selection for hydrogel network formation 
The selection of a hydrogel base material is reliant on the intended use of the 
hydrogel itself. In terms of OS and RA, a suitable selection would be a hydrogel 
material which mimics the consistency and appearance of connective tissue, given 
that RA treatment is required at the site of cartilage degradation and most 
osteosarcoma tumours occur along the edge of a long bone. Examples of hydrogel 
types, previously discussed (Table 2.1.), demonstrate a selection of hydrogels which 
may be suitable for the creation of the Hydrogel-PCP system. Previous work by 
colleagues within the research group have outlined the use of type I atelocollagen 
and its tuneable characteristics when functionalised with the photo-active molecule 
4-vinylbenzyl chloride (4VBC), making a collagen-based material a suitable 
candidate for the selected biomaterial [52, 174]. Other biomaterials include 
Polyethylene Glycol (PEG) and Hyaluronic Acid (HA), both of which are well 
researched. PEG is an artificial polymer and is thought to be the ‘gold standard’ of 
artificial matrices [175]. An advantage of artificial biopolymers over natural networks 
is the bioactive functionalities, including cell adhesive sequences and growth factors 
which can be implemented into precise densities whilst controlling substrate 
mechanical properties independently [176]. Properties of PEG that make it a 
desirable polymer, for example its intrinsic low-protein adsorption properties, reduced 
inflammatory profile and safe in in vivo conditions, not to mention the variety of 
different crosslinking strategies including both chemical and covalent crosslinking 
[175]. The controllable properties as well as the use of PEG as a drug delivery gel by 
research groups such as Ashley et al (2013) [177] would make PEG a strong 
selection as the biomaterial for the Hydrogel-PCP system, if not for one crucial 
disadvantage, the non-biodegradable nature of PEG [178]. For the design of the 
Hydrogel-PCP system, a biodegradable polymer is required to produce an as 
minimally invasive clinical delivery strategy as possible, if a non-biodegradable 
polymer was used, further surgery to remove the implanted polymer after treatment 
would be required, providing another invasive procedure and an increased risk of 
infection.  
The role of HA and collagen-derived biopolymers in bone regeneration and 
connective tissue, particularly in RA and Osteosarcoma, as well as their naturally 
biodegradable nature makes them ideal candidates as the building block to use in 
the Hydrogel-PCP system.  
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Hyaluronic acid is a biopolymer, synthesised by a class of integral membrane 
proteins called hyaluronan synthases which lengthen HA by adding D-glucuronic acid 
and N-acetyl-D-glucosamine to the polysaccharide backbone [179]. The naturally 
occurring HA is a crucial component of articular cartilage and has been reported to 
have beneficial effects on inflammatory arthritis, although this is biphasic. Roth et al 
(2005) found that HA therapies had anti-inflammatory effects and showed inhibition 
of cartilage degradation in early chronic phases, however in late chronic disease 
stages, HA promoted cartilage damage and joint swelling [180]. This could be 
overlooked depending on the type of drug delivered by the Hydrogel-PCP system, 
however HA also lacks free amino groups, instead containing only free carboxylic 
groups, hydroxyl groups and acetyl groups (Figure 2.3.). 
 
 
Figure 2.3. Structure of hyaluronic acid. Repeating chains of D-glucuronic acid 
and N-acetyl-D-glucosamine containing free carboxylic groups (-COOH), 
hydroxyl groups (-OH) and acetyl (-CH3CO) groups. 
 
Due to the nature of the peptide-conjugated prodrug synthesised here, the C-
terminal is free to react with a free amino group on the selected biopolymer backbone. 
In HA a linker would be required to conjugate the PCP, which could significantly alter 
the rate of drug cleavage by the chosen proteolytic target enzyme. For this reason, 
combine with the biphasic treatment of HA in inflammatory arthritis, HA was deemed 
unsuitable for use as the backbone biomaterial in the Hydrogel-PCP system. 
Collagen is one of the most abundant proteins within the human body and 
due to the unique molecular organisation, it is a commonly used material for 
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regenerative medicine [181] and wound healing [182]. The collagen superfamily 
contains 28 members and have a common structural feature, a triple helix which 
ranges from most of the structure (approximately 96% in type I collagen) to less than 
10% of the structure (collagen XII) [183]. The triple helix consists of three polypeptide 
chains, known as α chains which can be identical to form homotrimers (collagen II – 
[α1(II)]3) or different to form heterotrimers (collagen IX – [α1(IX), α2(IX), α3(IX)]). 
Sequences of the triple helices are comprised of Gly-X-Y repeats, X and Y frequently 
being proline and 4-hydroxyproline, respectively. The most abundant collagens are 
the fibrillar types (I, II, III, V and XI) and their extensive cross-linking capabilities 
provide mechanical strength that is needed for high stress tissue such as cartilage, 
bone and skin [184]. The mechanical properties of fibril-forming collagens are 
dependent on their cross-linking which can include 1) disulphide bonds (type III for 
example); 2) the Nε(γ-glutamyl) lysine isopeptide [185]; 3) reducible, mature cross-
links by the lysyl oxidase pathway and 4) advanced glycation end products [183, 186]. 
Lysyl-mediated crosslinking takes place at the intra- and intermolecular levels 
between collagen molecules and involves lysine, hydroxylysine and histidine 
residues belonging to either the same or different types of collagens [187]. 
Crosslinking of collagen is tissue-specific as opposed to type-specific, however 
collagen can be functionalised or crosslinked artificially to form a hydrogel with unique 
characteristics. 
Aside from being able to absorb large amounts of water and exudate as well 
as resist mechanical pressures, collagen hydrogels are enzymatically degradable by 
MMP activity, a family of enzymes overexpressed in OS and RA. The partially 
hydrolysed form of collagen, gelatin also makes a suitable selection for use as a 
hydrogel base material, of which photo-activated gelatin methacryloyl hydrogels have 
been used in the tissue engineering of cartilage constructs [188]. Due to being 
degraded collagen, gelatin can vary in molecular size significantly, characterised by 
the “bloom”. Generally, a high bloom gelatin is between 225-300g (molecular mass 
ranging between 50,000 and 100,000 Da), and consists of longer polypeptide chains, 
most similar to collagen. Gelatin is also capable of reforming the triple helix structure 
of collagen in a reversible manner when chilled or heated (above 37°C), allowing the 
gelatin biopolymer to auto-crosslink at room temperature through non-covalent 




Figure 2.4. Degradation of the collagen triple helix structure to form gelatin 
strands which when chilled are capable of reforming the triple helical structure 
through non-covalent crosslinking. 
 
The delicate nature of the novel study proposed here, requires a thorough 
understanding of the selected base material, which the research group has expertise 
in , e.g. with respect to the design of collagen and collagen-derived materials, holding 
the patent for collagen-derived 4VBC functionalised biopolymers [189]. This 
expertise will prove invaluable in the hypothesis that both collagen and high bloom 
gelatin would be ideal materials to use as a hydrogel base layer in OS and RA 
targeting, due to the degree of tuning and versatility through a variety of applications 
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[53, 190, 191] as well as the biodegradability due to enzymatic breakdown [192]. The 
PCP coupling to collagen or gelatin is also made simple by the repeating chains of 
amino acids within the biomaterials, particularly free amino lysine groups [193, 194]. 
The free amino lysine groups make ideal targets for peptide conjugation to the tail 
end of the PCP due to a free carboxylic group which can be activated using a 
carbodiimide reaction. 
The readily available nature of gelatin and the similarities it shares with 
collagen, makes both collagen and gelatin suitable choices to be used initially, with 
one to be excluded, should it become no longer viable as a hydrogel material for the 
Hydrogel-PCP system.  
 
2.3.5 Proteolytic enzyme targeting for drug release 
Many disease pathologies require changes in the regulation of inter and 
extracellular contributors such as cytokines and proteolytic enzymes, in order to drive 
the disease forward [195, 196]. Enzymes play major roles in several biological 
processes, in particular cell multiplication, collagen synthesis and turnover, wound 
repair and the removal of dead tissue debris following inflammation and digestion 
[197-199]. A family of proteins, known as proteolytic enzymes, lyse chains of proteins 
to carry out a range of functions. The super family can be further divided into 
exopeptidases, which target protein termini and endopeptidases which target sites 
within a protein [200]. For the nature of this study exopeptidases cannot be targeted 
due to each end of the peptide-conjugate being occupied, either by drug or hydrogel 
biomaterial, endopeptidases however, can be targeted for drug release. 
Endopeptidases account for various catalytic mechanisms, and within this group are 
endopeptidases such as: cysteine proteases, serine proteases, metalloproteases 
and more [201-203]. Each group of proteolytic enzymes contribute to a range of 
biological processes. In order for the Hydrogel-PCP system to be fully biodegradable 
the hydrogel itself, made of collagen or gelatin, must be accessible to collagenase 
and gelatinase proteolytic enzymes and as a result targeting one of these enzymes 
for drug release would be a suitable selection, if they are overexpressed in the target 
diseases. Of these proteolytic enzymes there are two families, metalloproteinases 
[204] and selected papain-like cysteine proteases [205], which are able to cleave the 
triple helical region of fibril-forming collagen, causing the unwinding and degradation 
of the collagen structure. Of these cysteine proteases cathepsins K and L are known 
to attack the triple helix of fibril-forming collagen [206]. Both Cathepsin K and L are 
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overexpressed in RA [207], where cathepsin K is linked to radiological destruction 
[208] and is overexpressed in some saos-2 osteosarcoma cells [209]. 
Peptide-conjugated prodrugs can release the active drugs through non-
selective degradation by several proteolytic enzymes, or through selective cleavage 
by one specific enzyme. The selective method of drug release involves the protected 
end of the peptide chain through the use of an endcap, whilst the middle section of 
the peptide chain is a specific and recognisable sequence to the particular target 
enzyme for cleavage and the initiation of drug release. In order to begin tailoring a 
peptide sequence specific to the recognition site of the targeted proteolytic enzyme, 
the enzyme must be selected. Overexpressed proteolytic enzymes within the 
targeted disease serve as a significant starting point for the selection of the enzyme. 
Ideally it is most suitable that the intended target enzyme is overexpressed in disease 
tissue but not the healthy surrounding tissue. As outlined, MMPs appear to be 
overexpressed in both osteosarcoma and rheumatoid arthritis, as well as possessing 
collagenase and gelatinase activity, therefore MMPs would make an ideal family of 
enzymes to select the target enzyme from.  
Matrix Metalloproteinases (MMPs) are a family of calcium-dependant zinc-
containing endopeptidases and are involved in the degradation of extracellular matrix 
(ECM) proteins [210, 211]. Due to their wide range of activity across a vast range of 
biological processes including: angiogenesis [212], wound healing [211], collagen 
turnover in development [213] and innate immune responses [214], it is unsurprising 


















Figure 2.5. Expression of MMP mRNA in human cell lines. Modified from the 
2010 study by Atkinson et al. MT-MMPs are elevated in human preclinical 
tumour models. Expression of MMP mRNA in human cell lines grown in 
vitro (A) and as xenografts in vivo (B) as measured by quantitative RT-PCR. 
Expression values after normalization to 18S-rRNA and are gene specific. 
Classification of expression levels was determined from the CT of each gene 
as either very high (CT ≤ 25), high (CT = 26-30), moderate (CT = 31-35), low (CT = 
36-39), or not detected (CT = 40); see key for colour scheme. (C) Immunoblot 
of MT1-MMP protein expression in HT1080 and MCF7 tumour models [103]. 
 
The MMP family can be further divided into two, secreted and membrane 
bound, however they are also often divided based on their substrate specificity and 
basic domain structure, for example collagenases, gelatinases and membrane type-
MMPS (MT-MMPs). Many MMPs are activated from their pro- state allowing their 
proteolytic activity to proceed. The membrane type 1-MMP (MT1-MMP) also known 








MMP14 is activated intracellularly by the Golgi apparatus and once activated at the 
cell surface, pro-MMP2 and pro-MMP13 are activated [215]. The MMPs which 
MMP14 activates, namely MMP2 and MMP13, have been demonstrated to play 
crucial roles in several diseases including cancer and rheumatoid arthritis [215-219]. 
Due to the crucial role played in activating key cancer and RA disease progression 
MMPs, MMP14 is an ideal target for the cleavage of the PCP peptide sequence. 
Furthermore, the expression and involvement of MMP14 within RA and OS makes it 
a key driver in the pathogenesis of both diseases, rather than solely an activator of 
disease-progressing enzymes [220-222]. In rheumatoid arthritis MMP14 has been 
identified as the key collagenolytic enzyme for invasion into the matrix from synovial 
cells [222] and is also linked to the degradation of other matrix components in 
cartilage such as aggrecan [223].  
In osteosarcoma cell lines, Kajita et al (2001) demonstrated the promotion of 
cell migration regulated by MMP14 by cleaving CD44H and releasing it from the cell 
surface in MG-63 cells, triggering and enhancing cell motility. Expression of only 
MMP14 or CD44H on the cell surface demonstrated no improved cell motility, 
suggesting MMP14 increases cell migration through the processing of CD44H [224]. 
Another tumour promoting role that MMP14 is involved, is tumour angiogenesis. 
Down regulation of MMP14 has shown the inhibition of angiogenesis by interfering 
with α2β1 receptor activity, negatively impacting osteosarcoma progression [225, 
226]. Osteosarcoma tissues expressing high MMP14 levels are found interact with 
collagen alpha-2 (I) encoded by the COL1A2 gene [227]. Gene expression levels 
between osteosarcoma and normal bone tissue revealed MMP14 as one of the most 
significantly upregulated genes [228]. 
The involvement of MMP14 in both osteosarcoma and rheumatoid arthritis 
makes it a suitable target for sequencing a peptide-drug conjugate for the selective 
release of the chosen active drug. Involvement aside, the selection of a suitable 
proteolytic enzyme still requires a long and careful process to ensure the optimal 
targeting sequence is selected. As a result, MMP14 provides a further indication that 
it would make a suitable target enzyme, as we have previously targeted MMP14 for 
the release of the previously discussed chemotherapeutic drug, methotrexate [21], 
working alongside the research group behind the vascular disrupting agent PCP, 
ICT2588 [103, 229]. The process of honing a peptide sequence suitable to a target 
enzyme is a long process, of which the recognition can be significantly altered as a 
result of a minor change in the sequence. Therefore, due to the pivotal roles played 
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in both OS and RA, combined with the previous work, carried out with colleagues 
from the University of Bradford, UK, providing a starting sequence for our Hydrogel-
PCP system, MMP14 makes an ideal enzyme to target for the selective and localised 
release of a chosen drug from a hydrogel support structure.  
 
2.3.6 Selection of an active drug to release from a Hydrogel-PCP system 
To treat a disease such as rheumatoid arthritis (RA) or osteosarcoma, a 
therapeutic agent is often required. There are a variety of drugs that could be selected 
to treat either of these diseases including, methotrexate (MTX) which is a well-known 
and researched drug for the treatment of both diseases. At first glance, MTX appears 
an ideal candidate for the selection of a therapeutic, particularly due to MTX 
containing, free, natural carboxylic acid groups (-COOH). The advantage of a free 
carboxylic group on a drug removes the need to use a linker compound when 
coupling the drug to a peptide-conjugate, which may cause unintended reductions in 
enzyme targeting and cleavage. Methotrexate however, contains two free carboxylic 
groups, which may cause complications when conjugating the MTX-prodrugs to a 
hydrogel, as the side-chain free carboxylic group in MTX’s structure may conjugate 
rather than the desired alpha -COOH. 
The nature of the novel system, proposed here relies on research from two 
scientific fields, which if successful opens up a new therapeutic direction for a variety 
of diseases. With this in mind, methotrexate, although a renowned first line treatment 
for both OS and RA, may not be the most suitable selection to prove such a delicate 
concept. Furthermore, the theory of using a peptide-conjugated prodrug delivery 
system is that, any disease overexpressing a proteolytic enzyme can be targeted to 
release the selected drug, once a selective sequence is established for the particular 
proteolytic enzyme. This can be achieved by adjusting the peptide-conjugate 
sequence to suit the binding site of the target enzyme.  As a result, the selection of a 
drug, is not intended to be a drug specific to a particular disease (but should still show 
significant evidence for treatment of both OS and RA), rather, one that is applicable 
to several diseases, such as a non-steroidal anti-inflammatory drug (NSAIDs) for 
example naproxen (NAP) [230, 231]. Inflammation plays a key role in a wide range 
of diseases, of which both acute and chronic inflammation have been linked to many 
different diseases [232]. Therefore, the use of NSAIDs in the design of a peptide-
conjugated prodrug hydrogel delivery system enables its’ usage across a broad 
spectrum of diseases and conditions, that are not solely limited to RA and 
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osteosarcoma. Furthermore, from a toxicological perspective, the links between 
NSAIDs and the occurrence of peptic ulcers leave room for the alternative delivery of 
NSAIDs to reduce the risk of off-target toxicity [233, 234]. 
There is growing evidence for the use of NSAIDs in the treatment of several 
cancers [235-237]. The majority of NSAIDs work through the inhibition of 
cyclooxygenase (COX), a key biological mediator in processes such as inflammation 
and cancer progression [238] and research has shown the overexpression of COX-
2 in the progression of RA and OS [239, 240]. There are several viable choices of 
NSAIDs to apply to the Hydrogel-PCP system such as ibuprofen, aspirin and 
naproxen, all of which possess a free -COOH group (Figure 2.6.). Naproxen, a 
commonly used NSAID for the treatment of RA is a longer acting drug than ibuprofen 
and aspirin and has been shown to have therapeutic effects for RA treatment when 
other NSAIDs have proven in-effective [241]. In terms of osteosarcoma, naproxen is 
proven by Correia et al, to have a dose-dependent therapeutic effect [242]. Correia 
and colleagues found naproxen blocked cell proliferation in MG-63 osteosarcoma cell 
lines as well as elevated levels of autophagosomes in cells treated with naproxen. 
An increase in apoptotic cells was also found suggesting the mechanism of action of 
the drug is through autophagy [242] which is in line with cells treated with another 
NSAID, meloxicam [243]. 
 
 
Figure 2.6. Chemical structure of naproxen, ibuprofen and aspirin. Possible 
non-steroidal anti-inflammatory drugs (NSAIDs) to use as the drug warhead in 
the peptide-conjugated prodrug design, due to the single carboxylic acid group 
each possess.  
 
Due to the longer lasting effects and the therapeutic effects upon both RA and 
OS, naproxen was selected to be the active drug warhead for the Hydrogel-PCP 
system. The non-selective effect naproxen possesses makes it an ideal option to 
make more selective and reduce the risk of gastric ulcers by providing an alternative 
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delivery route and making the release selective to further reduce any unwanted 
toxicity. Furthermore, the suggested drug release strategy could be made applicable 
to several other diseases, making the selection of a NSAID an ideal choice due to 




2.4 Hydrogel-PCP design and clinical application 
Therapeutic agents, particularly those with cytotoxic effects often require 
alterations to administer them more safely, whether this be through antibody drug 
conjugation [244], peptide drug conjugation [245] or the use of a delivery vehicle such 
as hydrogels [246] or micelles [247]. By combining two of these drug delivery 
methods the therapeutic index of the delivered agent could be further increased. The 
use of PCPs, coupled to hydrogels, forms a unique delivery system, which in a 
localised and selective manner releases a therapeutic drug, whilst providing 
structural support to a variety of tissues, depending on the hydrogel design. The 
release of the active drug from the anchored PCP, exploits the overexpression of the 
targeted proteolytic enzymes in the diseases selected to focus the design of the 
therapeutic system around, osteosarcoma and rheumatoid arthritis.  
 
2.4.1 Study design 
The proof of concept study centres around the design of a novel Hydrogel-
PCP, of which each system component is tailored to the intended disease targets, 
RA and OS, whilst maintaining the applicability to other diseases exhibiting 
inflammatory symptoms. Outlined in this sub chapter, is the design of the carefully 
constructed Hydrogel-PCP therapeutic system.  
The selected drug, naproxen is coupled to a peptide-conjugate, via its’ free -
COOH group to form a PCP. The peptide-conjugate is made up of a sequence of 8-
12 amino acids with a glycine-homophenylalanine (Hof-Gly) bond towards the centre 
of the sequence which is the site cleavable by MMP14, as previously shown by Gill 
et al [229]. Each of the remaining 6-10 amino acids are carefully selected to either 
aid MMP14 recognition or to freely dissociate once cleavage of the peptide-conjugate 
occurs and the amino acid ends become deprotected. Ordinarily, the PCP would 
possess an endcap, however the conjugation of the conjugate-tail to the collagen or 
gelatin hydrogel backbone, enables the hydrogel itself to serve as an endcap to the 
PCP component. The tuneable hydrogel system component provides structural 
support within RA, with an implantable device to take on the consistency of cartilage 
and in OS, the ability to withstand mechanical stress from cancerous effects such as 
inflammation and increased tumour mass [248, 249]. Therefore, the Hydrogel-PCP 
system is made up of naproxen, conjugated to a peptide-conjugate selective towards 
MMP14, coupled to a biopolymer material (collagen or gelatin), prior to induced 
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network formation and crosslinking to synthesise a hydrogel-naproxen PCP (Figure 
2.7.). 
 
Figure 2.7. The hydrogel-naproxen PCP system. Designed to be selectively 
cleaved, at the Hof-Gly peptide bond, by MMP14 to trigger the release of 
naproxen from the PCP component. Naproxen-PCP (NAPPCP), conjugated to 
free amino lysine groups of a collagen-based biopolymer is crosslinked to form 
a Hydrogel-NAPPCP. 
 
2.4.2 Clinical significance 
The outlined proof of concept study, suggests the local and selective release 
of an active therapeutic drug from a tissue scaffold support network anchored at the 
disease site. The verdict of whether to use a localised drug delivery treatment should 
be based upon clinical findings and therapeutic responses recorded in literature 
[250]. However, a proof of concept study, lacks concrete therapeutic evidence that 
the delivery system is suitable for the clinical application and therefore must use 
related literature and assess whether the desired end product is considered to be a 
clinically more desirable delivery method than current clinical options.  
Naproxen as a drug is widely shown to have therapeutic effects across a 
variety of diseases including RA and OS as previously discussed [251]. Considering 
the link between NSAIDs and peptic ulcers due to their inhibition of the COX-2 
isoform [252, 253], of which naproxen is considered to be a higher risk NSAID for 
causing peptic ulceration [234]. The undesirable toxic side effect of naproxen could 
be avoided through the use of a naproxen-based PCP. The proposed MMP14 
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targeting PCP strategy has shown promising results, albeit using an alternative drug 
warhead, demonstrating no increase in von Willebrand’s factor (vWf), a clinical 
marker of cardiotoxicity, compared to the selected drug alone, when using the PCP 
component [229]. As discussed in Chapter 2.2, drug-loaded hydrogels have exhibited 
low signs of off-target toxicity when targeting cancers. The loading of a drug to a 
hydrogel is less secure than the physical conjugation to the hydrogel itself, 
demonstrating a further safety measure employed in the Hydrogel-PCP system 
proposed here.  
Naproxen is a strong candidate for the treatment due to the reduced risk of 
thromboembolic cardiovascular events in RA and anti-tumour effects in OS, on top 
of the anti-inflammatory properties naproxen is normally used for [242, 254, 255]. 
Containing a single -COOH group, allows for straightforward coupling of naproxen to 
a peptide conjugate, temporarily disabling naproxen, allowing safer delivery to a 
disease site. The use of a naproxen-based Hydrogel-PCP system to target RA and 
OS provides a novel therapeutic strategy that if successful, could be simply adapted 
to target any disease overexpressing MMP14, using any drug that could be 
substituted for naproxen, such as methotrexate or ibuprofen.  
The alternative delivery route for naproxen combined with the reduced toxicity 
shown in the use of a PCP, as well as the structural support a hydrogel provides, 
suggests a strong argument for enhanced clinical relevance compared to current 
measures used. Delivery of the Hydrogel-PCP system relies upon one of two 
strategies to be investigated here: firstly, the surgical implantation of a readily formed 
Hydrogel-PCP system to administer therapeutic effects to the target disease and the 
surgical wound and secondly, an injectable system which undergoes in situ 
crosslinking to form a Hydrogel-PCP system within the disease area, bypassing the 



















3.0 Photo-activated biopolymer hydrogels. 
The purpose of this chapter is to investigate the formation of UV cured, 
collagen-based Hydrogel-PCP systems. Initial functionalisation of free amino lysine 
groups of collagen-based biopolymers with the photo-active molecule 4-vinylbenzyl 
chloride (4VBC) is carried out. Collagen-based materials, both native and 
functionalised undergo EDC/NHS-induced conjugation of a model drug, sulfasalazine 
(and later the synthesised naproxen peptide-conjugated prodrug). All 
functionalisation of biopolymers is assessed using a TNBS and/or a ninhydrin 
colorimetric assay.  
Two UV-induced crosslinking strategies are carried out to form 
photopolymerised collagen-based drug-conjugated hydrogel networks:  
• Dual functionalised collagen-based materials with 4VBC and drug 
• Encapsulation of a drug-conjugated collagen sample within a 4VBC-
functionalised collagen sample. 
Analysis of drug release by MMP14 selective cleavage was carried out by High 
Performance Liquid Chromatography (HPLC). 
 
3.1 Introduction 
 A wide variety of hydrogel materials and crosslinking methods are already 
well established and provide a broad range of unique characteristics, allowing them 
to be used for many different applications [47, 256, 257] whether that be magnetic 
hydrogels or releasing a substance in response to pH change, for instance. Ultraviolet 
free radical crosslinking is just one example of a well-established crosslinking 
strategy. Chemical crosslinking is another well-established strategy which can induce 
network formation in a variety of materials including gelatin biopolymers [258, 259]. 
Development of these hydrogel systems has begun to branch out into other 
scientific fields to produce selective drug delivery vehicles, whether that be in 
response to an external stimulus or through other means such as enzymatic activity. 
Examples of these hydrogel systems include, but are not limited to: 
hydrogel/micelles, so-called ‘nanogels’, thermo-responsive and magnetic hydrogels 
[260, 261]. The selectivity of these systems has demonstrated a reduction in 
associated drug-toxicity and has begun to overcome other complications associated 
with hydrogel-drug delivery facets, including solubility issues. Photo-crosslinking is a 
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thoroughly researched method enabling gel network formation, so that visible light 
can now be used to induce in situ gel formation, further improving the clinical 
relevance of this method in local applications [262]. The application of UV-cured gel 
networks for drug delivery has been extensively researched to provide a localised 
release of drugs from the network gels [263], limiting the need for alternative, 
potentially more toxic means of drug delivery. Highly selective release strategies 
have been investigated in UV-cured hydrogel systems, for example, the glucose-
sensitive release of metronidazole by the widening of hydrogel pores to control drug 
release [264].  
Previous research into the establishment of collagen and collagen-derived 
UV-cured hydrogel systems with the photo-active molecule 4-vinylbenzyl chloride 
(4VBC) [52, 174] has provided sufficient evidence to suggest it for the use as a 
selective and localised drug delivery vehicle. The programmable macroscopic 
properties, which can be obtained through 4VBC UV-crosslinking, have shown the 
formation of biocompatible collagen systems leading to a variety of unique hydrogel 
characteristics based on the degree of functionalisation of the collagen biopolymer 
[52, 265]. The strong platform of a tuneable, UV-curable hydrogel that is capable of 
taking on the consistency of connective tissue could be further strengthened by the 
addition of another novel unit, an MMP14 responsive peptide-conjugated prodrug, to 
accomplish localised, MMP responsive and highly selective drug release from the gel 
network in diseases such as rheumatoid arthritis and osteosarcoma. Peptide-
conjugated prodrugs (PCPs) allow for a selective release in diseased tissues by the 
cleavage of the peptide-conjugate through the activity of a specific overexpressed 
proteolytic enzyme [229, 266]. 
Selectivity in drug release plays a key role in the reduction of off-target toxicity 
[267]. Cancer is an example of a disease where the reduction of off-target toxicity is 
vital. Chemotherapies are extremely effective in killing cancerous cells; however, the 
crucial drawback is that chemotherapies are also lethal to healthy tissue, causing a 
reduction in the amount of therapeutic drug which can be administered. Selective 
methods of delivering therapeutic alternatives to traditional chemotherapy, such as 
the peptide drug-conjugates, nanoparticles and immunotherapy have become focus 
points in recent years due to their ability to reduce off-target toxicity and increase the 
therapeutic index of a particular treatment [103, 268], allowing for a greater dose to 
be administered before unacceptable levels of off-target toxicity are reached. These 
selective methods still require the successful delivery and anchoring or containment 
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within a disease site, which can pose challenges. An example of this could be seen 
in osteosarcoma, a disease that often effects children and adolescents where 
collagen turnover is accelerated to keep up with the demand of bone development. 
In the study by Sartorio et al, the levels of bone Gla protein (BGP), a marker of 
osteoblast function, for healthy children were over 3 times that of healthy adults [269], 
demonstrating increased bone development. The selected target enzyme, Matrix 
metalloproteinase-14 plays a key role in collagen turnover and is overexpressed in 
healthy tissues during bone development [270-272] making it vital that the risk of off-
target drug activation is minimised when using an MMP14 selective release strategy. 
Using a hydrogel drug delivery strategy as proposed here, could anchor the prodrug 
in place at the disease site allowing for overexpressed MMP14 within the disease site 
to release the therapeutic drug, minimising contact with healthy MMP14 expressing 
tissues, that would occur if the Naproxen Peptide-Conjugated Prodrug (NAPPCP) 
was administered intravenously. It is therefore crucial to synthesis a hydrogel 
network, capable of supporting drug coupling or loading for long enough to 
successfully implant or deliver the hydrogel at the disease site. 
 
The work described in this chapter investigates the potential of synthesising 
a UV crosslinked 4VBC-functionalised collagen or gelatin biopolymer network, 
conjugated with a naproxen-PCP, as well as the assessment of the selective release 
capabilities by MMP14 cleavage. This novel approach aims to link two evolving 
scientific fields, which have the potential to vastly accelerate one another, to form 






3.2 Materials  
All materials used that would not commonly be found in laboratories are 
listed below (Table 3.1.) with supplier information. All specialist equipment used is 
also detailed with supplier information (Table 3.2.).  
 
Table 3.1. Materials and reagents used. 










Novabiochem 856066 N/A 









































1001606014 9002-92-0 100ml 

























D/3840/17 68-12-2 2.5l 




20821.365 64-17-5 5l 




























Gelatin, Type A 
MP 
Biomedicals 





2611.5000 7647-01-0 5l 
Synthetic bone Sawbone 1522-05 N/A 40PCF 
Matrix 
Metalloproteinase 14 
























Alfa Aesar A10312 6066-82-6 100g 
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101085663 110-89-4 1l 
Rhodamine B Alfa Aesar A13572 81-88-9 50g 
Sodium Bicarbonate Alfa Aesar A170005 144-55-8 500g 








101513370 121-44-8 1l 




101650254 6485-79-6 50g 
Tris/HCl, 1M solution, 
pH 7.5 







663684B 9005-64-5 500ml 










Table 3.2. Equipment information. 



















2695 Separation Module 
996 PDA Detector 
Micromass ZQ Mass Detector 





OD Plate Reader 
Thermo 
Scientific 
3001 Varioskan Flash 









Spectrophotometer Jenway 6305  
Unstirred Water Bath Clifton N/A Heats up to 100°C 
UV Lamp Spectroline CM-10 












3.3.1 Functionalisation of biopolymer’s lysine amine groups with 4-vinylbenzyl 
chloride 
Gelatin – High strength gelatin (~250g BLOOM) was dissolved in 10% w/v 
PBS solution for 2 hours at 60⁰C. 1% v/v of Tween20 was added to the mixture, 
followed by triethylamine and finally 4-vinylbenzyl chloride at the desired molar 
excess and left to stir for 6-8 hours at 40⁰C. For example, to functionalise 10g gelatin 
with a 25 molar excess of 4VBC: 10g gelatin is dissolved in 100 ml PBS and left to 
stir at 60⁰C for 2 hours. Once full dissolved 1 ml (1% v/v) Tween20 is added to the 
solution, followed by 8.822 ml TEA and 8.914 ml 4VBC (calculated using the following 
equation, with a 25 molar excess) and left to stir at 40⁰C for 6-8 hours.  
 
𝐵𝑖𝑜𝑝𝑜𝑙𝑦𝑚𝑒𝑟(𝑔) × 𝑚𝑜𝑙(𝐿𝑦𝑠) × 𝑀𝑜𝑙𝑎𝑟𝐸𝑥𝑐𝑒𝑠𝑠 = 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 
(𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 × 𝑀𝑊)
𝐷𝑒𝑛𝑠𝑖𝑡𝑦
= 𝑉𝑜𝑙𝑢𝑚𝑒 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 (𝑚𝑙) 
where MW is the molecular weight. 
The reaction solution was then precipitated in ethanol (up to 10-fold volume 
excess of the reaction mixture) for 5 hours, before being drained and placed in an 
incubator to dry. 
Atelocollagen – Pepsin-extracted type I bovine atelocollagen (AC, 6 mg/ml) 
was diluted to 3 mg/ml with 10mM HCl, followed by neutralisation to a pH of 7.4. 
Tween20 (at 1% v/v), triethylamine and 4-vinylbenzyl chloride were added using the 
above equation as demonstrated in gelatin, and left to stir for 24 hours at room 
temperature. Following this, the reaction solution was precipitated by stirring in up to 
a 10-fold volume excess of ethanol for 24 hours before being centrifuged at 11,000 
rpm for 45 minutes, after which the biopolymer was collected and dried at room 
temperature. 
The dry substances were stored at room temperature prior to quantification 




3.3.2 Determination of free amino groups occupied after functionalisation 
Two colorimetric assays, TNBS and ninhydrin [273, 274], commonly used for 
the determination of amino groups in proteins were employed to assess the degree 
of functionalisation of AC. Both TNBS and ninhydrin have recently both exhibited 
correlations with 1H-NMR spectroscopy when carried out to assess the 
characterisation of reacted collagen-based [275]. Therefore, the selection of TNBS 
and ninhydrin assays was made to determine the molar content of free lysine groups 
in both native and reacted pepsin-solubilised AC samples, allowing the indirect 
quantification of F to be calculated.  
 
3.3.2.1 Trinitrobenzenesulfonic acid assay 
Determination of occupied free amino lysine groups (degree of 
functionalisation, F) of collagen or gelatin, after coupling of 4VBC was carried out 
using a Trinitrobenzenesulfonic (TNBS) colorimetric assay as per [273]. Briefly, 11 
mg reaction sample was placed into vials before adding 1 ml 4% NaHCO3 and 1 ml 
0.5% of TNBS solution. Blank control vials initially contained 1 ml of 4% NaHCO3 and 
3 ml HCL (6M).  
Samples were incubated at 40⁰C, under shaking for 4 hours, prior to 3 ml HCL 
being added to the reaction vials and 1 ml of 0.5% TNBS solution added to the blank 
control before shaking at 60°C for a further hour. All vials were then left to cool at 
room temperature before the addition of 5 ml water to each vial. Unreacted TNBS 
was removed with diethyl ether (3 x 20 ml washes). Next, 5 ml of aqueous phase was 
aliquoted out and heated for 15 minutes to remove any remaining diethyl ether. 
Finally, 15 ml water was added, before the absorbance was measured at 346nm, and 




2 ×  𝐴346 × 0.02
(1.46 ×  104)  ×  𝑏 ×  𝑥
 




where A346 is the absorbance at 346nm, 0.02 is the volume (in litres) of the final 
sample solution, 1.46x10-4 equates to the molar absorption coefficient for 2,4,6-
triniitrophenol lysine (M-1cm-1), b is the path length (1 cm) and the sample weight (g) 
is defined as x. 
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3.3.2.2 Ninhydrin assay  
Further confirmation of the number of functionalised free amino groups, and 
degree of functionalisation, was accomplished using a ninhydrin assay [274, 275], 
which was also used to assess the extent of drug conjugation, as the drug was 
expected to be coupled to the remaining free lysine groups after 4VBC 
functionalisation. 
First, a calibration curve was established by preparing a molar range between 
0 and 5x10-06 mol·g−1, derived from a glycine stock solution, before being made up to 
4 ml with water. An 8% w/v ninhydrin solution was prepared in DMSO and 1 ml of 
ninhydrin solution was added to each sample vial, giving a total of 5 ml per vial. 
Samples were reacted at 95 ⁰C for 15 minutes, before being cooled on ice and 1 ml 
of ethanol added to halt the reaction. The addition of ethanol made a total dilution of 
6-fold for each sample. The absorbance was measured at 570nm and plotted against 
the glycine molar content.  
The linear region of the calibration curve (Figure 3.1.), ranging between 
2.0x10-06 and 4.5x10-06 mol·g−1 was used to accurately determine the occupation of 
free amino lysine groups, providing an accurate measurement within the linear 




Figure 3.1. Ninhydrin calibration curve. Isolated linear region of a ninhydrin 
assay calibration curve, demonstrating the region at which the quantity of free 
amino groups can be accurately determined with in a biopolymer. 
 
Functionalised samples were prepared as described; however, 10 mg of 
sample was weighed out and 4 ml water added prior to the addition of 1 ml ninhydrin 
solution, before following the protocol and plotting the absorbance onto the calibration 
curve to determine the degree of functionalisation between samples.  
 
3.3.3 Drug conjugation via 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride/N-hydroxysuccinimide reaction 
The EDC/NHS activation of drug carboxylic groups was carried out with 
varying molar ratios with respect to the free lysine mol·g−1 of the biopolymer the drug 
was conjugated to, similar to the method of 4VBC functionalisation (Chapter 3.3.1). 
Initial conjugation reactions were carried out with sulfasalazine (SSZ), a readily 
available drug compound with a single carboxylic acid group, prior to the conjugation 
y = (4x106)x - 7.8358 
R2 = 0.9991 
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with naproxen and naproxen peptide-conjugated prodrugs, which were less readily 
available (Figure 3.2.).  
 
 
Figure 3.2. Structural differences between study drugs. Sulfasalazine (red), 
naproxen (blue) and the naproxen peptide-conjugated prodrug (NAPPCP). 
 
Drugs were dissolved in minimal DMSO, before the addition of EDC and NHS 
to the solution, and left to react for 1 hour at room temperature (Figure 3.3.). The 
volume of DMSO required to dissolve the drug is not sufficient to significantly 
negatively impact the coupling reaction, after which the coupled biopolymer is dried 
and washed, removing the DMSO used to initially dissolve the drug. Following this 
reaction, 2-Mercaptoethanol (BME) was added and reacted for 15 minutes to quench 
any unreacted EDC, before adding the activated drug solution to a dissolved solution 
of biopolymer and left to react at the conditions required to dissolve the respective 
biopolymer. Once reacted, gelatin drug-conjugated biopolymers were precipitated for 
5 hours in a 10-fold volume excess of ethanol, collected and then air dried. 
Atelocollagen drug-conjugated biopolymers were also placed in 10-fold volume 
excess of ethanol, however were stirred for 24 hours, prior to centrifugation at 11,000 





Figure 3.3. EDC/NHS-induced drug coupling to biopolymers. Coupling of 
naproxen (blue) or sulfasalazine (red) to a collagen-based biopolymer via 
EDC/NHS reactions to activate drug carboxylic groups before mixing with the 





3.3.4 Synthesis of UV-cured biopolymer networks 
4VBC-Functionalised atelocollagen or gelatin products were dissolved at 
fixed concentrations of 0.8 wt.% and 10 wt.% respectively in 10mM HCl (pH 2.1), 
containing 1% I2959 photoinitiator. To prepare 1% I2959 solutions, I2959 was 
dissolved at 60°C for 3 hours. The dissolved polymer solutions were cast onto 24 
well plates at known masses, and irradiated by UV light (346nm, 8mW cm-2) for 30 
minutes on both the top and bottom sides. The UV-cured hydrogel networks were 
carefully removed from the well plates and washed with diH2O, prior to washing in 
ascending ethanol concentrations and air drying before storing.  
 
3.3.5 Synthesis of peptide-conjugated naproxen prodrug 
The synthesis of peptide-conjugated naproxen prodrugs was carried out by 
automated means. Peptide conjugates were synthesised onto H-Tyr (tBu)-2-(ITrt) 
resin at a substitution value of 0.76 mmoles/g, prepared by swelling in DMF for 20 
minutes. The resin was washed and shaken in 40% piperidine/DMF for 3 minutes to 
deprotect the Fmoc protecting group from the previous amino acid in the sequence. 
This step was repeated a further 2 times with drainage of the piperidine/DMF after 
each cycle. The calculated amino acids in the coupling sequence and HCTU mass 
(2.5 equivalents) were mixed and dissolved in the minimum amount of DMF 
(calculated by the synthesiser) and were loaded into the synthesiser with the 
calculated quantities added for each coupling cycle, of which 3 cycles occurred for 
each new amino acid addition. Alongside the amino acid and HCTU, DIPEA/NMP 
were added to improve coupling efficiency. Each amino acid coupling cycle was 
intermittently shaken for 15 minutes, before being drained and repeated until 3 cycles 
had occurred. After the third coupling reaction, the resin and sample vessel were 
washed 3 times with DMF. The deprotection and coupling stages were then repeated 
until all of the amino acids and naproxen were added, with the drug coupling step 
being manually input into the automated synthesiser.  
Once naproxen was coupled, the resin was thoroughly washed initially in 
DMF, followed by methanol and finally dichloromethane, before being dried under 
vacuum overnight. Conventional cleavage was carried out next to remove the 
sidechain protecting groups and release the compound from the resin, by preparing 
a 2 ml cleavage ‘cocktail’ containing 95:2.5:2.5 TFA:triisopropysilane:water. The 
cleavage cocktail was added to the peptide conjugate, which was left to stand for 4 
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hours with gentle agitation hourly (using a glass pipette to blow air over the solution 
to disturb the resin beads). The cocktail, containing peptide conjugate and resin was 
transferred into a sintered glass funnel and a minimal quantity of TFA was added to 
completely dissolve the compound in order to maximise the amount filtered. The 
filtrate was collected in a round bottomed flask and the solvent was evaporated in a 
rotary evaporator, to leave the peptide conjugate behind. The peptide was triturated 
with cold diethyl ether and washed a further 3 times in the glass sintered funnel. The 
peptide remained in the funnel, and was dissolved in 95% acetic acid before 
collection in another round bottomed flask. The flask was then rotated in a dewer 
bowl containing dry ice and acetone to form a frozen shell around the inside of the 
flask to increase surface area prior to overnight freeze drying. 
 
3.3.6 LCMS confirmation of peptide-conjugated prodrug synthesis 
Confirmation and analysis of successful peptide-conjugated prodrug 
synthesis was carried out using an LCMS method. A HICHROM RPB column 25cm 
x 2.1mm (HICHROM-250AM) was used. The flow rate used during each LCMS cycle 
was 0.30 ml/min, with a gradient method beginning with 90% mobile phase A (9:1 
water:methanol, containing 0.1% formic acid) and 10% mobile phase B (1:9 
water:methanol, containing 0.1% formic acid) and increasing linearly to 95% mobile 
phase B over 40 minutes (Table 3.3.). The detection method used was the tracking 
of absorbance at 330 nm, a peak absorbance for naproxen (the drug used in the 
synthesis of the peptide-conjugated prodrug) [276].  
 
Table 3.3. Methodology of gradient changes throughout LCMS and HPLC 
cycles. 
Time (min) Mobile Phase A (%) Mobile Phase B (%) Flow Rate (ml/min) 
0.00 90.0 10.0 0.30 
40.00 5.0 95.0 0.30 
41.00 90.0 10.0 0.30 





3.3.7 MMP14 recombinant enzyme assay 
To confirm drug release from the hydrogel networks, an MMP14 recombinant 
enzyme assay was carried out. Briefly, an MMP reaction buffer consisting of: 50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM CaCl2 and 0.025% Brijj-35 was prepared. 
Recombinant MMP14 was reconstituted in MMP reaction buffer and dry hydrogels 
were also swollen in MMP reaction buffer. In a 12 well plate well, containing a swollen 
hydrogel sample, a calculated quantity of enzyme was added (0.5 µg enzyme to 10 
µM of drug on the gel) and made up to 3 ml with MMP reaction buffer. The reaction 
was incubated at 37°C for 3 days. At the end of the reaction, hydrogels were blotted 
and left to dry at room temperature and the remaining MMP reaction buffer solution 
was collected and centrifuged at 10,000 g for 5 minutes before removing the 
supernatant. The pellet was re-dissolved in a known volume of methanol prior to 
analysis by HPLC or LCMS.  
Alongside the MMP14 recombinant assay, acid degradation of hydrogels was 
also performed. Briefly, hydrogel samples were left submerged in 3 ml of 6 M HCl at 
37°C until the hydrogel had fully dissolved, at which point 6 M NaOH was added to 
neutralise the acidic conditions. Samples were spun down on a centrifuge at 10,000 
g for 5 minutes before discarding the supernatant and collecting the pellet as 
described in the above.  
 
3.3.8 HPLC drug release analysis 
HPLC analysis of MMP reaction buffer was carried out, following the same 
methodology, as that used during the LCMS peptide-conjugated prodrug 
confirmation (Table 3.3.), using the same column, a HICHROM RPB column 25cm x 
2.1mm (HICHROM-250AM), again with a 0.30 ml/min flow rate. Again, detection 





3.4 Results and Discussion 
3.4.1 Functionalised biopolymers synthesis and UV inducible network formation 
concept 
Following reaction with 4VBC, the degree of functionalisation (F), 
representing the coupling of photo-active molecules to the AC backbone was 
determined. The reaction of AC with 4VBC monomers occurs through lysine-initiated 
nucleophilic substitution causing the consumption of free amino acid groups, as well 
as the coupling of 4-vinylbenzyl residues.  
The overall content of primary lysine groups in native gelatin 
(2.53·10−4 mol·g−1) and atelocollagen (3.03·10−4 mol·g−1) was recorded via TNBS 
assay and results proved to be similar to values reported in literature (Table 3.4.)  
[275, 277]. In AC, both colorimetric methods demonstrated a comparable decrease 
in amino groups molar content for 4VBC, and drug conjugates (Table 3.5.). Coupling 
of 4VBC to atelocollagen biopolymers, exhibited in Table 3.5. are in line with previous 
reports [278], 1H-NMR was not carried out due to sample complications in 4VBC-
functionalised AC of overlapping AC species [275].  
 
Table 3.4. Functionalisation of gelatin with 4-vinylbenzyl chloride. Degree of 
functionalisation (F) measured in the 4VBC-reacted gelatin product via TNBS 
assay (n=3). Gelatin was reacted with 4-vinylbenzyl chloride (4VBC) at a range 
of molar excesses. 
Sample ID Amine Groups / mol·g−1 (x 10−4) F / % 
Native 2.53 ± 0.07 N/A 
Gel4VBC8 1.58 ± 0.08 37 ± 3 
Gel4VBC10 1.34 ± 0.05 47 ± 2 
Gel4VBC15 1.16 ± 0.07 54 ± 3 
Gel4VBC25 0.83 ± 0.06 67 ± 2 
 
The functionalisation of gelatin with 4VBC and drug conjugates were carried 
out prior to similar methods of functionalisation in AC due to the ready availability of 
gelatin and comparable chemical composition and molar content lysine. For 
conceptual purposes, a 25-molar excess of 4VBC was reacted with gelatin as the 
initial functionalisation, proceeded by a further coupling of 1 molar excess of 
sulfasalazine (SSZ) to the remaining free lysine groups. Functionalisation of gelatin-
4VBC25 was confirmed via TNBS only (Table 3.4.), due to the limitations of the 
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ninhydrin assay being unable to measure the amount of free lysine groups accurately 
below 1.9·10−4 mol·g−1 (i.e. below 25% functionalisation in gelatin and 37% 
functionalisation in AC). Although the ninhydrin assay is limited in accurately 
quantifying the full range of functionalisation, the ninhydrin assay allows for the 
quantification of coupling with compounds displaying similar peak absorbance to the 
one of TNBS (346 nm), e.g. naproxen [279]. The ninhydrin assay releases a 
chromophore with a peak absorbance wavelength of 570 nm, which is far away from 
the absorbance peak of TNBS (346 nm). Therefore, if the desired degree of 
functionalisation of the selected biopolymer with a particular compound is within the 
linear region of the ninhydrin calibration curve then an accurate quantification of free 
amino groups can be calculated and thus the functionalisation can be determined.  
Further coupling of SSZ via an EDC/NHS reaction was carried out, resulting 
in a pale orange biopolymer colour, as opposed to the off-white appearance of 
gel4VBC. The orange colour remained after several washes, indicating the 
successful coupling of SSZ. The ninhydrin assay could not be used to confirm drug 
presence, due to the high degree of functionalisation of 4VBC and the SSZ peak 
absorbance of 359 nm [280] which overlaps with the TNBS peak absorbance. 
Therefore, the degradation of gel4VBC25 and gel4VBC-SSZ in acid was carried out 
and the absorbance measured at 359nm, the peak absorbance of SSZ. The results 
showed little absorbance in the degraded gel4VBC, however in gel4VBC-SSZ a 
significantly higher absorbance reading was recorded compared to the control, 
further suggesting the successful coupling of SSZ to gel4VBC25, as SSZ was the 
only alteration to gel4VBC. As the coupling of compounds to gelatin served as a 
concept only, the results of the successful coupling were not quantified or displayed, 
however the EDC/NHS coupling method was later confirmed by ninhydrin and acid 
degradation, indicating successful coupling of SSZ.  
Crosslinking of gel4VBC under ultraviolet light in the presence of I2959, a 
method widely used in research [281-283], confirmed the formation of 3-dimensional 
insoluble polymer matrices. The network formation via UV crosslinking of gel4VBC-
SSZ was not initially carried out, as the purpose of gel4VBC-SSZ was to confirm 
whether drug coupling to a 4VBC functionalised biopolymer was possible.  
Following successful dual functionalisation of gelatin biopolymers, dual 
functionalisation of AC was attempted at varying molar excesses, (Table 3.5.). All 
col4VBC samples were photo-crosslinked in I2959, with col4VBC10 forming a weak 
gel which upon handling breaks down, likely due to the lower degree of 
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functionalisation, resulting in less covalent bonding during crosslinking. Due to the 
fragile nature of handling col4VBC10 it was excluded from the study as it is unlikely 
the gel would withstand the mechanical pressures within an RA target environment 
(within the synovial membrane). Col4VBC25 yielded an approximate 17% 
functionalisation of free amino lysine groups, whereas col4VBC40 and col4VBC50 
yielded around 30% 35% respectively, as demonstrated by TNBS.  Due to the 
coupling of SSZ to col4VBC requiring a ninhydrin assay to confirm and quantify 
degree of drug functionalisation, col4VBC40 and col4VBC50 were removed from this 
study as the maximum degree of functionalisation that can be accurately determined 
using the ninhydrin assay in AC is 35%. Another justification for the exclusion of three 
of the col4VBC excesses is that col4VBC25 is widely characterised and col4VBC25 
hydrogels provide sufficient enough structural support [52, 174], ignoring the potential 
added structural support provided by drug conjugation. Further functionalisation of 
col4VBC25 was carried out by conjugating the model drug SSZ to the remaining 
2.51·10−4 mol·g−1 lysine amino groups at a 1 molar excess. The retrieved product was 
analysed using the ninhydrin assay, whereby the results fell within the nonlinear 
region of the ninhydrin calibration curve (which in AC occurs above 35% 
functionalisation) and were therefore excluded. It can however be noted that a further 
18% of the total AC free lysine groups were occupied after SSZ drug conjugation, 
proving a successful drug conjugation. A separate sample of AC was also reacted 
with a 1 molar excess of SSZ to estimate the approximate degree of functionalisation 





Table 3.5. Degree of functionalisation in atelocollagen. Quantification of amino 
group molar content and degree of functionalisation (F) in atelocollagen 
products (n=3) following either 4VBC, SSZ or NAPPCP coupling. Degree of 
Functionalisation was calculated using an overall molar amino content of 3.03 
x 10-4 mol·g-1 in native AC, demonstrated by TNBS and Ninhydrin assays.  
1 Denotes F calculated using TNBS native free Lys figure. 
2 Denotes F calculated using Ninhydrin native free Lys figure. 
Sample ID 
Amine Groups / mol·g−1 (x 10−4) 
F / % 
TNBS Ninhydrin 
Native AC 3.03 ± 0.05 3.03 ± 0.02 N/A 
Col4VBC10 2.69 ± 0.10 2.58 ± 0.19 12 ± 3 1 
Col4VBC25 2.49 ± 0.02 2.51 ± 0.14 17 ± 1 1 
Col4VBC40 2.11 ± 0.02 N/A 30 ± 1 1 
Col4VBC50 1.99 ± 0.03 N/A 34 ± 1 1 
ColSSZ1 N/A 1.96 ± 0.002 34 ± 0.1 2 
ColNAPPCP1 N/A 1.97 ± 0.001 35 ± 0.02 2 
 
The resulting col4VBC25-SSZ, as well as col4VBC25 were reacted 
separately at a collagen concentration of 0.8 wt.% in 1% I2959 solution made up with 
10mM HCl as described in Chapter 3.3.4 in accordance with previous research [52, 
275]. The 0.8 wt.% of AC was used compared to the 10 wt.% used in gelatin solutions 
[284] due to the larger molecular weight and lower solubility of AC with respect to 
gelatin. Network formation of col-4VBC25 occurred as expected (Figure 3.5.), 
however, unexpectedly no network formation was observed in the col4VBC25-SSZ 




Figure 3.4. Confirmation of network formation of col4VBC25 hydrogel. UV 
irradiation A) Dry hydrogel for storage and B) wet, swollen hydrogel. 
 
As a result, UV crosslinking was attempted in the previously synthesised 
gel4VBC25-SSZ, as well as the previously successful network forming gel4VBC as 
a control, following the 10 wt.% in 1% I2959 solution methods described previously. 
Similarly, to the col4VBC25-SSZ no network formation was observed in the drug 
conjugated sample, yet successful network formation resulted in the gel4VBC25 
mixture. A theory for the absence of network formation by UV irradiation in drug 
conjugated-4VBC25 biopolymers, may be due to a shielding effect, often seen in 
peptide conjugation. An example of this would be the recent research by El-Sayed et 
al who conjugated dextran to arginine deiminase (ADI), causing a fortification effect, 
resulting in an increased resistance to proteolysis by proteinase K and trypsin at the 
ADI recognition sites [285]. This may have occurred when SSZ was coupled to the 
4VBC25 biopolymers, shielding remaining lysine groups from photo-activated 4VBC, 
thus preventing UV-induced network formation.  
To confirm whether the lack of network formation via UV crosslinking was due 
to SSZ alone, the focus drug, naproxen peptide-conjugated prodrug (NAPPCP), was 
synthesised to assess the possibility of dual functionalisation of a biopolymer with 




3.4.2 Confirmation of peptide-conjugated prodrug synthesis 
Synthesis of naproxen peptide conjugated prodrug (Figure 3.5.) products 
produced consistent yields with purity in excess of 80% (Figure 3.6.), due to three 
cycles of peptide and drug coupling. A purity of over 80% was deemed acceptable 
for the proof of concept study carried out here, due to the detectable quantities which 
could be identified during the release phase of the study. The predicted molecular 
weight of NAPPCP was 1288.47 g·mol−1 (C65H85N13O15), The exact mass of the 
compound was 1287.63 g·mol−1. Fragmentation of NAPCP and the relevant mass 
per charge as seen through mass spectrometry (exact mass) were also calculated 
(Table 3.6.). 
Previous works in peptide synthesis, involving two amino acid coupling 
cycles, required purification after synthesis of the PCP prodrugs, of similar sized 
sequence chains [21]. The decision to employ 3 coupling cycles per amino acid and 
drug was made to reduce the need for HPLC purification after synthesis. As 
mentioned for the proof of concept a purity of >80% was deemed to be acceptable. 
Many coupling reactions yield a higher rate of coupling, if a higher equivalents ratio 
is used. The addition of a third coupling reaction further increases the equivalents 
ratio, resulting in a higher percentage of successful couplings and therefore, a lower 
percentage of unsuccessful couplings which in turn may couple to the next amino 
acid in the sequence, leading to impurities in the final sample. This is a similar 
concept to the increased degree of functionalisation of a biopolymer observed after 
reactions at a higher molar excess of functionalising compound.  
Prior to conjugating the newly synthesised NAPCP, LCMS was carried out to 
confirm the successful synthesis of the prodrug by identifying the doubly charged 
species of the compound (644.89 m/z) (Figure 3.6.).  
 
 




Figure 3.6. LCMS confirmation of naproxen-peptide conjugated prodrug. 
Identification of NAPPCP - photo diode array absorbance spectrum at 330 nm 
(top); mass Spectrometry for peak at 7.46 mins, showing a doubly charged 
species of MW 644.89 consistent with the desired product (bottom). Purity in 
excess of 80% as shown by the lack peaks (other than NAPPCP), large enough 
to display a peak area. 
 
 
Table 3.6. Naproxen Peptide-Conjugated Prodrug Fragments. Fragmentation of 
Naproxen Peptide-Conjugated Prodrug (NAPPCP), single, double and triple 
charged ions, as observed by mass spectrometry. 
NAPPCP Fragment Sequence MH MH2+ MH3+ 
NAP-Arg-Ser-Cit-Gly-Hof-Tyr-Leu-Tyr 1287.63 644.82 430.21 
NAP-Arg-Ser-Cit-Gly-Hof-Tyr-Leu 1123.58 562.79 375.53 
NAP-Arg-Ser-Cit-Gly-Hof-Tyr 1010.50 506.25 337.83 
NAP-Arg-Ser-Cit-Gly-Hof 847.43 424.72 283.48 
NAP-Arg-Ser-Cit-Gly 686.35 344.18 229.83 
NAP-Arg-Ser-Cit 629.33 315.67 210.78 
NAP-Arg-Ser 472.24 237.12 157.41 
NAP-Arg 385.21 193.61 128.40 




The peptide-conjugate sequence of NAPPCP which is modelled from another 
peptide-conjugated prodrug known in literature as ICT2588, a PCP for the vascular 
disrupting agent azademethylcolchicine, was developed by a research team at the 
University of Bradford, UK [103, 229]. The proteolytic cleavage site of the peptide-
conjugate lies between homophenylalanine (Hof) and glycine (Gly) and is recognised 
by membrane-type matrix metalloproteinase 1 (MT-MMP1), or MMP14 [229]. 
Permission to use this particular peptide-conjugate sequence significantly increased 
the possibility of developing a selective and localised drug-conjugated biopolymer 
and proving the initial concept. This is due to the sensitivity surrounding the synthesis 
of a peptide-conjugated prodrug, the alteration of a single amino acid can vastly alter 
the rate of conjugate cleavage in the presence of MMP14 and increase potential for 
other proteases to cleave it in non-target tissues, therefore the ability to use an 
already recognised sequence provides a greater possibility of successful MMP14 
cleavage, when the NAPPCP is conjugated to a biopolymer. 
 
3.4.3 Synthesis and UV network formation of NAPPCP conjugated col-4VBC25 
As the primary aim of this study was to conjugate a naproxen peptide-
conjugated prodrug to a biopolymer, sulfasalazine was employed as a model drug to 
confirm initial conjugation was possible. Using sulfasalazine, conjugation to 
biopolymers, via an EDC/NHS reaction was confirmed, however UV initiated network 
formation subsequently failed. Therefore, using minimal quantities required, the 
conjugation of NAPPCP to col4VBC25 was carried out in an attempt to successfully 
UV crosslink a drug conjugated-4VBC25 biopolymer. The decision to trial NAPPCP 
conjugation in AC as opposed to gelatin, was made to significantly reduce the 
quantity of naproxen peptide-conjugated prodrug required to obtain a peptide-drug 
conjugated hydrogel.  
The previously discussed, drug conjugation to col4VBC25 via the ninhydrin 
assay can only be accurately quantified if drug conjugation is below 18% of the AC 
total amino lysine groups. Therefore, as with sulfasalazine, a sample of AC was 
conjugated to NAPPCP at a 1 molar excess to determine the degree of 
functionalisation of AC. It was expected that the degree of functionalisation with SSZ 
and NAPPCP would be similar due to both compounds being readily reactive and 
only containing a single carboxylic group. The degree of functionalisation of AC with 
NAPPCP was calculated to be 35% (Table 3.5.) therefore it can be deduced that the 
total degree of functionalisation of col4VBC25 with NAPPCP was between 18 and 
74 
 
52%. The reason of synthesising col4VBC25-NAPPCP was to confirm whether or not 
successful UV induced network formation was possible following UV irradiation and 
if so alternative means of accurately quantifying the degree of functionalisation by 
NAPPCP were to be explored.  
Following the successful coupling of NAPPCP to col4VBC25, UV induced 
crosslinking was carried out. As observed in both col4VBC25-SSZ and gel4VBC25-
SSZ, col4VBC25-NAPPCP also exhibited no network formation in response to UV 
light in the presence of I2959 photoinitiator, despite the col4VBC25 control 
successfully forming a network. To confirm the photoinitiator batch was not a 
contributing factor to the lack of drug-conjugated network formation, an alternative 
batch was used in a repeat of the UV curing, with the same results obtained. Due to 
the NAPPCP-conjugated col4VBC25 sample also failing to form a hydrogel network, 
the possibility of molecular shielding seems a likely explanation for the unexpected 
lack of UV-induced network formation. 
Ordinarily, UV irradiation generates free radicals causing the 4VBC molecule, 
to react with other strands of the AC or gelatin polymer, increasing the concentration 
of coupled strands, leading to a network formation as the coupled strands interact 
and react with other strands as well as other 4VBC molecules on the same strand 
(Figure 3.7.) [52, 286].  
 
 
Figure 3.7. UV-induced Crosslinking of collagen-based biopolymers. Following 
4VBC functionalisation collagen-based biopolymers were crosslinked in the 
presence of I2959 photoinitiator. 
 
In the presence of a conjugated drug, it is thought the network formation due 
to UV-induced photoinitiation is blocked by a shielding effect, caused by the 
conjugation of the drug molecule. The specific type of shielding is thought to be due 
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to the steric hinderance of the molecules, which is known to slow chemical reactions 
due to the blocking of nucleophilic attacking molecules, in this case the free radicals 
created from UV irradiation. It could be said that the degree of functionalisation of 
4VBC on gelatin is considerably larger (67%) than that of the coupled SSZ, however 
the size and structure of SSZ may be sufficient enough to considerably slow the 
reaction enough to appear as though no crosslinking was possible. To assess this 
samples were left overnight under UV light, which again exhibited no gel formation, 
over 12 times longer than the previous methods state. Steric shielding is shown to 
play roles within free radical reactions of nitroxide  [287-289]. It is likely that steric 
shielding is the explanation behind the lack of gel formation in the presence of UV 
irradiated free radical molecules, however whether complete gel formation is 
prevented or the reaction is significantly slowed remains unclear. 
As a result of the inability of col4VBC25-NAPPCP to form hydrogel networks 
under UV light, an alternative method of forming a NAPPCP conjugated biopolymer-
based hydrogel was investigated. 
 
3.4.4 UV crosslinking photo-active biopolymers to encapsulate drug-conjugated 
biopolymers 
The utilisation of hydrogels for drug delivery often occurs by one of two 
methods 1) drug conjugation directly onto the hydrogel, the initial strategy proposed 
here, and 2) drug loading onto a hydrogel network [177, 290]. A method of drug 
loading involves the encapsulation of a drug within a hydrogel network [291]. Loading 
of a drug onto a hydrogel network, has a major flaw compared to a conjugation 
approach, in that, the drug has an increased chance of diffusing out of the hydrogel 
away from the target site, thus increasing the potential of off-target toxicity. Unless 
the loading of a drug is controlled by stimuli such as temperature or pH, a drug, if 
small enough, has the potential to diffuse out of the gel network.  
The inability to synthesise a UV networked drug-conjugated col4VBC 
hydrogel, forced an alternative approach. This approach involved the 
functionalisation of two separate samples of AC, one functionalised with 4VBC at a 
25-molar excess, as previously described and the other, a drug conjugated AC 
sample (colNAPPCP). The two samples were mixed and UV crosslinked. Successful 
network formation was observed indicating the ability to encapsulate a colNAPPCP 
material within the network of col4VBC25 during the UV curing process to form 
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col4VBC25encap-NAPPCP (Figure 3.8.). The formation of a UV irradiated, drug-
encapsulating hydrogel is in line with related literature where alternative drugs have 
been loaded onto a variety of photo-crosslinked hydrogels [292, 293], namely the 
work by Cao et al (2014). Cao et al encapsulated bone morphogenic protein-loaded 
nanoparticles within a gelatin-based photopolymerisable hydrogel, to deliver a 
sustained growth factor release to increase the rate of bone regeneration [294]. 
 
 
Figure 3.8. Confirmation of successful network formation of encapsulated 
hydrogels. Hydrogel network of col4VBC25 encapsulating either colSSZ or 
colNAPPCP A-B) colSSZ and C-D) colNAPPCP. Left side of figure depicts the 
encapsulated hydrogels in their dry state, whereas the right side shows the 




Using a hydrogel as a drug delivery vehicle serves several key purposes, 
including a localised delivery, a selective form of release, whether by stimuli or other 
means and a greater drug therapeutic index. If encapsulating (a type of loading) a 
drug within a gel network decreases off-target toxicity compared to the drug alone, 
the drug requires a method of keeping it loaded to the gel, otherwise diffusion of the 
active drug may occur prematurely. In efforts to reduce the risk of premature 
diffusion-induced drug release, the NAPPCP prodrug was conjugated to a separate 
sample of AC prior to encapsulation. It was expected that by conjugating to AC, it 
would prevent NAPPCP from diffusing out of the gel network due to the gel network 
consisting of functionalised AC as well as the molecular size of AC (approximately 
300kDa), being significantly larger than the prodrug alone. 
 
3.4.5 MMP14 selective recombinant enzyme assay 
After the successful formation col4VBC25encap-NAPPCP hydrogels, the 
release of NAP from the NAPPCP component, which relies on the selective cleavage 
by the proteolytic enzyme MMP14 was assessed using recombinant MMP14. 
Cleavage of the peptide-conjugate triggers drug release [295] leading to the 
deprotection of the peptide chain ends, allowing the remaining 4 amino acids to be 
easily metabolised and removed from naproxen to release the drug in an active state 
[103, 229]. The selection of a recombinant MMP14 assay over an ex vivo biological 
assay using homogenised tissue overexpressing MMP14 was pursued to confirm 
cleavage of the peptide-conjugate occurs through MMP14 activity. The recombinant 
enzyme demonstrates that MMP14, the target enzyme is capable of cleaving 
NAPPCP between the Hof-Gly peptide bond. In an ex vivo assay of this type it would 
not be possible to identify which specific enzyme was cleaving the prodrug. Due to 
the nature of the study, proving the concept for the release of the active drug, 
naproxen from the hydrogel-NAPPCP system, was thought to be the priority over, the 
assessment of the drug’s half-life and breakdown after the initial release.  
HPLC analysis of the MMP14 recombinant assay buffer was carried out to 
assess the release of the NAPPCP cleavage metabolite (NAP-Arg-Ser-Cit-Gly) into 




Figure 3.9. HPLC spectra (absorbance chromatograms at 330 nm) of reaction 
buffer for MMP14 recombinant assay. Assessment of the release of naproxen 
metabolites from a col4VBC25encap-NAPPCP hydrogel network: pink: 
naproxen drug control, cyan: col4VBC25encap-NAPPCP gel, green: col4VBC25 
control, blue: col4VBC25encap-NAPPCP gel repeat, and black: reaction buffer 
negative control.  
 
Unexpectedly no expected naproxen containing compound metabolite peaks 
were detected in the col4VBC25ecap-NAPPCP samples, suggesting no release of 
NAP metabolites from the hydrogel networks. The naproxen control sample was 
calculated to be the maximum possible concentration of NAP on gel, within the 
reaction buffer, and the detection limits of the HPLC was <0.1µM, further suggesting 
no cleavage by MMP14 took place due to the high sensitivity of the HPLC equipment. 
To confirm the unsuccessful cleavage by MMP14, col4VBC25 and col4VBC25encap-
NAPPCP networks were separately degraded in 6M HCl prior to preparation to 






Figure 3.10. HPLC analysis of acid degradation assay (absorbance 
chromatograms at 330 nm). Green: naproxen drug control, blue: 
col4VBCencap-NAPPCP and black: col4VBC25 control.  
 
As observed in the MMP14 recombinant assay, acid degradation produced 
no traces of naproxen-based compounds. An initial theory for this was the instability 
of NAPPCP occurring once conjugated to the AC biopolymer, or during the UV-
crosslinking process. Ultraviolet light could have some effects upon the NAPPCP 
component as well as the collagen itself. In collagen, under UV light research has 
demonstrated an increased viscosity, compared to native collagen, thought to be due 
to the formation of intermolecular crosslinks via tyrosine dimers, shown by the 
production of blue fluorescence, with a peak of approximately 350nm [296]. A more 
recent study has shown UV irradiation of tyrosine and phenylalanine (and likely 
homophenylalanine) produces free radical residues that crosslink collagen fibres 
[297, 298]. In the case of the NAPPCP it is unlikely that subsequent crosslinking 
between tyrosine and other aromatic amino acid components of collagen occurred 
as this would result in the conjugation of NAPPCP to collagen during the photo-
crosslinking process, anchoring naproxen to the hydrogel network. Given that the 
HPLC is capable of detecting concentrations of NAP <0.1µM, if any naproxen was 
present it is likely it would have been detected, when the gel was fully degraded in 
acid.  
Tyrosine - an amino acid within the NAPPCP prodrug, is shown to be 
irradiated by UV light [299] shown to result in the inactivation of enzymes [300] which 
in NAPPCP, may have broken the peptide conjugate, releasing NAPPCP within the 
crosslinking solution, which when subsequently washed would allow the naproxen-
metabolite to freely diffuse out through a hydrogel pore. These findings indicate the 
absence of colNAPPCP within the network prior to the start of the MMP14 
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recombinant assay which could only be explained by the unexpected diffusion of 
colNAPPCP or NAPPCP metabolites containing NAP from the col4VBC25 network 
during the washing and hardening phases after hydrogel formation. The wash step 
is a crucial step which cannot be avoided post-UV crosslinking, due to the acidic 
conditions required to initially dissolve col4VBC25 as well as the free radicals 
produced during network formation, which would not be safe to deliver into the 
disease site. Due to the remnants of the crosslinking solution mixture (and 
encapsulated colNAPPCP) remaining within the newly formed encapsulating 
hydrogel, when the wash step takes place it is possible that the dissolved 
colNAPPCP or NAP-based metabolites are washed out as it diffuses and mixes into 
the solution the hydrogel is washed with, in turn exhibiting no naproxen peaks on the 
HPLC spectra.   
 
3.5 Conclusions 
Photo-active 4VBC, collagen-based hydrogels appear to lack the ability to 
support drug attachment, observed in the inability of dual functionalised collagen and 
gelatin biopolymers to undergo UV-induced photo-crosslinking. The unexpected 
ability of colNAPPCP to remove itself from the encapsulating hydrogel further 
demonstrated photo-crosslinking 4VBC is not a suitable method to support a 
Hydrogel-PCP system. As a result, alternative approaches must be taken in order to 
synthesise a collagen-derived hydrogel delivery vehicle capable of delivering and 



















4.0 Chemically crosslinked biopolymer hydrogels 
Here, the exploration into an alternative crosslinking strategy, to synthesise a 
more clinically relevant Hydrogel-PCP is undertaken. Chemical crosslinking by 
DMTMM, is employed to crosslink NAPPCP-conjugated gelatin, under physiological 
conditions. Initial assessments of gel-NAPPCP hydrogel properties are carried out 
through assessments of: 
• Gel content 
• Swelling ratio 
• Gelation kinetics 
• Rheology. 
The release of naproxen, by MMP14 cleavage of the peptide-conjugate, as well as 
acid degradation, was analysed by Liquid Chromatography Mass Spectrometry 
(LCMS). Finally, preliminary investigations into a less invasive and more clinically 
desirable delivery strategy, injection, are carried out under physiological conditions. 
 
4.1 Introduction 
Extensive research into UV-curable gel networks, and their potential for drug 
delivery has been carried out, however UV-curing did not prove a suitable method to 
enable full solution gelation and the formation of mechanically competent covalently 
crosslinked hydrogel networks. Another widely investigated crosslinking method for 
medical therapies, is chemical crosslinking which has produced an alternative range 
of unique characteristics. Whereas UV-cured hydrogels often have the ability to 
withstand higher temperatures or greater mechanical pressure [301], chemically 
crosslinked hydrogels have the potential to be crosslinked in a crosslinking solution, 
without the need of an alternative source, such as a UV light, which in some 
environments is not possible without invasive surgery, i.e. deep within tissue or bone 
constructs. This feature alone, is a clinically desirable property, as in many cases the 
need for an invasive implantation can be substituted for an injectable form, which 
gels in situ, of which, several research groups have investigated the potential of these 
alternative hydrogels in a range of biomedical applications [302, 303]. Chemical 
crosslinking has a range of crosslinkers available, dependant on the polymer 
backbone used, for example a biopolymer such as gelatin, a carbodiimide reaction, 
activating free carboxylic groups to readily react with the free amino groups of gelatin, 
chemically crosslinking the polymer.  
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In some research areas, the use of hybrid hydrogels has arisen, enabling the 
modulation of microscale hydrogel properties as well as incorporating the tailoring of 
drug or gene delivery capabilities [304]. In 2015 a study by Qu et al demonstrated 
the use of a thermo-responsive hybrid hydrogel for the delivery of DOX in breast 
cancer through the incorporation of gold nanorods into the hydrogel itself [305]. 
However, there is still much potential for a solely chemically crosslinked hydrogel 
system that delivers a selective and localised drug delivery system whilst acting as a 
support network, when necessary.  
The decision to exclude the AC biopolymer material at this stage of the 
research was made due to greater accessibility towards gelatin amino lysine groups 
when conjugating our peptide-conjugated prodrugs. When collagen is degraded, the 
triple-helix is broken into randomised, more linear coils known as gelatin. The degree 
of denaturation is relative to the amount of triple-helical structures, with lower 
amounts found in gelatin compared with collagen [306, 307].  The process of collagen 
denaturation into gelatin is attributed to hydrogen bonds and covalent crosslinks 
which break endothermically and exothermically, respectively [308]. The collapse of 
the triple helix, which is necessary to stabilise the collagen fibril ultrastructure [309] 
occurs, resulting in the unfolding and fragmentation of collagen, leaving 
functionalisation sites more accessible for conjugation of NAPPCP. The ratio of drug 
conjugated to the gelatin biopolymer, a 1 molar ratio to free amino groups, as 
previously used in AC, is no longer necessary to achieve the same degree of 
functionalisation, because of the increased lysine accessibility in gelatin. This is 
supported by the degree of functionalisation achieved in collagen versus the degree 
of functionalisation obtained in gelatin after 4VBC (at a 25-molar excess) 
functionalisation 17% ± 1 and 67% ± 2, respectively (Table 3.4. and 3.5.). 
A revised strategy was employed after the previously discussed, 
unsuccessful coupling and loading of naproxen conjugated PCPs (NAPPCP) to 
collagen or gelatin UV-cured hydrogels. The revised strategy aims to chemically 
crosslink a drug conjugated form of the collagen-derived biopolymer, gelatin. The 
original aim of the study hoped the UV-curing method would bypass the non-selective 
delivery of naproxen by surgically implanting the NAPPCP-conjugated hydrogel 
network to lower the risk of off-target toxicity, as previously discussed. This chapter, 
focuses around the proposed concept surrounding: gelatin-NAPPCP chemically 
crosslinked hydrogels under physiological conditions and the drug release profile of 
naproxen. The change from photo-crosslinking to chemical crosslinking, as well as 
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the change in material streamlines the hydrogel synthesis procedure, both in the 
number of steps required and the time taken. Three steps are required in the photo-
crosslinking method: monomer attachment, prodrug conjugation and UV curing, all 
of which, in collagen takes approximately 5-6 days if all materials are to hand, and in 
gelatin the same method takes roughly 3 days. On the other hand, the chemical 
crosslinking method in gelatin requires, prodrug conjugation followed by chemical 
crosslinking and takes 2 days to synthesis a Hydrogel-PCP. Therefore, the increased 
efficiency of the procedural change, works in favour of the production of a Hydrogel-
PCP system. The new strategy also covalently couples the drug to the biopolymer 
which is in turn crosslinked, preventing the drug from escaping from the hydrogel 
after the crosslinking process, as observed in the UV-curing encapsulation 
experiments.  
 
4.1.1 Delivery route – implantation versus injection 
Drug development requires a suitable delivery route, tailored to the disease 
target. Common routes of delivery include: oral, transdermal, intravenous (IV), 
implantation and injection [310]. The most popular of these is oral delivery, however, 
many drugs are unsuitable via oral delivery due to compliance issues of the patient 
or degradation in acidic conditions within the stomach. These complications can be 
bypassed using IV delivery as an alternative. A disadvantage of IV is the need for a 
healthcare professional to administer the treatment. Similarly, transdermal delivery 
overcomes many oral delivery routes, yet it comes with further disadvantages. Few 
drug compounds possess the necessary properties, for example: good solubility, low 
molecular weight and high partition coefficient [311], required to pass through the 
outer barrier of the skin.  
With these disadvantages, as well as the lack of localised delivery none of 
oral, IV or transdermal drug deliveries were selected to investigate as possible 
delivery routes for the novel Hydrogel-PCP system. Implantation of the Hydrogel-
PCP was initially hypothesised to be the more suitable delivery route, due to the 
crosslinking method originally used. Photo-crosslinking requires light; therefore, an 
injectable device would not be suitable when targeting deep tissue disease such as 
osteosarcoma or rheumatoid arthritis. The major disadvantage of implantation is the 
invasive procedure it requires, increasing the risk of toxicity through infection. 
Collagen-based hydrogels however, are biodegradable [312], and once implanted 
would not require surgery to remove the device. The device could also be implanted 
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at the time of tumour removal in osteosarcoma [313] removing the need for a second 
surgical procedure.  
The change in direction from the original crosslinking methodology, prompted 
a revision of the clinical delivery route. By using a chemical crosslinker, network 
formation can be triggered and the treatment administered, before the formation of 
the hydrogel network, without the need for an external activator (such as UV light). 
This allows the injectable delivery route, a non-invasive procedure, to be explored. 
As well as implanted hydrogels, injectable hydrogels are able to provide localised 
and selective drug release, with an added advantage of no required surgery. This is 
key in providing a more clinically desirable delivery route. The injectable method also 
allows for recurring treatments at regular intervals, where necessary, and unlike the 
implanted delivery, the injectable route could be administered at key sites to provide 
structural support to surrounding tissues [314, 315]. An example of this would be the 
site of cartilage degradation, between a joint in rheumatoid arthritis, helping to 
prevent bone erosion [316]. 
The revised crosslinking strategy provides a more clinically desirable 
therapeutic device, capable of in situ gelation to selectively release naproxen in a 






Figure 4.1. Injection delivery strategy. Gel-NAPPCP system, injected between 
the rheumatic joints, at the site of cartilage degradation, where in situ chemical 
crosslinking occurs to form a gel-NAPPCP hydrogel with a cartilage-like 
consistency. Structural support is provided by the hydrogel, whilst selectively 
releasing the anti-inflammatory drug, naproxen, through the cleavage of the 
peptide-conjugated sequence by MMP14. 
 
 
Here, initial findings suggest the potential for the use of an injectable PCP-
conjugated hydrogel as a suitable delivery vehicle for selectively released naproxen 
by proteolytic MMP14 cleavage. Further work is however required to optimise 





All non-conventional research materials and equipment information is listed 
in Chapter 3.2 (Table 3.1. and 3.2.). 
 
4.3 Methods 
4.3.1 Synthesis and confirmation of naproxen peptide-conjugated prodrug 
Peptide-conjugated prodrug synthesis and confirmation of successful 
synthesis, followed the same methods as described in Chapters 3.3.5 and 3.3.6. 
 
4.3.2 Drug conjugation to native biopolymer material 
Naproxen and naproxen peptide-conjugated prodrugs were coupled to free 
amino lysine groups of gelatin biopolymers through EDC/NHS activation of free drug 
carboxylic groups (-COOH). The coupling drug was dissolved in minimal DMSO 
before molar ratio-dependent quantities of EDC and NHS were added to the solution 
and stirred for 1 hour at room temperature. Again, the volume of DMSO required to 
dissolve the drug is not sufficient enough to significantly impact the coupling reaction 
after which the compound is dried and washed, removing the DMSO used to initially 
dissolve the drug. The excess EDC was quenched by the addition of 2-
Mercaptoethanol for 15 minutes before adding the solution to a 10% w/v solution of 
gelatin containing 10% v/v DMSO/PBS to prevent drug precipitation which was found 
to gradually occur in 100% PBS over the reaction time of 24 hours whilst stirring at 
40°C. The resulting solution was precipitated in a 10-fold volume excess of ethanol 
for 5 hours, before collection and air drying of the drug-conjugated gelatin biopolymer 
occurred.  
 
4.3.3 Confirmation of drug conjugation to gelatin biopolymers 
Confirmation of successful drug-conjugation was carried out using the 




4.3.4 Chemically-induced gelatin network formation and gelation kinetics 
After the successful conjugation of naproxen-based drugs to gelatin 
biopolymers, drug-conjugated and gelatin samples were dissolved separately at 10 
w/v ratio in PBS solution at 40°C, before placing the solution in a 37°C incubator 
under stirring and the addition of DMTMM at a 2 molar ratio to remaining free amino 
lysine groups and dissolving for 5 minutes in a screw top vial. Once dissolved and 
mixed, the solution was plated out into well plates and left to gel at 37°C for 30 
minutes to ensure total gelation had occurred (Figure 4.2.). After gelation, the 
resulting hydrogels were washed in 50% ethanol to remove unreacted activators and 
drug-conjugations and left to air dry.  
 
Figure 4.2. Chemical crosslinking of gelatin using DMTMM crosslinker. DMTMM 
activation of gelatin carboxylic groups, before reaction with free amino lysine 
groups of other gelatin strands, resulting in the formation of a hydrogel 
network. 
 
Gelation kinetics were prepared in the same way, except the crosslinking 
solution was removed from stirring and left to crosslink at 37°C instead of being plated 
into well plates, allowing the samples to be angled to confirm liquid to solid transition 
progress, at given timepoints. Briefly, 0.5g sample was dissolved in 5 ml PBS at 40°C 
until completely dissolved. Gelatin control samples were mixed with a minimal 
amount of rhodamine to dye the gels pink to show the gelation clearly. Once 
completely dissolved, DMTMM fixed molar excesses were added (calculated using 
the equation in Chapter 3.3.1) and stirred at 37°C. At 5-minute time intervals, the 
mixture was held at approximately 45° to assess whether gelation had occurred. The 





4.3.5 Quantification of swelling ratio and gel content 
Dry chemically crosslinked samples (n = 4) of known mass (md) from both 
gelatin-only and gel-NAPPCP hydrogels were individually incubated in 5 ml of 50mM 
Tris HCl (pH 7.5), 150mM NaCl, 5mM CaCl2 and 0.025 wt.% Brijj-35 (MMP reaction 






where mₛ is the mass of the DMTMM-crosslinked sample equilibrated in MMP 
reaction buffer (swollen sample) and md is the dry mass of sample. 
Gel content was measured to assess the overall proportion of the covalent 
hydrogel network, insoluble in MMP reaction buffer. Dry chemically crosslinked 
samples (n=4) of known mass (md: 40 mg – 50 mg) were incubated in 3 ml of MMP 
reaction buffer for 3 days. MMP reaction buffer and a 3 day time scale were selected, 
to allow comparisons between gel content before and after the drug release assay to 
be made, to assess the stability of the network within the presence of MMP14. 
Resulting samples were air dried and weighed. The gel content (G) was calculated 





Where m1 is the dry mass of the collected sample. 
 
4.3.6 Rheological assessments 
Rheological assessments involved amplitude and frequency sweeps on both 
gelatin-control and gelatin-NAPPCP conjugated hydrogels. Amplitude sweeps of 
newly formed hydrogels (n=4) were measured by a modular compact rotational 
rheometer from Anton Paar, at a fixed frequency of 1 rad·s-1 at time interval increases 
of shear strain %. During the Frequency sweeps, frequency was increased, whilst the 
shear strain remained at a constant percentage of 10%, to accommodate the linear 
viscoelastic region of both gel sets. Both assessments were carried out at 
physiological temperatures (37°C) and a parallel plate (Ø=8 mm) was used to apply 
the shear force, with a plate gap of 1.8mm. Storage (G’) and Loss (G”) modulus 
values were recorded throughout the sweeps.  
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4.3.7 MMP14-Selective Recombinant Enzyme Assay 
MMP14 recombinant enzyme assay carried out as described in Chapter 3.3.7 
and analysed as described in Chapter 3.3.6 using the same methods used to confirm 
naproxen peptide-conjugated prodrug synthesis. 
 
4.3.8 Initial Investigations of Injectable Device and In Situ Gel Formation 
Gelation solutions were prepared as described in Chapter 4.3.4, however 
rather than setting the crosslinking solution in well plates, the solution was taken up 
by syringe, and injected using a 0.3 mm outer diameter needle, into pre-prepared 
cavities of sawbone and left to crosslink under physiological temperatures. The 
resulting gels were photographed to demonstrate anchorage potential of the newly 
formed hydrogels. Similar to the investigation of gelation kinetics, gelatin control 
samples were mixed with a minimal amount of rhodamine to dye the gels pink to 
clearly show swelling within the cavities.   
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4.4 Results and Discussion 
4.4.1 Confirmation of drug conjugation to native biopolymer material 
Native gelatin was reacted with activated carboxylic groups of naproxen 
(NAP) (previously depicted in Figure 3.3.) or Naproxen peptide-conjugated prodrug 
(NAPPCP) compounds, through an EDC/NHS reaction [317]. Coupling of this nature 
occurs through a nucleophilic attack, whereby the free amino groups, for example the 
ones found in lysine react with the activated carboxylic groups of drug compounds.  
Naproxen-conjugated gelatin biopolymers were synthesised and the degree 
of functionalisation with naproxen drug compounds was confirmed for each molar 
ratio sample (Table 4.1.) [275]. The design of the coupling reaction ensured the 
avoidance of unintentional activation of gelatin -COOH groups, evading unwanted 
crosslinking of gelatin during the coupling reaction [318]. Activating the single -COOH 
of NAP and later NAPPCP, before quenching EDC, prevented the activation of gelatin 
-COOH when mixing the separate solutions together.  
Gelatin was first conjugated to naproxen, to act as a guide for NAPPCP 
coupling, molar ratio. As expected, doubling the molar ratio from 0.1 to 0.2, exhibited 
approximately double the degree of functionalisation, from 8% to 17%, however a 
molar ratio of 0.3 showed a degree of functionalisation of just 20%, suggesting 
approximately two thirds of the naproxen reacted with gelatin was successfully 
coupled compared with 80 and 85% in 0.1 and 0.2 molar ratio reactions respectively. 
The molar ratio of 0.2 was employed for gelatin functionalisation with NAPPCP, and 
yielded 17% functionalisation of free amino lysine groups. The selection of the molar 
ratio, 0.2, was made for two key reasons 1) the quantitity of unreacted drug versus 
degree of functionalisation, as the results suggested an almost complete saturated 
degree of functionalisation of this coupling method in our gelatin system was 20% 
and 2) the 17% degree of functionalisation of gel-NAPPCP(0.2) was half that of the 
35% of col-NAPPCP, equating to approximately 3 times the quantity of NAPPCP per 
gelatin hydrogels of equal networking solution mass compared to col-NAPPCP (due 






Table 4.7. Functionalisation of gelatin with naproxen and NAPPCP. Naproxen 
peptide-conjugated prodrugs (n=3) at varying concentrations, confirmed by 




The method of conjugating drugs to gelatin, provides a potentially significant 
advantage when attempting to overcome solubility issues of certain drugs in 
physiological solutions. The precipitation and washing steps between the coupling 
and crosslinking stages of hydrogel production, allows various different solutions to 
be used to dissolve drugs. Drugs can be dissolved in dimethyl sulfoxide (DMSO) and 
reacted with EDC/NHS to activate the carboxylic acid groups, before mixing with 
dissolved gelatin solution allowing the drug to stay in solution whilst reacting with free 
amine groups of gelatin, before washing out the DMSO during precipitation.  Dimethyl 
sulfoxide is an aprotic solvent which is often capable of dissolving water insoluble 
therapeutic and toxic agents [319]. However, DMSO has significant penetration 
potential and can be detected in the blood 5 minutes after application to the skin and 
in 20 minutes DMSO can be detected in all organs of the body. Delivery of a drug, 
for example intravenously, requires the drug to be solubilised, however using DMSO 
to dissolve a water insoluble drug so that it can be intravenously administered could 
enhance the penetrative effects of the drug, therefore increasing the risk of off-target 
toxicity as well as causing DMSO-induced side effects including: erythema and in 
some cases systemic symptoms [320, 321]. In relation to drug-conjugation of gelatin 
biopolymers, DMSO allows less water insoluble drugs, for example sulfasalazine 
(SSZ) with a 0.2mg/ml water solubility, and a DMSO solubility of approximately 
30mg/ml, to be dissolved in a high enough concentration (to achieve the desired 
degree of functionalisation) to limit the dilution of a dissolved gelatin solution when 
the two reaction mixtures are combined, without the added complications of 
enhanced drug penetration when delivered into the body in a drug-conjugated 
Sample ID Amine Groups / mol·g−1 (x 10−4) F / % 
Native Gelatin 2.53 ± 0.006 N/A 
Gel-NAP (0.1) 2.34 ± 0.004 8 ± 0.14 
Gel-NAP (0.2) 2.10 ± 0.002 17 ± 0.08 
Gel-NAP (0.3) 2.04 ± 0.003 20 ± 0.11 
Gel-NAPPCP (0.2) 2.08 ± 0.003 18 ± 0.11 
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hydrogel format. Any remaining DMSO is washed off the drug-conjugated biopolymer 
after the coupling reaction, allowing an insoluble drug to be coupled to a delivery 
vehicle precursor, without risking the enhanced risks which the use of DMSO brings. 
 
4.4.2 Chemically-induced gelatin network formation 
Upon successful drug conjugation to gelatin biopolymers, the newly NAP-
conjugated gelatin and gelatin-control biopolymers were reacted separately with 
DMTMM to initiate chemical crosslinking, prior to the crosslinking of the gel-NAPPCP 
biopolymer. Chemical crosslinking, through DMTMM activity was observed in the 
native gelatin control and gelatin-naproxen sample, confirming the formation of drug-
conjugated hydrogels. This agrees with other studies where DMTMM has been used 
to crosslink materials including recombinant human collagen type I [322], whilst also 
been used to ligate amines to modify and form hyaluronan hydrogels [323]. Following 
the successful network formation of both gel-CT and gel-NAP, chemical crosslinking 





Figure 4.3. Hydrogel network formation by DMTMM-induced chemical 
crosslinking. Gelatin-control A) dry B) wet and gelatin-NAPPCP C) dry and D) 
wet. 
 
The gel-CT hydrogels, appeared paler and more transparent, compared to 
gel-NAPPCP, which when swollen, appeared more clouded and greyer in colour. The 
successful formation of a gel-NAPPCP hydrogel, demonstrates the initial synthesis 
of a PCP-conjugated collagen-derived (gelatin) hydrogel material is possible through 
nucleophilic reactions. Chemical crosslinking enables the formation of gel-NAPPCP 
hydrogels, which when compared to the UV crosslinking strategy, is significant 
progress in proving the concept of providing a selective, localised peptide-conjugated 
prodrug hydrogel delivery system. The conjugation of NAPPCP to the gelatin 
backbone as opposed to an encapsulation method, significantly reduces the risk of 
the NAPPCP eluding the gel network. In an ideal crosslinking reaction, the 2-molar 
excess of DMTMM reacted with free or remaining amino lysine groups of the gelatin-
based biopolymers would occupy every group. We observed from other 
functionalisation reactions that the applied molar ratio with respect to remaining 
amino lysine groups rarely achieves complete occupation (Table 4.1.) [52]. Further 
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ninhydrin assays were carried out on DMTMM chemically crosslinked gel-CT and 
gel-NAPPCP, however due to the low number of remaining lysine groups, falling 
outside of the linear region (Chapter 3.3.2.2) the ninhydrin results were inconclusive 
in determining the exact degree of crosslinking. 
Gelation time of gel-CT and gel-NAPPCP was measured in PBS (Figure 4.4. 
and 4.5. respectively) crosslinking solutions with DMTMM, and repeated 3 times for 
each sample. In both the control and drug conjugated samples, gelation time 
occurred in under 30 minutes and in each replicate gel-NAPPCP gelation times were 
5 minutes faster than that of the gel-CT times and considerably quicker than some 
literature states, which may be due to a difference in crosslinker used [324, 325]. The 
gelation kinetics were repeated at higher volumes (10, 15 and 20 ml total volume) 
with no effect on the network formation times observed, indicating the size of the 
hydrogel produced does not hinder the gelation kinetics, which is unsurprising due to 
the same molar excess of DMTMM crosslinker to free amino lysine groups used, 
under the same conditions. In the initial crosslinking batch, the crosslinking solution 
contained, 10mM HCl pH 2.1, compared to future batches consisting of PBS and it 
was observed that in the presence of acidic conditions the crosslinking time 
approximately doubled, however this was not recorded due to the change in 
crosslinking solution. This result is in line with previous research, demonstrating 
prolonged crosslinking times in acidic conditions [275]. Liang et al observed slower 
gelation times in acidic crosslinking solutions, which is in line with previous work by 
Ratanavaraporn et al (2008) [326]. Native collagen is known to be altered depending 
on factors such as pH, ionic strength and salt concentrations, due to their effect upon 
amino acidic terminations (ionisation), as well as their secondary interactions [275, 
327-329]. Given that the nature of gelatin is degraded and partially hydrolysed 
collagen, it is possible that these variations also occur in gelatin, explaining why the 
differences in gelation times may have been observed between HCl and PBS based 
crosslinking solutions. The change to PBS solution was made in pursuit of the 
possible injectable delivery strategy. The decision to use a 2 molar excess of 
DMTMM with respect to free Lys groups was made as a result of other gelation kinetic 
experiments, using gelatin-only polymers, aiming at injection as the ideal clinical 
delivery route. Other molar ratios of DMTMM used were 0.1, 0.5, 1 and 3, the figures 
for which are not displayed due to the repetition of data. The 0.1 DMTMM molar ratio, 
failed to form a solid gel, instead appearing as a viscous liquid, due to the partial 
network formation that likely occurred. The ratios of 0.5 and 1 formed hydrogels 
however the time taken was considerably longer than that observed in the 2 molar 
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excess experiments, taking 70 and 45 minutes respectively. Using a 3 molar excess 
of DMTMM yielded a hydrogel, in the same time as the 2 molar excess for hydrogels 
(Figure 4.4.). As a result of the varying molar ratios of DMTMM, a 2 molar excess 
was selected as a hydrogel was formed in under 30 minutes which is thought to be a 
suitable enough time to mix and deliver the Hydrogel-PCP system and allow gelation 
to occur with minimal disruption to the patient’s daily routine.  
Unfortunately, gelation kinetics using DMTMM crosslinked gelatin or gelatin-
NAPPCP was not possible using a rheometer. Evaporation of the crosslinking 
solution occurred when attempting gelation kinetics on the rheometer at 37°C, 
despite countering the humidity. A lower temperature to reduce evaporation was 
rejected, due to the auto-crosslinking nature of gelatin below 30-35°C, resulting in 
the reassembly of the triple helical structures [258, 330]. Additionally, a higher 
temperature than 37°C was not assessed either, due to the increased evaporation 
that would be observed, as well as the overall delivery of the Hydrogel-PCP system 
aiming to be an injectable solution, physiological temperatures more relevant than 





Figure 4.4. Gelation kinetics of chemically crosslinking gel-CT. Mixed with 
phosphate buffer saline and DMTMM crosslinker at A) 5 minutes B) 10 minutes 




Figure 4.5. Gelation kinetics of chemically crosslinking gel-NAPPCP.  Mixed 
with phosphate buffer saline and DMTMM crosslinker at A) 5 minutes B) 10 
minutes C) 15 minutes and D) 20 minutes after. 
 
The decreased crosslinking time of the NAPPCP-conjugated gelatin 
biopolymer, compared to the control gel, provides stronger support of an injectable 
delivery method. Additional support for the injectable delivery route is the ability for 
the system to undergo network formation in physiological conditions. Furthermore, 
the biodegradable nature of the hydrogel system [331], allows for a simple end to 
treatment, without the need to invasively remove the hydrogel network. The formation 
of PCP-conjugated hydrogels, is a crucial step towards obtaining a novel, selective 
and localised drug release, whilst providing structural support within the targeted 





4.4.3 Assessment of gel content, swelling ratio and rheological properties 
Following the quantification of functionalisation degree, the gel content (GC) 
and swelling ratio (SR) were measured to further assess the structural characteristics 
of the chemically crosslinked gelatin networks. All chemically crosslinked networks 
displayed an average gel content above 90% in MMP reaction buffer (Figure 4.6.). 
Both the gel-CT and gel-NAPPCP showed high gel contents with minor variations 
observed between samples, confirming conjugation of NAPPCPP to gelatin had little 
effect on the GC and resulted in a highly crosslinked network, above the accepted 
criteria of other studies [275].   
 
Figure 4.6. Gel content (GC) chemically crosslinked hydrogels. Gel-CT (96.18 ± 
1.55 %) and gel-NAPPCP (91.11 ± 1.05 %) hydrogels (n=4). A statistical 
difference (p<0.05) between gel-CT and gel-NAPCP gel contents was observed 
using a T-test analysis. 
 
To assess other characteristics NAPPCP coupling may have had upon the 
gel-NAPPCP hydrogel, the swelling ratio (SR) was also determined (Figure 4.7.). The 
conjugation of NAPPCP, again showed little variation in SR compared to gel-CT, 
















hydrogels on averaged swelled to over 900% (9 times) their dry weight. The evidence 
suggests that NAPPCP conjugation to gelatin carries only minor decreases in SR 
when conjugated to gelatin.  
 
Figure 4.7. Swelling Ratio of chemically crosslinked hydrogels. Gel-CT (950.98 
± 43.02 %) and gel-NAPPCP (914.19 ± 33.06 %) hydrogels (n=4), using DMTMM 
as a crosslinking activator. No statistical difference was observed (p>0.05) 
from a T-test statistical analysis, comparing gel-CT and gel-NAPPCP. 
 
The combination of GC and SR provide evidence, suggesting conjugation of 
NAPPCP has little effect on network formation when chemically crosslinked with 
DMTMM, or the ability of the hydrogel to absorb liquid during the swelling process, at 
least when conjugated at a 0.2 molar ratio to free amino lysine groups of gelatin.  
Although the assessment of gel content and swelling ratio demonstrate the retention 
of network formation and swelling properties in NAPPCP conjugated hydrogels, it 
doesn’t confirm whether network formation occurred in the same way, for example 
whether NAPPCP acted as a linker during the crosslinking process or whether it 

















To further investigate the potential effects NAPPCP conjugation has, initial 
rheological assessments were employed, namely, amplitude and frequency sweeps. 
Amplitude sweeps were used to assess the percentage shear strain that can be 
exerted on the gel before minor cracks in the network begin to show, unto the point 
at which these cracks result in major network damage, ultimately leading to the 
collapse of the hydrogel network. Gel-CT and gel-NAPPCP samples were assessed 
at a constant frequency of 1 rad·s-1, under increasing shear strain. The loss modulus 
(G”) linear viscoelastic (LVE) region of gel-CT was found to be between 6 and 30% 
shear strain (Figure 4.8.). Comparing this to the LVE region of gel-NAPPCP (9-30% 
shear strain) it can be deduced, gel-NAPPCP is more resilient at than gel-CT, before 
the gel network begins to exhibit minor cracks - the beginning of the LVE region. 
During this time the network remains largely intact, maintaining an overall structure 
as only a small proportion of bonds in the network rupture, whilst the surrounding 
network remains intact. The minor cracks described are a result of internal friction 
during shearing which increases the G” modulus linearly [332]. In Figure 4.8., G” is 
displayed, indicating the loss modulus of the respective hydrogels, as increasing 
shear strain is exerted upon them. The loss modulus was selected to measure the 
LVE region, as gels were put under increasing deformation amplitude until the point 
at which the gels exhibit significant structural damage, causing a plateau of the G” 
curve. G’ was not displayed due to the presence of large fluctuations between each 
sample, however, the amplitude sweep was used to determine the percentage shear 
strain of the LVE region which can be determined from the loss modulus curve.  The 
fluctuations of G’ may be a result of the DMTMM crosslinked gelatin gel’s consistency 
and viscosity allowing the gel to flow in response applied shear strain, however this 
would also be expected to some degree in the loss modulus curve. Further, more in-
depth investigations, once confirmation of selective drug release is achieved, are 










Figure 4.8. Amplitude sweep showing the loss modulus G” LVE region. A) gel-






































Conjugation of NAPPCP to gelatin appears to strengthen the hydrogel, 
allowing it to resist greater shear strain force than gelatin control hydrogels before 
the network begins to break. The G” plateau, or the end of the LVE region, observed 
in both hydrogel types occurred at approximately 30% shear strain, at which point it 
can be assumed that the minor cracks had grown to form a continuous macro crack 
running through the samples, causing the gel to break and begin to flow, exhibiting 
total network collapse [333]. Interestingly, although gel-NAPPCP withstood greater 
shear strain before beginning to display network breakage, the point at which total 
network collapse is similar to that of gel-CT suggesting NAPPCP conjugation only 
strengthens the gel at lower shear strain force, and network collapse occurs at the 
same point in both hydrogels.  
The frequency sweeps were carried out at a constant shear strain of 10%, 
within the LVE region of both gel-CT and gel-NAPPCP, and describes the behaviours 
of the gels within the non-destructive deformation range in increasing frequencies 
[334]. At lower frequencies both gel types remained undamaged by the increasing 
frequency, likely due to the vibrations failing to oscillate through the network, causing 
it to remain rigid. At approximately 8 rad·s-1 gel-CT began to crack under the 
vibrational force leading to a total network collapse around 10.5 rad·s-1 (Figure 4.9.). 
Gel-NAPPCP remained intact up until 10 rad·s-1, however once the network began 
to crack, gel-NAPPCP broke down rapidly as the total network collapsed at 11 rad·s-
1. The results of the frequency sweeps suggest, similarly to that observed in the 
amplitude sweep, gel-NAPPCP is capable of withstanding greater force (vibrational 
force in frequency sweeps) before the network begins to crack compared to gel-CT. 
However, the point at which the networks collapse remained approximately equal in 
each of the hydrogel types, indicating gel-NAPPCP is more resistant to lower 







Figure 4.9. Frequency sweep showing storage (G’) and loss modulus (G”). A) 
gel-CT and B) gel-NAPPCP, under a constant shear strain of 10%, a value within 







 G' of CT gel

















 G' of NAPPCP gel
















Overall, the data collected from the gel content, swelling ratio and rheology 
suggests no negative impact from the conjugation of NAPPCP to gelatin occurred, 
for the application the gel-NAPPCP hydrogel would be intended. Conjugation of 
NAPPCP maintains the swelling potential of the hydrogel, allowing it to swell to fill a 
cavity, as well as the network forming potential, when compared to chemically 
crosslinked gelatin control gels. Furthermore, although NAPPCP, fails to enhance the 
maximum gel strength in relation to shear strain and frequency, NAPPCP achieves 
increased resilience to both shear strain and frequencies before initial network 
cracking occurs. The non-detrimental characteristics of NAPPCP conjugation provide 
support for the continuation of research into the novel system. In depth assessments 
into the unique properties of the hydrogel, will however, be delayed until a proof of 
concept to confirm drug release is carried out to avoid lost research time. It remains 
unclear, the role, if any, that NAPPCP plays in DMTMM induced chemical 
crosslinking. That said, the minor enhancements observed from the rheological data 
provide some insight into how functionalisation of biopolymers with PCPs may 
provide beneficial and unique characteristics in the future.  
 
4.4.4 MMP14 selective recombinant enzyme assay 
After the successful network formation of NAPPCP-conjugated gelatin 
biopolymers to form, gel-NAPPCP hydrogels, the drug release capabilities by 
MMP14 were assessed. As previously discussed, the peptide sequence, donated by 
the research team at the University of Bradford, UK is selective to MMP14, a matrix 
metalloproteinase, found overexpressed in multiple diseases due to the key role it 
plays in a variety of cellular functions [335, 336]. MMP14 is shown to selectively 
cleave the peptide sequence at the Hof-Gly peptide bond [229]. A recombinant 
enzyme assay was employed to confirm the release of NAP-based metabolites 
through the activity of MMP14.  
After 72 hours incubation, observational differences were noticeable between 
the gel-CT and gel-NAPPCP assay hydrogels (Figure 4.10.). In the gel-CT gel, the 
reaction buffer showed no visible deposits, whereas in the gel-NAPPCP drug gels 
grey-white specs were visible, indicating initial degradation of the network. In line with 
the observations, the gel-NAPPCP hydrogel appeared to have lost structural integrity 
and had flattened in shape, further indicating the beginning of a collapsed network. It 
is well known that MMP14 degrades various extracellular matrix components, 
including fibrillar collagen types I, II, III and gelatin [337], amongst many other 
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extracellular matrix macromolecules [338]. Gelatin degradation can occur as a result 
of MMP14 activity, either by direct cleavage or through the activation of other 
gelatinase MMPs. The 2013 study by Albrechtsen et al demonstrated activation of 
MMP14 in breast cancer resulted in gelatin degradation, reduced apoptosis and 
increased tumour growth [339]. It was shown that inhibition of MMP14 halts gelatin 
degradation, demonstrating a direct link between MMP14 and gelatin degradation. 
Due to the MMP14 cleavage sites of gelatin, as well as MMP14’s ability to activate 
gelatinase MMPs, there was a risk that MMP14 would be more selective towards the 
gelatin network than the NAPPCP peptide conjugate. However, the gel-CT appeared 
to maintain the structural integrity, remaining of similar shape and size as they did 
prior to the start of the recombinant enzyme assay, indicating MMP14 has little 
cleavage activity upon the DMTMM crosslinked gel-CT gel. 
 
 
Figure 4.10. Photographic depiction of hydrogels after MMP14 assay. The 
deposits and sunken appearance of the A) gel-NAPPCP hydrogel after 72 hours 






Initial observations indicated MMP14 more readily attacks the gel-NAPPCP 
hydrogel, compared to the gel-CT, however why this occurs is unclear due to both 
hydrogels consisting largely of gelatin. The addition of the NAPPCP to the 
biopolymer, may alter how network formation occurs, exposing more MMP14 
degradation sites on the gelatin backbone. This remains unlikely due to the 
significantly larger molecular size of gelatin, which can be up to 125 KDa [340] 
compared to that of NAPPCP at approximately 1.3 KDa, however further investigation 
would be required to rule this out as intermolecular forces play key roles in 
biopolymers participating in biological functions such as molecular assembly, self-
assembly and the selectivity of enzymes [341].  
The collection of deposits from the MMP reaction buffer were dissolved in 
methanol and analysed by LCMS to identify any drug release that had occurred. The 
gel-CT, as expected exhibited no naproxen-based metabolites, tracked using the 
photo diode array at 330nm. The NAPPCP prodrug control sample displayed only 
one peak at 7.43 minutes, which was later identified using mass spectrometry (MS) 
as the un-cleaved NAPPCP and unexpectedly no naproxen-based metabolites were 
detected, suggesting no successful cleavage by MMP14 occurred. In the gel-
NAPPCP a small peak around 7.43 minutes was present which is the same elution 
time as the NAPPCP prodrug. Similarly, at 17.33 minutes a metabolite containing 
naproxen eluted which was later confirmed, using MS, to be a mass of 384.43 which 










Figure 4.11. LCMS analysis of MMP14 recombinant assay. Tracking the release 
of naproxen peptide-conjugated prodrug metabolites A) NAPPCP control B) 
gel-CT control gel and C) gel-NAPPCP gel. Confirmation of key peaks 
confirmed by Mass Spectrometry D) 7.43 MS of NAPPCP peak shown by MH2+ 
charged mass and E) 17.28 MS of NAPPCP metabolite peak of MH charged 









The expected metabolite from the MMP14 recombinant enzyme assay was 
NAP-Arg-Ser-Cit-Gly which has an MH mass charge of 686.35 m/z. The metabolite 
observed, NAP-Arg was unexpected and interestingly not observed in the NAPPCP 
control, suggesting coupling NAPPCP to gelatin may enhances the drug release by 
means other than MMP14. NAPPCP showed no successful cleavage by MMP14 at 
the expected scissile bond, as demonstrated by Atkinson et al (2010) [103]. This was 
a possibility, as the conjugated sequence is an MMP14 cleavable sequence for the 
prodrug known as ICT2588, a vascular disrupting agent with an 
azademethylcolchicine drug warhead [103] and as discussed, changing a single 
amino acid or the drug itself can alter the release profile. The substitution of 
azademethylcolchicine for naproxen and the removal of the Fluorescein 
Isothiocyanate (FITC) endcap may have prevented NAPPCP cleavage from 
occurring. Whether the substitution of the drug warhead or removal of the FITC 
endcap has the stabilising effect (or shielding of the cleavage site to MMP14) is 
unknown as altering the endcap also has the potential to change the properties of 
the compound [342]. The removal of the FITC endcap was a necessary step to couple 
NAPPCP to the gelatin biopolymer, as it lacks a free carboxylic group to couple to 
the free amino groups of gelatin. One key difference between the NAPPCP and 
ICT2588 is the position in which the drug warhead is conjugated, in NAPPCP, NAP 
is coupled to the N-terminus of the peptide conjugate, whereas in ICT2588, 
azademethylcolchicine is coupled to the C-terminus, which may impact the rate of 
cleavage by MMP14 (Figure 4.12.). The structure of NAPPCP differs from ICT2588, 
and due to PCPs being 3D structures, it is possible that the expected cleavage site 
is still recognisable but inaccessible to MMP14 because of the altered structure. 
At this time, it is not possible to know which, or to what extent the 
modifications of ICT2588 to form NAPPCP had upon the MMP14 recognition and 
proteolytic activity of the Hof-Gly cleavage site. Structural analysis and sequence 
modifications could enhance the MMP14 activity around the cleavage site in the 
future to increase the rate of drug release, as even a single amino acid change can 
drastically alter the recognition by MMP14 [343]. Cleavage may also be possible 
through an alternative MMP or protease, which could be identified using an ex vivo 
assay or a series of recombinant enzyme assays against a panel of MMPs, which 







Figure 4.12. Structural differences between A) ICT2588 and B) NAPPCP. 
Demonstrating the active drug components (blue) are coupled to alternative 
ends of the peptide conjugate with azademethylcolchicine coupled to the C-
terminus and naproxen coupled to the N-terminus. The N-terminus of ICT2588 
is occupied by the FITC endcap (red).  
 
The NAP-Arg metabolite, released from gel-NAPPCP, confirms the release 
of naproxen from the hydrogel network, although this metabolite was unexpected, 
even more so due to the metabolite being undetectable in the NAPPCP drug control 
sample. MMP14 may be responsible for the cleavage between Arg and Ser in gel-
NAPPCP, but not in the NAPPCP drug control due to a key difference between the 
two structures; gel-NAPPCP contains the gelatin biopolymer network as an endcap 
which as previously discussed can alter the release profile of a drug. It was initially 
hypothesised that NAPPCP conjugation to gelatin, or the crosslinking process, 
causes a previously inaccessible MMP14 cleavage site to become accessible, 
however this theory is doubtful because the degradation of gel-NAPPCP and gel-CT 
hydrogels in 6M HCl (and no MMP14 presence) exhibited the NAP-Arg metabolite in 






Figure 4.13. Acid degradation analysis using LCMS. A) gel-NAPPCP B) gel-CT 
and C) using MS to identify the peak located at 17.34 minutes in gel-NAPPCP, 
identified as NAP-Arg.  
 
The release of the NAP-Arg metabolite observed in both the gel-NAPPCP 
MMP14 recombinant assay and the acid degradation assay indicate that release of 
the metabolite from the hydrogel network is unlikely to have occurred through 
enzymatic cleavage as first thought. The most likely explanation as to why, in both 
MMP14 recombinant assays carried out (Collagen, Chapter 3.4.5 and Gelatin, here) 
it appeared no cleavage of the NAPPCP occurred at the known MMP14 cleave site 
(Hof-Gly) was initially attributed to the inactivity of the supplied MMP14 enzyme itself. 
This however is ruled out by the delivery of the active MMP14 arriving with 
confirmation of activity as well as internal investigations of the active enzyme using 
an ICT2588 variant peptide, donated by the University of Bradford, UK, cleaving at 
the Hof-Gly cleave site as expected. The spectra of the confirmed cleavage were 
requested not to be displayed due to ongoing research surrounding variants of the 
ICT2588 prodrug.  
A theory which would support the presence of NAP-Arg in both the MMMP14 






control, is that conjugation of NAPPCP to gelatin and/or network formation by 
DMTMM causes the NAPPCP component to become unstable and degrade 
naturally. Testing this theory would be possible through a series of gel content-like 
assays, on both gel-NAPPCP biopolymer and gel-NAPPCP hydrogels, by 
synthesising and submerging both the biopolymer and hydrogel forms at varying time 
points after synthesis, in weak acid or ethanol so not to degrade the gelatin, before 
neutralising and analysing through LCMS to assess changes in NAP-Arg metabolite 
vs NAPPCP or NAP-only peaks. If instability of NAPPCP is affected by conjugation 
or network formation, it would be expected that increasing quantities of NAP-Arg or 
NAP-metabolites would be observed as time went on. Due to the lack of cleavage of 
the NAPPCP drug itself, resources would be more suited towards optimising the 
cleavage by MMP14, to continue to develop a selective and localised drug release. 
The degradation theory however, poses another potential release strategy for the 
hydrogel network. A greater peak area was observed in the acid degradation of 1.76 
times compared to the MMP14 recombinant enzyme assay, indicating acidic 
conditions further contributes to release of NAP-Arg.  
Another, likely possibility is that the conjugation of NAPPCP, partially hinders 
the chemical crosslinking process, so that acidic degradation or MMP14 cleavage 
became more favourable in the gel-NAPPCP hydrogel compared to the gel-CT, 
causing the degradation of gelatin. This would account for the increased gel-
NAPPCP debris observed after the MMP14 recombinant assay, as MMP14 would 
have more accessibility to degrade the gelatin network, releasing NAP-Arg as a 
result.  
The NAP-Arg metabolite identified may have also occurred as a result of 
crosslinking in PBS solution, due to the guanidium group of arginine carrying a 
positive charge under physiological conditions [344, 345] and therefore may readily 
have reacted with DMTMM activated carboxylic groups on the gelatin biopolymer 
leading to NAPPCP acting as a linker within the crosslinking process. Armstrong et 
al (2016) discuss the hydrogen bonding potential between the Arg guanidinium group 
is satisfied by oxygen hydrogen bond acceptors of the carboxylate (-COO-) containing 
amino acids, which is the same method by which DMTMM activated -COOH groups 
to enable chemical crosslinking [346]. This would cause NAPPCP to be conjugated 
both at the tyrosine end chain -COOH and the arginine guanidium side chain. Drug 
release would then rely on two cleavage locations on the peptide-conjugate as 
opposed to one, making this theory less probable, considering MMP14, the only 
113 
 
proteolytic enzyme present in the MMP reaction buffer appears to not cleave 
NAPPCP at the previously shown cleavage site. Furthermore, if successful cleavage 
of both sites were to occur, evidence of this would likely be observed in the NAPPCP 
spectra and would be expected in larger quantities, than that detected in the gel-
NAPPCP MMP14 recombinant enzyme assay. The small peak of NAPPCP detected 
in gel-NAPPCP is likely due to MMP14 degradation of the hydrogel network which 
appeared to have collapsed under visual observations (Figure 4.10.). Alternative, 
future sequences could exclude the use of Arg to eliminate the possible risk of 
crosslinking at the Arg guanidium site. 
It is possible that, NAPPCP acting as a linker during network formation, may 
have indirectly caused the observed collapse in the network, if MMP14 attacked the 
gelatin biopolymer around the NAPPCP linker regions, causing NAPPCP to elute, 
identified as a small peak of NAPPCP and NAP-Arg, which may occur as a result of 
natural break down once the sequence is deprotected. The observed network 
collapse of the gel-NAPPCP hydrogel is further supported by the gel content carried 
out on the MMP14 recombinant enzyme assay gels (Figure 4.14.). No statistical 
difference was found in the gel content of gel-CT hydrogels before and after the 
MMP14 recombinant assay, which supports the findings displayed in Figure 4.10. 
demonstrating an intact network. On the other hand, from the observations, the Gel-
NAPPCP network appeared to collapse over the 3-day assay and as a result a 
decrease of 15.42% was observed in gel content, which was found to be statistically 
significant. The significant reduction in gel content could be a result of the 
hypothesised steric hinderance of the coupled NAPPCP, preventing total chemical 
crosslinking by DMTMM, instead catering for a physical crosslinking of the hydrogel. 
This method has been observed in a study by Yu et al (2020) where they overcame 
polymer low grafting degree of functional groups and steric hinderance by designing 
a novel hydrogel through non-covalent interactions [347]. It is possible that non-
covalent crosslinking of gelatin (which is capable of auto-crosslinking) occurred as a 
result of inhibited chemical crosslinking because of steric hinderance. Over several 
days in solution with MMP14 the gel-NAPPCP hydrogel may breakdown due to MMP 
attack, but also naturally as a result of the weaker non-covalent bonds present, 
unable to support a swollen structure. This could be investigated by comparing the 
gel content of auto-crosslinked gelatin hydrogels with DMTMM crosslinked gels, over 
a several days in solution to assess the changes in GC. The non-significant change 
observed earlier in the swelling ratios support the theory of steric hinderance. 
Ordinarily, a more crosslinked hydrogel swells less than a less crosslinked hydrogel 
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because of a more tightly compact network preventing large amounts of solution from 
expanding the network. The hydrophobicity of the aromatic rings within the NAPPCP 
prodrug, may prevent additional swelling by repelling water from the network, thus 





Figure 4.14. Gel content carried out on gel-CT and gel-NAPPCP hydrogels. A) 
after 3-day MMP14 recombinant enzyme assay and B) table exhibiting 
percentage values of gel content before and after the assay. Statistical analysis 
between gel-CT and gel-NAPPCP hydrogels before and after were compared 
using a T-test. No significant difference was observed between the gel-CT 
hydrogels, however a statistical difference in gel-NAPPCP was observed, 



















Gel Type Before/After Assay G /wt (%) 
Gel-CT Before 96.18 ± 1.55 
Gel-CT After 95.42 ± 0.86 
Gel-NAPPCP Before 91.11 ± 1.05 
Gel-NAPPCP After 75.69 ± 0.86 
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Gel content in the gel-CT remains consistent with the content observed prior 
to the MMP14 recombinant enzyme assay, however gel-NAPPCP exhibited a 15.4% 
decrease in gel content on average, suggesting a sixth of the network had collapsed 
or being degraded. The decreased gel content confirms the start of network collapse 
within the gel-NAPPCP hydrogel, however if MMP14 were responsible for this 
collapse, a more decreased gel content for gel-CT would have been expected, 
however NAPPCP conjugation may cause MMP14 cleavage sites on the gelatin 
biopolymer to become more recognisable for cleavage. The network collapse may 
be due to instability of the NAPPCP prodrug acting as a linker molecule in part, during 
the crosslinking process. This theory would require further assessment of the 
structural integrity of the network to confirm the presence of NAPPCP as a partial 
linker within the gel network, combine with the previously discussed time-dependent 
stability assessment of the gel-NAPPCP biopolymer and hydrogels. The decrease in 
gel content following the assay may be attributed to secondary interactions 
established between the NAPPCP and the gelatin biopolymer and/or other NAPPCP 
compounds, however future investigations are necessary to confirm which of the 
theories is correct, if any.  
 
4.4.5 Investigating the clinical delivery route – injectability  
Clinically, the advantage of being able safely and effectively deliver 
therapeutic agents via non-invasive means is crucial when developing a new 
therapeutic treatment. In some instances, surgery is a necessary feat, for example 
the implantation of stents, or the removal of a tumour mass that it is too higher risk to 
leave in place and reduce with chemo/radio therapy. However, where possible, the 
use of surgery as a therapy should be avoided, particularly in drug delivery. If a drug 
can only be delivered to the site of disease by surgical implantation, the risk of 
disease site toxicity, through infection significantly increases [349]. Many drugs can 
be delivered by non-surgical means, including taking drugs orally or by intravenous 
methods. It is not possible to deliver every therapeutic drug via these methods, as 
part of, or whole drugs, such as the tail of peptide-conjugated prodrugs would be 
degraded by stomach acid if taken orally. Similarly, not all drugs can be delivered 
intravenously, for example, using the NAPPCP or a methotrexate-PCP (MTXPCP) to 
target osteosarcoma, activation and release is triggered by MMP14 cleavage, which 
is overexpressed in some off-target healthy regions, due to MMP14 involvement in 
bone development and regulation [18]. Therefore, intravenously delivering a drug 
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similar to MTXPCP which has the potential to release the cytotoxic MTX at a high 
concentration within healthy tissue, away from the osteosarcoma site, from a clinical 
perspective is not viable. A need for a selective, localised and non-invasive method 
of drug delivery is clinically appealing for the more complex drug deliveries, as well 
as those where efficacy can be improved. The hydrogel system established here has 
the potential to selectively release a drug whilst remaining anchored at the disease 
site. 
There are two obvious delivery strategies for the gel-NAPPCP hydrogel 
system 1) surgical implantation and 2) network mixture injection. The biodegradable 
nature of collagen and collagen-derived hydrogels remain stable, as a support 
network for approximately 7-10 days within the body and therefore initial implantation 
of a hydrogel system would be suitable as part of a surgical procedure such as 
removing an osteosarcoma mass. This method however, would not be viable as a 
long-term therapy because surgery every 7 to 10 days, to provide continued drug 
release is not possible, due to time it takes for surgical wounds to heal after surgery 
which would take two to six weeks if implanted during an arthroscopy [350]. Also, the 
surgical implantation again would not be an effective strategy in diseases that often 
do not require surgery, including rheumatoid arthritis (RA). The second delivery 
strategy, the injection of a network mixture, allows for a non-invasive drug delivery 
system and at a more frequent rate, weekly or fortnightly perhaps, although this would 
depend on the drug dosage conjugated to the hydrogel. The advantage of an in situ 
network formation enables a straight forward delivery route and due to the 
consistency of the gelatin-based hydrogel network, being similar to that of cartilage 
and other connective tissues, structural support could be provided in several 
diseases including RA, where cartilage degradation occurs and MMP14 
overexpression can be observed [351]. The chemically crosslinked nature of the gel-
NAPPCP hydrogels, allows network formation to occur under physiological 
conditions within 20-25 minutes, once mixed with the DMTMM crosslinker. Therefore, 
the injectable delivery system wouldn’t be hindered by long network formation times, 
relying on the patient resting for prolonged periods of time post-injection to allow 
gelation to occur. A question to be answered in future research is whether or not the 
crosslinking reaction is toxic to cells, however DMTMM is shown to be a non-toxic 
compound [352], and therefore the components involved in crosslinking all possess 
low levels of toxicity and therefore can be hypothesised that the crosslinking reaction 
should be safe. 
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Although shorter gelation times of a hydrogel are an advantage, gelation to 
fill a cavity or anchor themselves within the disease environment is critical to avoid 
potential gelation within a healthy tissue environment as this could lead to, no drug 
release or unwanted off-target toxicity due to the release of the drug within healthy 
tissues, naturally expressing MMP14. To investigate the anchorage potential of 
gelation, cavities were created within solid sawbone pieces to replicate femur bone 
ends, where cartilage degradation would be most prevalent in RA, and network 
forming mixtures injected into the cavity to gel under physiological conditions. Both 
gel-CT and gel-NAPPCP network forming mixtures underwent successful chemical 
crosslinking with DMTMM in sawbone cavity holes (Figure 4.15.), however only gel-
CT was displayed due to clarity of the newly formed hydrogel sample, as the control 
was dyed using rhodamine. Both hydrogel types, 25 minutes after cavity injection 
were able to be stood vertically on end and turned upside (not displayed), remaining 
intact, anchored within both cavity hole shapes.  
 
 
Figure 4.15. Gelation of gelatin-control hydrogels in polyurethane synthetic 
bone. Crosslinked with DMTMM under physiological conditions A) horizontal 
image of cavities prior to network forming mixture injection B) horizontal image 
of cavities 25 minutes post network forming mixture injection and C) vertical 
image of cavities 25 minutes post network forming mixture injection. 





The consistency when handling the hydrogels within the cavities, compared 
to those conventionally formed in a well plate, appeared the same, as did the 
anchoring; when turned vertically or upside-down the hydrogels remained firmly 
anchored in place, with no indication of leaking out of the cavity.  
After observing gel anchoring within cavities, anchoring through the sawbone 
was investigate to give an indication of how gelation might occur within a joint (Figure 
4.16.). Gelation through the sawbone was observed in both the control and NAPPCP 
conjugated hydrogels, providing further evidence for the theory of in situ network 






Figure 4.16. Hydrogel gelation through polyurethane synthetic bone tunnel 
cavity. Gelatin-control A) front-facing B) side profile and gelatin-NAPPCP C) 
back-facing and D) side profile. 
 
The results demonstrate the clinical delivery potential for an injectable, in situ 
crosslinking hydrogel to provide a selective and localised release of a therapeutic 
drug to lower the risk of unwanted off-target toxicity within the body. An injectable 
strategy enables a non-invasive delivery route that is applicable to a broad range of 
diseases that can be reached by injectable means. The concept of using an injectable 
hydrogel to anchor a peptide-conjugated prodrug at a disease site and provide 
structural support where needed, is a novel approach, one that requires further work 
to confirm the suitability of the delivery approach, with regards to the diversity of the 




Drug delivery can play a major role in the amount of associated off-target 
toxicity of a therapeutic drug, reduced by controlling the release, activation of a 
prodrug, or by changing the physical delivery method, i.e. orally or localised injection. 
Here, successful gel-NAPPCP hydrogels were synthesised using a DMTMM 
chemical crosslinker, capable of crosslinking in physiological conditions within 
sawbone cavities. The release of NAP triggered by MMP14, appeared unsuccessful 
however release of a NAP-Arg metabolite was observed in both the recombinant 
enzyme and acid degradation assays. Future work is required to develop the 





















5.0 Final Discussions 
The thesis describes the fusion of two well researched scientific fields, 
biomaterials and medicinal chemistry to propose the concept of a selective and 
localised form of drug delivery. Biomaterials design as a research field has shown 
advances in tissue scaffolding and regenerative medicine in recent years [353-355], 
whereas medicinal chemistry has demonstrated key alternatives to current 
therapeutics aiming to reduce toxicity associated with certain disease treatments, 
leading to improved clinical success [356]. It is therefore unsurprising that the 
combination of structural tissue support and less toxic therapeutic agents would be 
desirable and advantageous when treating diseases such as rheumatoid arthritis or 
osteosarcoma. The study aimed to prove the concept of peptide-conjugated prodrugs 
coupled to a biopolymer which then undergoes network formation (crosslinking) to 
produce a hydrogel system with selective means of releasing the drug component.  
The initial network formation strategy focused around the UV-induced 
network formation due to the wealth of knowledge obtained through previous work 
within the research group into collagen and the 4VBC molecule, not to mention the 
patent that the University of Leeds, UK currently holds on collagen and collagen 
derived photo-active functionalised polymers [189]. Although the project focused, 
initially around collagen and collagen-derived biopolymers (4VBC functionalised and 
UV crosslinked) which were in used studies as previous work [52, 275], this project 
differed, as it took the previously characterised collagen-derived biopolymers and 
applied them towards using them as therapeutic drug delivery systems whilst 
incorporating a novel peptide-conjugated prodrug. The novelty of the system 
described here, sheds new light on the therapeutic stalemate RA and OS have seen 
in recent years and aims to bring forward new therapies which provide tissue support 
in the form of a selective drug release hydrogel system. 
The results showed that collagen and gelatin biopolymers, when sequentially 
coupled to a drug and the photo-active molecule, 4-vinylbenzyl chloride (4VBC), do 
not lead to network formation, by UV crosslinking. It is hypothesised that this is due 
to molecular shielding (prodrug-induced steric hinderance), preventing the 
combination of free radical-propagation chains of the 4VBC-functionalised 
biopolymer. The method of UV crosslinking would have been a desirable system, 
allowing for efficient curing methods, whilst including the possibility to cure in situ 
whilst implanting the system, allows for an enhanced variety of cavities or areas to 
be filled prior to curing, enabling increased delivery accuracy compared to injectable 
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methods. Injectable methods, as previously discussed have more significant 
advantages including minimally invasiveness and reduced risk of infection. The 
advantage of using a peptide-conjugated prodrug (PCP) is that it could be applied to 
any disease, overexpressing a proteolytic enzyme, with changes to the peptide-
conjugated sequence made to make it selectively recognisable by the new target 
enzyme [357]. This allows for a wide variety of different diseases to be targeted, 
drugs that can be administered and polymer materials that can be used, which all 
together provide a unique and tailored therapeutic approach to many disease 
conditions.  
After the unexpected inability to form a PCP-conjugated hydrogel system, the 
encapsulation of col-NAPPCP within a crosslinked network of col4VBC25 was 
carried out and successful network formation was accomplished following UV 
irradiation. However, it appeared that the col-NAPPCP molecules impregnated in the 
4VBC-functionalised collagen network diffused out of the system following sample 
incubation in aqueous environment. This was confirmed when complete acid 
degradation of the col4VBC25encap-NAPPCP showed no naproxen-based peaks 
during HPLC analysis.  
The change in strategy from a photo-crosslinked Hydrogel-PCP system to a 
chemically crosslinked system was therefore employed in light of the potential 
prodrug-induced steric hinderance effect during UV irradiation preventing 
combination of free radical propagating chains and successful biopolymer network 
formation. By chemically crosslinking the biomaterial, the use of a photo-active 
molecule was no longer necessary, allowing NAPPCP to be conjugated directly onto 
a biomaterial as the suspected steric shielding was no longer present. Gelatin was 
deployed as the frontline material to synthesis a Hydrogel-PCP system from, using 
the chemical crosslinker DMTMM, due to the increased ease of functionalisation 
discussed previously. The successful conjugation of NAPPCP to gelatin was 
confirmed using a ninhydrin assay prior to network formation. The success of network 
formation under physiological temperatures, accomplished the key objective for the 
proof of concept study by synthesising a Hydrogel-PCP system that was capable of 
undergoing network formation in physiological conditions. Further, initial investigative 
assessments were carried out, including gel content and swelling ratio as well as 
rheology, comparing the gel-NAPPCP with a gelatin control gel. The results of the 
hydrogel properties investigated, displayed no significant detrimental effects from the 
coupling of NAPPCP to gelatin, further supporting the suggestion of a Hydrogel-PCP 
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system. The decision to carry out rheology and other investigative experiments on 
the chemically crosslinked systems and not the UV-crosslinked systems was due to 
resources available at the time of each development. The collagen-based UV-
crosslinked systems produced finite quantities of conjugated PCP systems, of which 
the MMP14 enzyme assay was deemed more crucial to assess over the investigative 
experimental work. The MMP14 assay was a critical step in the aims of the study, 
demonstrating the release of NAP from the hydrogel system. if the collagen-based 
systems had demonstrated drug release from the hydrogels, a larger quantity of drug-
conjugated biopolymer would have been synthesised to allow further investigative 
work to be carried out. The lack of drug release from collagen systems at a crucial 
stage in the research project favoured the change in crosslinking method, to establish 
a Hydrogel-PCP system, as opposed to carrying out characterisation of a hydrogel 
system which would require further modifications, likely altering the characteristics 
which would have already been investigated, thus using up the finite resources at 
hand.  
Following the investigative analysis, drug release was assessed in an MMP14 
recombinant enzyme assay. No cleavage between the Hof-Gly site was detected 
using LCMS, however a NAP-Arg metabolite was released from the structure. It is 
unlikely that MMP14 is responsible for the release of NAP-Arg, as the NAPPCP-only 
control did not produce the NAP-Arg metabolite, however conjugation to gelatin may 
allow MMP14 to target the Arg-Ser site. Although the attempt to confirm drug release 
through MMP14 cleavage, appeared to fail, the overall results of the project are 
promising as the peptide-conjugate sequence is known to be cleaved by MMP14 
[229], therefore suggesting that slight alterations to the peptide sequence are 
required to accommodate the change in active drug used. Furthermore, acidic 
conditions appeared to display larger quantities of the NAP-Arg metabolite, 
suggesting potential for an alternative selective release strategy, triggered in 
response to a decrease in pH [358, 359].  
 
Another key aspect of the project was the establishment of a delivery strategy 
for the proposed Hydrogel-PCP system to address the needs of RA and OS, whilst 
being as minimally invasive as possible. Many well researched diseases already 
have established therapeutic treatments to cure them, however therapies for more 
complex diseases such as RA, focus around managing the disease. Some, but not 
all of these therapeutic treatments could be further enhanced by either: alternative 
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drug delivery routes or the alteration of the treatment compound to reduce the chance 
of unwanted off-target toxicity, for example using a prodrug. Osteosarcoma and 
rheumatoid arthritis are two complex diseases requiring clinical intervention to 
improve the therapeutic index of current treatments.  
The development and approval of any new treatment must be clinically viable, 
a treatment is null and void if significant systemic toxicity is associated or the 
therapeutic cannot be delivered effectively [360]. Cytotoxic or chemotherapeutic 
drugs in particular, are therapeutic agents where reducing off-target toxicity is crucial 
[361]. This can be achieved by reducing the administered dose, which may result in 
a less effective treatment, limiting the spread of the therapy, either by anchoring it at 
the treatment site or making the treatment more selective [98, 362]. Another area to 
consider is the delivery strategy, even the most effective treatments won’t gain 
approval if the clinical delivery route is not viable and safe.  
Here, the proof of concept study addressed the key areas which oppose a 
new therapeutic strategy by combining several research fields to suggest the release 
of a selective therapeutic prodrug, anchored at the disease site by a tissue support 
structure, delivered by injectable means, negating the need to surgically implant the 
device. No proof of concept study of this nature produces a finalised therapeutic 
product, however, the progress made here paves the way for future studies to adapt 
and fine-tune the novel Hydrogel-PCP concept to produce an effective therapeutic 
system.  
The particular concept in this study demonstrated its’ clinical potential by 
being able to temporarily disable the active drug through conjugation of a peptide 
sequence, as well as being injectable as part of an in situ forming tissue scaffold. 
Furthermore, by bypassing the oral administration of naproxen, off-target toxicity, 
peptic ulceration - a common side effect of prolonged NSAID treatments, may be 
avoidable. The drug release profiling, requires further work, however the initial aims 
as well as a delivery route have been achieved. Overall, the described study lays the 
foundations for future work across a vast variety of diseases, through the alteration 
of a peptide-conjugate sequence, to target and exploit the overexpression of 
proteolytic enzymes within the disease.  
As the study developed the versatility of the system was further highlighted, 
demonstrating the potential to incorporate the system into several future study 
designs, not only using PCPs but to investigate other selective release methods such 
as in pH responsive, but also, using a peptide-conjugate as an anchoring chain to 
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the hydrogel. This diversifies the variety of diseases that could be targeted using a 
Hydrogel-PCP system. The research focussed heavily around meeting the clinical 
needs of OS and RA, as both diseases require updated therapeutic treatments. 
Osteosarcoma, in the form of more targeted treatments displaying reduced off-target 
toxicity and reduced patient side-effects. Whereas RA requires a localised and 
selective drug delivery within a structural support network, reducing the risk of bone 
erosion. Both of these disease treatments are possible through the use of a hydrogel 
as a drug delivery vehicle, administered by injection to meet another desirable clinical 
attribute, reducing the need for invasive procedures to deliver a therapeutic 
treatment.  
 
A concept with desirable clinical attributes, such as reducing the associated 
off-target toxicity, providing a non-invasive delivery or the provision of a tissue 
support structure are favourable treatment methods [363]. The combination of these 
attributes makes the discussed study a clinically advantageous strategy to reduce 






















The project described here has demonstrated a need for new research into 
the therapeutic targeting of rheumatoid arthritis and osteosarcoma, to break the 
deadlock of currently used, outdated therapies. The outlining of new knowledge 
brought forward through the development of novel drug delivery system to kick start 
a resurgence in RA and OS therapeutics, was achieved following research 
objectives, described in Chapter 1.1. Key objectives met included: 
• The establishment of a novel Hydrogel-PCP system 
Synthesis of the Hydrogel-PCP system is the first system to our 
knowledge to conjugate PCP to a biopolymer prior to network 
formation. 
 
• The use of DMTMM as a chemical crosslinker 
Traditionally, the carbodiimide, EDC alongside NHS, has been used 
in the activation of carboxylic acid groups and chemical crosslinking. 
The emerging use of DMTMM in literature has been strengthened 
here, demonstrating itself as a substantial alternative to EDC/NHS.  
 
• A substantial and credible delivery strategy for the newly synthesised 
Hydrogel-PCP system 
The establishment of a minimally invasive, injectable device, which is 
capable of in situ network formation under physiological temperatures, 
looks to overcome the complications of surgical implantation, which 
was originally proposed as a delivery strategy at the beginning of the 
research project.  
 
Peptide-conjugated prodrugs have become advantageous drug delivery 
compounds, which have demonstrated a selective release and a much-reduced risk 
of drug associated off-target toxicity. A key example of this would be ICT2588, 
demonstrating no significant off-target cardiotoxicity in vivo [229]. The use of a 
hydrogel to deliver and anchor a PCP in place at a disease site, was proposed here 
and is thought to further enhance the PCP drug release whilst providing a structural 
tissue support. 
Here, the key objective of the project, to synthesis a novel Hydrogel-PCP 
system was established, through chemically crosslinking a collagen-derived 
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hydrogel, after exhausting crosslinking capabilities in the UV-induced Hydrogel-PCP 
systems. Aiming to the use of a Hydrogel-PCP system, identification of a clinically 
desirable delivery route was another significantly important objective. The 
establishment of an injectable Hydrogel-PCP system, capable of crosslinking under 
physiological temperatures, which provides a novel drug delivery system with a 
targeted and minimally invasive delivery route, whilst crosslinking to provide 
structural support, is possibly the most exciting result of this study, open up several 
future directions of work to expand knowledge within the research field.  
Further investigations are required to define the ideal peptide sequence and 
release mechanism of NAPPCP (Chapter 7), however, the concept of developing an 
in situ forming Hydrogel-PCP system has being demonstrated as well as initial 
investigations into the properties and clinical delivery routes.  
In all, the study provides insights into the design of a novel concept to provide, 
localised and selective drug delivery using a tissue support network as an anchor for 
the drug, which in theory can be applied to the treatment of any disease, not only 
rheumatoid arthritis and osteosarcoma, but indeed any disease overexpressing a 



















7.0 Future works 
The proof of concept study, discussed here provides a strategy foundation for 
several therapeutic directions involving the use of DMTMM-crosslinked gelatin 
hydrogel systems. In this sub-chapter the individual directions will be outlined to 
provide a base from which future work can be carried out.  
 
5.3.1 Peptide-conjugated prodrug functionalised gelatin hydrogels 
The most obvious of the future strategies is the continuation of a Hydrogel-
PCP system research using a proteolytic enzyme to trigger drug release. The 
alterations made to the ICT2588 sequence to accommodate synthesis of the gelatin-
NAPPCP system led to the stabilisation of the prodrug in regards to MMP14 
cleavage. The stabilised condition can be altered to produce a more cleavable 
peptide-conjugate by adjusting the peptide sequence [364], allowing for increased 
NAP metabolite release due to MMP14 activity. The establishment of an MMP14 
cleavable NAPPCP would allow for a selective release within a disease, increasing 
the therapeutic index, by reduction of off-target toxicity [365]. Substitution of a single 
amino acid can cause significant effects on the rate of drug release as previously 
seen in MTX-PCPs. Previous work, demonstrated the substitution of β-Ala for Cit 
causes the rate of drug release to increase across all three assessed tissues which 
is an undesirable trait in healthy tissues, such as the liver and kidneys [21]. A balance 
between effective drug release in diseased tissues and the degree of off-target 
toxicity caused to healthy tissues must be established, with the degree of off-target 
toxicity being lower than that of existing therapeutic treatments in order to be clinically 
desirable.  
The design of future Hydrogel-PCP systems of the concept described here, 
requires a careful and systematic approach, using the basis of ICT2588’s peptide 
sequence as a starting point. Initial work, removing the hydrogel component of the 
system may be useful to establish a peptide-conjugate sequence that when coupled 
to naproxen is selectively released by MMP14. This would confirm whether the 
sequence, when conjugated to the hydrogel is unrecognisable due to the hydrogel 
and not the change in drug component to the sequence, reducing the amount of 
resources lost.  Batches of PCP sequences containing single changes could be 




After successful synthesis and purification, if required, release assessments 
will be carried out either through an MMP14 recombinant assay or an ex vivo assay 
using homogenised tissue with an overexpression of MMP14. Both assays have 
advantages over the other. The recombinant assay demonstrates MMP14 is capable 
of cleaving the peptide sequence releasing a drug metabolite, which in the body 
would be deprotected and open to metabolism, leading to the release of the active 
drug. Selectivity of MMP14 could be determined by follow-up recombinant enzyme 
assays using alternative MMPs. The ex vivo assay would assess release in a tissue 
environment, and could be carried out in a variety of tissues, both healthy and 
diseased to indicate the drug release profile and potential associated toxicity of the 
NAPPCP. The analysis of both assays could be carried out using LCMS and the drug, 
half-life calculated. The biological assay, as a suggestion would be used initially to 
determine peptide cleavage and drug release to efficiently identify the more 
successful PCP release sequences before confirming which expressed MMP carries 
out the initial cleavage – likely to be MMP14 due to the modified ICT2588 sequence. 
If an alternative MMP was identified for the initial cleavage then diseases 
overexpressing the newly identified protease could be investigated further to 
establish a therapeutic treatment. 
With regards to the sequence modifications from the ICT2588 sequence, Arg 
would be an ideal starting point to substitute for an alternative amino acid, due to the 
previously discussed guanidium group of arginine, which would remove the risk of 
the PCP acting as a linker molecule during hydrogel network formation. The 
successful NAPPCP sequences would then be coupled to gelatin and chemically 
crosslinked to form a hydrogel before reassessing the drug release assays to 
compare the changes, if any to the drug release. Should drug-release remain 
unchanged the following steps would involve the hydrogel characterisation, including 
but not limited to, techniques such as rheology, swelling ratio and gel content. 
Ordinarily, assessments of hydrogel properties are carried out prior to the drug 
release assays, shown here, however due to the results and nature of the Hydrogel-
PCP system the logical route is to assess drug release first. If drug release from the 
Hydrogel-PCP system was not possible then there would be no reason to carry out 
hydrogel characterisation as the PCP sequence would require further modifications 




5.3.2 Acidic release investigation 
As the results of this study confirmed, a drug metabolite, NAP-Arg was 
released in more acidic conditions. Although the method of drug release appears to 
be in response to pH changes, further investigations are required to confirm this. 
Changes in the pH can trigger drug release [366], due to the changing of molecular 
charges. Investigations into the effect pH changes have on drug release from the gel-
NAPPCP system could allow for a new range of applications to be explored, including 
wound healing. Furthermore, further investigations into the structure of gel-NAPPCP 
may provide insight into the discussed theories surrounding the role NAPPCP plays, 
if any, during network formation. Minor alterations to the peptide sequence could 
enhance the pH-selective release of NAP, should confirmation of pH-sensitive drug 
release be confirmed.  
Exposure of equal mass gel-CT and gel-NAPPCP hydrogels to varying pH 
levels across a range of time points, incubated at 37°C, prior to neutralisation and 
analysis, using LCMS to measure the release of NAP metabolites, would confirm the 
optimal pH for drug release. The effects of alkaline conditions may also be assessed 
in this manner as NAP metabolites may also be released in alkaline conditions.  
Should a pH induced drug release be proven, the system may be deployed in 
an in vitro or in vivo model to further assess the drug release and provide an idea of 
the degree of off-target toxicity associated with this form of drug delivery. 
Comparisons between current NAP treatments and the hypothesised pH-induced 
NAP release could be made in in vivo models to determine whether the pH-induced 
release strategy is more beneficial, clinically, than current NAP treatments.  
 
5.3.3 Cinical device developmental investigations 
The third direction of future research, is the development of the clinical 
delivery device – the injectable, in situ crosslinking Hydrogel-PCP system. Here, we 
have shown the initial steps towards an injectable system by demonstrating that 
network formation is possible under physiological conditions using a networking 
solution of phosphate buffer saline, dissolved gel-NAPPCP and DMTMM, as well as 
injecting it within sawbone to visualise and depict the gelling capability within a bone 
cavity or between two bones. Future research could expand on the progress made 
here, using bovine bone and drilling a series of different cavities to assess gelation 
in a more dynamic range of cavity sizes, whilst assessing gelation in other solution 
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types to optimise gelation times and strength, as the use of a gelation solution may 
affect the strength of the networked hydrogel. Once assessment of in situ gelation 
from an injectable hydrogel solution has been made ex vivo bone, the investigation 
could be carried out in vivo by injecting a series of hydrogel solutions into cavities to 
assess gelation within the model, however this would likely only be at a stage when 
the drug release strategy was ready for in vivo assessments too. 
The investigation into the development of a clinical device is future work which 
would be suitable alongside one of the other two described research directions as 
there is little need to assess the delivery without a means of releasing the therapeutic 
treatment once established within the model.  
 
5.3.4 Peptide-conjugated photo-crosslinked hydrogels 
Future work may also involve the investigations into the failings of the photo-
crosslinking strategy to gain further insight into why the dual functionalisation of 
collagen with 4VBC and NAPPCP led to an inhibition of network formation. 
Furthermore, the theory of how the encapsulated col-NAPPCP yielded no drug after 
complete acid degradation of the encapsulating hydrogel still remains unanswered.  
It may be that dual functionalisation with a photo-active molecule that doesn’t 
contain an aromatic ring such as methacrylate (MA) [54] may be a sufficient enough 
change to allow network formation to occur under UV light, however it is likely that 
due to the suspected steric effects and UV effects on certain amino acids as 
previously described, a complete resequencing of the PCP sequence may be 
required to enable photo-crosslinking capabilities.  
Steric shielding could be investigated using solvent accessible surface area 
analysis [367] and has been used to determine the effect of steric shielding on 
another popular biopolymer, polyethylene glycol (PEG) by Mu et al [368]. This could 
be applied in future works to investigate and confirm the role steric shielding may 
have played in the prevention of network formation through photo-crosslinking 
methods.  
If photo-crosslinking can be achieved, to form a Hydrogel-PCP system, similar 
steps to the ‘Peptide-Conjugated Prodrug Functionalised Gelatin Hydrogels’ direction 
could be carried out produce an implantable clinical delivery route for applications 
such as dentistry. Photo-crosslinking is possible under visible light and has gained 
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much attention in recent years [262] and may be of greater use than a chemically 
crosslinked hydrogel in certain applications, however investigations would be 
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